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Worldwide, millions of people suffer from chronic respiratory diseases that affect the airways and 
structural components of the lung. The most common chronic airway diseases are asthma and 
chronic obstructive pulmonary disease (COPD). They have major adverse effects on the quality of 
life and are one of the major grounds for consulting healthcare centres. Currently, these diseases 
cannot be cured, however various treatment options are available to relieve the patient’s 




Asthma is a chronic respiratory disease of the conducting airways, affecting 334 million people 
worldwide [2]. According to the Global Initiative for Asthma (GINA), asthma is described as “a 
heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the 
history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that 
vary over time and in intensity, together with variable expiratory airflow limitation” [3, 4]. The 
airway of asthmatics is characterized by several pathological changes, including inflammatory cell 
infiltration, goblet cell metaplasia, airway hyperresponsiveness (AHR), airway wall remodeling 
and reversible airway obstruction (Figure 1) [5].  
 
 
Figure 1: Bronchial tube of a healthy person (right) and asthmatic patient (left), characterized by inflammatory cell 




Asthma can be diagnosed based on the patient’s characteristic pattern of respiratory symptoms 
that vary over time and intensity and the presence of a bronchial hyperresponsiveness and 
variable airflow limitation. The airflow obstruction is measured with spirometry and defined as 
the ratio of the forced expiratory volume in one second (FEV1) to the forced vital capacity (FVC), 
the tiffeneau index. FEV1 is the maximum volume of air that can be forcedly exhaled in one second 
after complete inspiration, whereas FVC is defined as the maximum volume of air that can be 
forcedly exhaled. In asthmatics, the airflow limitation is largely reversible which means that their 
FEV1 should improve rapidly after inhalation of a bronchodilator during bronchial provocation 
tests [3].  
Over the years it became clear that asthma is a complex and heterogeneous disease with different 
underlying disease processes. More specifically, multiple phenotypes can be distinguished based 
on the patient’s clinical characteristics and inflammatory profile (Figure 2) [6]. The best 
characterized phenotype is (early-onset) allergic asthma, defined by the presence of allergen-
specific immunoglobulin E (IgE) in serum and/or a positive skin prick test to common allergens, 
such as house dust mite (HDM), in association with type 2 mediated immune responses. Other 
phenotypes are i.e. late-onset eosinophilic asthma and smoking-associated neutrophilic asthma 
[6, 7].  
 
Figure 2: Emerging asthma 
phenotypes. Multiple 
asthmatic phenotypes can 
be distinguished based on 
the type of inflammation, 
severity and age at onset. 
EIA: Exercise-induced 
asthma; AERD: Aspirin 
exacerbated respiratory 
disease. Reprinted by 
permission from Macmillan 
Publishers Ltd: [Nature 
Medicine] (Wenzel SE. Nat 
Med 2012;18: 716-25[6]). 






1.2.1 Pathogenesis of allergic asthma 
 
The lung is continuously exposed to different environmental factors (allergens, microbes, viruses 
and pollutants). In healthy individuals, specialized regulatory mechanisms are present to achieve 
immune tolerance and maintain homeostasis against self-antigens or foreign matter [8, 9]. Failure 
of these tolerance mechanisms can however lead to excessive immune responses and 
development of inflammatory diseases such as asthma (Figure 3).  
Most asthmatics become sensitized to common aeroallergens, especially those derived from 
house dust mite (HDM), animal dander, fungi and pollen [10]. Sensitization to an allergen is 
defined as the process between the first encounter and the formation of allergen-specific IgE 
complexes while no allergic symptoms are present [11]. Initially, allergens are taken up by 
specialized antigen presenting cells, the dendritic cells (DCs). These DCs reside near the 
epithelium and can sample the airway lumen for danger signals derived from the allergen itself 
and/or the airway epithelium (see chapter 3). The DCs process the allergen into small peptides 
and traffick to the lymph nodes, where antigen presentation to naïve CD4+ T cells occurs. During 
their migration, the DCs mature by expressing an array of co-stimulatory molecules (i.e. CD80 and 
CD86) and high levels of MHCII molecules to induce proliferation and differentiation of allergen-
specific T helper 2 (TH2) cells. These TH2 cells will then in turn secrete IL-4 and IL-13, type 2 
cytokines that are both capable of stimulating an immunoglobulin switch of B cells from IgM to 
IgE. This allergen-specific IgE can then bind with high affinity receptors (FcɛRI) expressed on a 







Figure 3: Pathogenesis of allergic asthma. DCs mature to competent antigen presenting cells in response to various 
danger signals, such as allergens. Allergen-loaded DCs migrate to the lymph nodes and interact with naïve T cells to 
drive TH2 polarization. Type 2 cytokine production of TH2 cell stimulate B cells to produce IgE which will bind with 
FcɛRI expressing cells. Allergen re-exposure will lead to an inflammatory process wherein inflammatory cells are 
recruited to the airways and cell activation occurs, resulting in the release of specific mediators contributing to the 
characteristic features of asthma.  
  
Once sensitization has occurred, allergen re-exposure will induce a local infiltration of allergen-
specific TH2 cells which will produce type 2 cytokines, i.e. IL-5 and IL-13, contributing to the 
hallmarks of asthma. Moreover, the recruitment of various inflammatory cells, such as mast cells 
and eosinophils, to the airways will occur. Crosslinking of allergen-specific IgE molecules on mast 
cells for instance will lead to their activation and release of preformed mediators containing 
histamine, lipid mediators (leukotrienes and prostaglandins), cytokines, chemokines and growth 
factors, responsible for bronchoconstriction, vasodilation, increased vascular permeability, 
excessive mucus production and ongoing inflammatory cell recruitment. Furthermore, an 
infiltration of eosinophils into the lung will occur, mediated by IL-5, a type 2 cytokine which is 
responsible for the proliferation, activation and survival of eosinophils. These prominent cells are 
a rich source of inflammatory proteins, including major basic protein, leukotrienes and cytokines, 
contributing to tissue damage, bronchoconstriction and airway wall remodeling [5, 10, 13].  
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Besides TH2 cells, also innate lymphoid cells (ILC) have emerged as important contributors in the 
pathogenesis of asthma. Their role and mechanism of action will be extensively discussed in 
chapter 4.  
 
1.2.2 Risk factors 
 
Although the precise causes of asthma remain unclear, studies suggest that several risk factors 
can influence the development and phenotype of asthma, categorized as host factors and 
environmental factors (Figure 4).  
Figure 4: Risk factors contributing to the development and phenotype of asthma. The development of asthma is 
strongly regulated by heritable components (genetics and epigenetic mechanisms) and exposure to environmental 
factors. Asthma is a heterogeneous disease wherein multiple phenotypes can be distinguished based on clinical 
characteristics and the inflammatory profile. The disease is characterized by a chronic airway inflammation, reversible 
airway obstruction, airway wall remodeling and airway hyperresponsiveness.  
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Genetics have a strong influence on the development of asthma, meaning that individuals can be 
genetically predisposed to be protected or susceptible to develop asthma. Twin studies provided 
convincing evidence that asthma is a heritable disease, wherein approximately 60-80% of asthma 
susceptibility is determined by genetic factors such as nucleotide variants [14, 15]. Such genetic 
polymorphisms, related to asthma susceptibility, have already been identified by the development 
of genome wide association studies (GWAS). As an example, polymorphic changes in the TSLP and 
IL-33 gene have brought attention to the airway epithelium as a key factor in the development of 
asthma (see chapter 3) [16, 17]. Despite the identification of such disease-associated loci, only a 
small proportion of heritability can be explained by genetic variants [18, 19].  
The rapid increase in the incidence of asthma over the last decades and the discordance of 
developing asthma that is observed in twin studies, point to the fact that the etiology of asthma is 
also influenced by environmental factors. It is for instance demonstrated that also complex gene-
by-environment interactions occur, mediated by epigenetic mechanisms. Epigenetics can be 
defined as mechanisms that regulate gene expression without altering the underlying DNA 
sequence itself. Epigenetic changes include DNA methylation, histone modifications and non-
coding RNAs [19-21]. Currently, several environmental factors, such as pollutants, infections and 
allergens, can exert epigenetic changes, contributing to the pathogenesis of asthma [21, 22]. 
An enhanced susceptibility to the onset and exacerbation of asthma can be further attributed to 
environmental factors, including exposure to air pollution (see chapter 2) and allergens (i.e. 
HDM, pollen, animal dander) which can induce and facilitate inflammatory immune responses 
[23]. The most important source of perennial indoor allergens is HDM, a complex organism found 
in 70% of the bedsheets and mattresses where they feed on human skin scales. Mite allergy is 
highly prevalent in the world, with around 50-85% of asthmatics that are sensitized to HDM 
allergens [24, 25]. The most common mite species are Dermatophagoides pteronyssinus and D. 
farinae [26]. So far, over 20 different protein families have been identified as HDM allergens (Table 
1), which are present in high amounts in the mite bodies and fecal pellets [24, 25]. Among these 
different HDM allergens, proteases are highly abundant and being held responsible for the 
inflammatory properties of HDM [27, 28]. Especially group 1 and 2 allergens have been identified 
as major allergens as 80% of allergic patients are sensitized to Derp1 and Derp2. Derp1 belongs 
to the cysteine protease family [24, 29] and has been shown to target tight junction proteins, 
increasing the permeability of the airway epithelium (see chapter 3) [27]. The second major 
allergen is Derp2, a lipid binding protein that can activate innate immune responses through toll-
like receptor 4 (TLR4) signaling [30]. Moreover, also lipopolysaccharide (LPS) and β-glycans can 





Table 1: Characterized allergens of Dermatophagoides pteronyssinus. All 
allergens listed are officially listed in the WHO/IUIS allergen database [31].  
Allergen group Allergen Protein family 
1 Derp1 Cysteine protease 
2 Derp2 NPC2 family 
3 Derp3 Trypsin 
4 Derp4 α-Amylase 
5 Derp5 - 
6 Derp6 Chymotrypsin 
7  Derp7 - 
8 Derp8 Gluthathion-S-Transferase 
9 Derp9 Serine protease 
10 Derp10 Thopomyosin 
11 Derp11 Paramyosin 
12 Derp12 - 
13 Derp13 Fatty acid-binding protein 
14 Derp14 Apolipophorin 
15 Derp15 Chitinase-like protein 
18 Derp18 Chitin-binding protein 
20 Derp20 Arginine kinase 
21 Derp21 - 
23 Derp23 Peritrophin-like protein domain 
24 Derp24 biquinol-cytochrome c reductase binding protein 
26 Derp36 - 
 
Besides the well-known association between environmental exposures (i.e. pollution and 
allergens) and increased respiratory symptoms, it was demonstrated that microbial exposures 
can protect against the development of atopic diseases such as asthma, the so called “hygiene 
hypothesis” [32]. This hypothesis was originally raised by David Strachan who observed an 
inverse relationship between the number of siblings and the rate of allergic diseases [33]. 
Furthermore, rural living conditions (growing up on farms) have been associated with a reduced 
risk of asthma development. A recent study for instance demonstrated a lower prevalence of 
asthma in the Amish community that practice traditional farming (high microbial exposure) 
compared to the Hutterites that implement industrial farming [34]. Recently, the protein A20, 
located in lung epithelium, was identified as an important determinant on how high endotoxin 
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levels or farm dust could protect mice from developing HDM-induced allergic airway 




Despite the fact that asthma is not curable, there are several treatment options to improve the 
patient’s symptoms and quality of life. The most common treatment is focused on the combination 
of relieving airway obstruction with short- or long-acting β2-adrenergic receptor agonists and 
reducing airway inflammation by using inhaled corticosteroids [3, 36, 37]. However, for patients 
with severe asthma that require high doses of inhaled or even oral corticosteroids, there is an 
urgent need for more targeted approaches [38, 39]. Identifying the different asthmatic 
phenotypes [6], is becoming more important in asthma treatment, that is evolving to precision or 
personalized medicine [40]. To date, there are few approved biologics available as add-on therapy 
in the treatment of asthma that are currently reserved for poor-controlled patients with a specific 
asthma phenotype. Omalizumab is a humanized monoclonal IgE-targeting antibody 
recommended for allergic patients. Omaluzimab forms complexes with circulating IgE, preventing 
its interaction with FcɛRI expressed on mast cells, eosinophils, dendritic cells and basophils, 
which are important cells in the pathogenesis of asthma [37, 41]. Adding omalizumab to standard 
therapy in severe allergic asthmatics led to reduced asthma exacerbations and corticosteroid-
sparing effects [42]. Mepolizumab and reslizumab, humanized monoclonal IL-5 targeting 
antibodies, reserved for patients with a persistent eosinophilic inflammation, will target IL-5, an 
important type 2 cytokine that promotes the growth, maturation and activation of eosinophils [37, 
41, 43]. Treatment with such anti-IL-5 monoclonal antibodies has led to a reduction in the 
exacerbation rate and/or reduced use of corticosteroids in asthmatic patients with elevated 
eosinophils in the blood or sputum [44-46]. Interestingly, a post hoc analysis revealed that 
especially patients with late-onset eosinophilic asthma greatly improved with reslizumab as add-
on therapy compared to early-onset asthma [47]. Currently, promising results are also obtained 
with anti-IL-4Rα (dupilumab) and anti-IL-5R (benralizumab) monoclonal antibodies as add-on 
treatment for persistent asthmatics [48, 49]. Moreover, a diversity of new molecules (i.e. 
monoclonal antibodies directed against epithelial-derived cytokines) are tested for safety and 
efficacy in clinical trials [43]. It was for instance recently demonstrated that severe uncontrolled 
asthmatics who received a monoclonal anti-TSLP antibody (Tezepelumab) had significant fewer 




1.3 Chronic Obstructive Pulmonary Disease (COPD) 
 
COPD is a respiratory disease of the smaller airways and parenchyma, affecting 210 million people 
worldwide. In 2015, it was estimated that about 3 million deaths were attributable to COPD, 
making it the fourth leading cause of death [51]. COPD is defined by the global initiative for chronic 
obstructive lung disease (GOLD) as “a common, preventable and treatable disease that is 
characterized by persistent respiratory symptoms and airflow limitation that is due to airway 
and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases”. 
Patients who suffer from COPD typically present with symptoms as progressive and persistent 
dyspnea, chronic cough and sputum production, often accompanied by systemic effects and 
comorbidities [52].  
The golden standard to diagnose COPD is by performing spirometry in symptomatic patients that 
have a history of exposure to risk factors. By assessing the severity of the airflow limitation, which 
is based on the FEV1 post-bronchodilator value, COPD is classified into 4 different stages: mild 
(FEV1 ≥ 80%; GOLD I), moderate (50 % ≤ FEV1 ≤ 80 %; GOLD II), severe (30 % ≤ FEV1 ≤ 50 %; 
GOLD III) and very severe (FEV1 < 30 %; GOLD IV) COPD. Recently, a new classification method 
was proposed, the ABCD assessment tool, that takes into account the evaluation of symptoms and 
the history of exacerbations on top of the severity of airflow limitation [52].  
The main risk factor for developing COPD is tobacco smoking. Other risk factors include indoor 
and outdoor air pollution and occupational exposures to dusts and fumes. However, considering 
that only 20% of smokers develop COPD, also genetic factors will predispose individuals to 
develop COPD. Typical pathophysiological hallmarks of COPD include a chronic airway 
inflammation, lymphoid neogenesis, emphysema and airway wall remodeling [53].  
Although COPD cannot be cured, it is currently managed by controlling symptoms and reducing 
exacerbations with bronchodilators and inhaled corticosteroids [52].  On top, smoke cessation is 
key to influence the natural history of COPD and specifically slowdown the accelerated decline in 




















Air pollution is a major cause of environmental health problems, leading to increased morbidity 
and mortality. It is estimated that each year approximately 3 million deaths are solely attributed 
to ambient (outdoor) air pollution [55]. It is a complex mixture including particulate matter (PM), 
chemicals, such as ozone, and biological substances. Although all components of air pollution are 
harmful for human health, severe effects have been attributed to PM since they can carry a broad 
range of toxic substances into the respiratory tract [56]. Ambient PM consists of solid and liquid 
particles that are generated as a result of natural processes as well as human activity, such as 
industry, cigarette smoke and traffic. The particulates differ in their chemical composition and are 
divided into 3 categories based on their aerodynamic diameter: coarse PM (< 10µm, PM10), fine 
PM (< 2.5µm, PM2.5) and ultrafine PM (UFPM) (< 0.1µm, PM0.1).  
The ability of ambient PM to induce lung injury and inflammation is determined by several key 
characteristics, such as particle size, surface area and chemical composition [57-59] (please also 
see addendum, review). Importantly, the most health-damaging effects have been attributed to 
UFPM, since they can deposit deep in the pulmonary tissue, into the smaller airways and alveoli, 
and some will even translocate to the systemic circulation, causing extra-pulmonary effects 
(Figure 5) [60]. Moreover, as the particle size decreases, its surface area increases, allowing a 
greater proportion of metals and organic carbons at the particle’s surface, which are  implicated 










Figure 5: Deposition particulate matter.  Coarse PM (PM10) deposits mainly in the nose and large conducting airways, 
whereas the deposition of PM2.5 is located throughout the respiratory tract, particularly in the small airways and alveoli. 
The ultrafine PM fraction PM0.1 will further deposit in the pulmonary tissue and some will even translocate from the 
alveoli to the pulmonary circulation. 
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A major component of (ultra)fine traffic-related ambient PM are diesel exhaust particles (DEPs). 
These particles are mainly derived from vehicles during the combustion of diesel fuels. DEPs 
consist of a carbon core which can adsorb several organic compounds, such as polycyclic aromatic 
hydrocarbons (PAHs) and quinones. Additional, traces of sulphates, nitrates and metals can be 
observed [64, 65]. 
 
2.2 Impact on human health 
 
About 90% of the world’s population breathe air that is not conform to the WHO guidelines (i.e. 
annual mean values of 10 µg/m³ for PM2.5), resulting in a serious disease burden attributable to 
ambient air pollution [55]. In 2015, exposure to 10 µg/m³ PM2.5 was exceeded at 75% of the 
European measuring stations (Figure 6). Although the air quality in Europe is slowly improving, 
the European Environment Agency (EEA) states that air pollution still has a significant impact on 
Europeans’ health. Air pollution is still associated with more than 500.000 premature deaths per 
year in Europe, making it the leading environmental cause of premature deaths. Four out of five 
premature deaths were directly linked with fine PM [66]. Alarmingly, it was recently 
demonstrated that also pollution levels below the current national standards are associated with 
an increased risk of death [67]. 
Several epidemiological studies already demonstrated a positive correlation between air 
pollution and multiple chronic diseases, ranging from respiratory diseases, such as asthma, COPD 
and lung cancer, to cardiovascular illness and all-cause mortality [60, 68-70]. To date, 
cardiovascular diseases are the leading causes of death worldwide [71]. Notably, in 2016, > 2 
million premature cardiovascular deaths out of 17 million were attributed to ambient air pollution 
[72]. Specific causal associations were found between PM exposure and myocardial infarction, 
hypertension, congestive heart failure, arrhythmias and cardiovascular mortality [73]. Besides 
cardiovascular events, exposure to air pollution was also associated with increased cancer 
incidence, especially lung cancer [74]. In the ESCAPE study, a large European cohort, long-term 
exposure to PM air pollution contributed to the lung cancer incidence in Europe [75]. It was 
therefore not surprising that in 2013, the International Agency for Research on Cancer (IARC) 
reported ambient air pollution, as well as PM as a separate component, as group 1 human 
carcinogens [74].  
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Figure 6: The annual mean PM2.5 concentration in 2015 [66].  
 
While the WHO estimates that 18% of air pollution-related premature deaths are due to COPD and 
acute lower respiratory infections [76], various epidemiological studies indicated that exposure 
to ambient PM and DEPs can also contribute to the onset as well as exacerbation of both childhood 
and adult-onset asthma [60, 77-81]. Living near major roads was for instance associated with 
significantly more respiratory symptoms and adverse effects on lung function in children and 
adults [70, 82-85]. Interestingly, the first 8 years of life can be considered as a susceptible period, 
as traffic-related PM exposure during that period was associated with an impaired lung function 
growth [86]. Furthermore, when asthmatic individuals were exposed to high levels of particulate 
pollution, they were more likely to experience worsened symptoms and impaired lung function, 
leading to uncontrolled asthma and hospitalizations [79, 81, 87]. Asthmatics walking on a polluted 
street in London had a higher airway inflammation and reduction in lung function compared to 
those walking in a low traffic environment [88]. Although PM and DEPs are without a doubt 





2.3 Diesel exhaust particles and acute immune responses  
 
It has been well accepted that DEPs can cause several adverse effects on their own, inducing acute 
inflammatory responses in the nose, throat and lungs [23]. Both human and animal studies have 
shown that exposure to DEPs is associated with increased proinflammatory cytokine/chemokine 
release, generation of reactive oxygen species (ROS), inflammatory cell influx in the lung, airway 
resistance and remodeling [89-93] (see addendum, review). The underlying mechanisms that 
contribute to these DEPs-induced acute immune responses need however to be further 
elucidated. It was already demonstrated that DEPs modulate DC biology, influence its recruitment, 
maturation and migration towards the mediastinal lymph nodes (MLN), resulting in Th2 
polarization. Influencing DC function could therefore be an important mechanism by which DEPs 
contribute to asthma [94, 95].  
  
2.4 Diesel exhaust particles and allergen-induced immune responses 
 
In addition to these acute effects, DEPs can facilitate allergen-induced immune responses, 
contributing to the pathogenesis of asthma [23]. In murine models, DEPs can promote the 
development of an allergic airway inflammation towards for instance house dust mite (HDM). 
More specifically, combined DEPs+HDM exposure increased eosinophilic airway inflammation, 
type 2 cytokine production, allergen-specific immunoglobulins, AHR and remodelling compared 
to sole DEPs or HDM exposure [96-98]. Controlled human exposure studies further confirmed that 
allergen-specific responses, such as airway eosinophilia, type 2 cytokine expression and allergen-
specific IgE, can be augmented when the individuals were exposed to both DEPs and an 
(neo)allergen [99-101]. Whereas for the moment predominantly descriptive studies have been 
performed, the underlying cellular and molecular mechanisms remain to be investigated. In this 
dissertation, mechanisms contributing to the enhancing effects of DEPs on the allergic airway 
























The airway epithelium is an important line of defence to a wide variety of environmental factors, 
including allergens and pollutants (Figure 7) [102]. A first crucial defence mechanism that 
protects the lung from foreign particles is the mucociliary apparatus located on top of the 
epithelial surface. This mucus layer traps inhaled substances which are transported out of the lung 
by ciliary beating and coughing, a process called mucociliary clearance. In asthmatics however, 
excessive mucus production and ciliary dysfunction leads to an impaired clearance, resulting in 
plug formation and airflow obstruction [103, 104].  Moreover, in PM-exposed human bronchial 
epithelial cells (HBEC) the ciliary beat frequency was progressively attenuated [105], suggestive 
for a delayed clearance of such particles out of the lung.  
The integrity of the epithelial barrier is further regulated by a coordinated expression of apical 
tight junctions (claudins, occludin, zonula occludens (ZO)-1, 2, 3), underlying adherens junctions 
(E-cadherin, β-catenin) and desmosomes [102, 104, 106]. Cleavage of such epithelial junctional 
complexes and disruption of the barrier structures can be mediated directly by inhaled 
substances that penetrate the mucus layer [106]. Proteolytically active allergens, such as HDM, 
can disrupt junctional proteins and therefore breach barrier function [27]. In addition, also PM 
can increase airway epithelial permeability, as demonstrated by a down-regulation or disruption 
of the adhesion molecule E-cadherin or tight junction proteins, occludin and ZO-1 [107-109]. 
Moreover, inflammatory mediators and cytokines, such as IL-13, can indirectly disrupt the 
epithelial barrier integrity [106, 110]. As a consequence, inhaled particles, allergens and viruses 
can easily penetrate beyond the epithelial surface, facilitating the induction and sustention of 
innate and adaptive immune responses [106]. Loss of E-cadherin for instance can facilitate allergic 
sensitization by modulating the DC biology [111]. Furthermore, epithelial barrier disruption can 
lead to intracellular signaling, as a siRNA knockdown of E-cadherin led to the production of 
epithelial-derived TH2 promoting cytokines [112]. In asthmatic airways, evidence of epithelial 
disruption and fragility has already been demonstrated [102, 104]. In biopsies of human asthmatic 
patients, a loss of E-cadherin and ZO-1 could be demonstrated compared to non-asthmatic 
subjects [113].  
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Figure 7: Defensive mechanisms of the airway epithelium against foreign particles. The airway epithelium exerts 
a mucociliary clearance and functions as a physical barrier through a tight regulation of apical junction complexes (tight 
and adherens junctions). Moreover, activation of different pattern recognition receptors, expressed on the epithelial 
cell surface, will lead to the release of multiple pro-inflammatory chemokines and cytokines, contributing to innate and 
adaptive immune responses. ILC2: Innate lymphoid cell type 2; PAR: Protease-activated receptor; TLR: Toll-like 
receptor.  
 
Initially, the airway epithelium was considered as a passive barrier, preventing access of harmful 
agents to the underlying tissue. Nowadays, it is widely accepted that the epithelial layer also has 
an active role in respiratory defence mechanisms, regulating both innate and adaptive immune 
responses. Airway epithelial cells express an array of pattern recognition receptors (PRR) (i.e. 
TLR, protease-activated receptor (PAR), NOD-like receptors and C-type lectin receptors) that can 
detect and respond to pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs) released upon cellular damage, death and stress [102]. TLR4 
triggering on these structural cells for instance was crucial to induce asthma after HDM exposure 
[114]. Moreover, also ambient PM was found to trigger TLR, including TLR2 and TLR4, to induce 
airway inflammation [115, 116]. Triggering these PRRs and induction of ROS will induce the 
activation of nuclear factor κB (NF- κB), leading to the release of several pro-inflammatory 
chemokines and cytokines that can attract and activate immune cells [117, 118]. Epithelial-
derived CCL2 and CCL20 for example can be secreted following HDM or DEP exposure to attract 
monocytes and immature DCs towards the lung [95, 114, 119]. Moreover, the recruitment of DCs 
can also be mediated by the chemoattractant chemerin that is released from airway epithelial cells 
upon environmental exposure (see chapter 3.2) [120, 121]. In response to HDM or DEPs the 
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epithelium can also release several pro-inflammatory cytokines, IL-1, IL-25, IL-33, TSLP and GM-
CSF, which can regulate the induction of type 2 immune responses [114, 122, 123] (see addendum, 
review). These cytokines share the capacity to activate DCs which can promote TH2 responses in 
the lung, contributing to the pathophysiology of asthma. Furthermore, recent advances in the field 
demonstrated that type 2 mediated immunity can also be promoted by the activation of innate 
immune cells, such as ILC2s (see chapter 4) [102, 117]. The central role of these epithelial-derived 
cytokines is further supported by the fact that GWAS have identified that polymorphisms in genes 
encoding for TSLP, IL-33 and its receptor IL1RL1 are associated with asthma risk [16, 17]. Indeed, 
increased TSLP and IL-33 expression in the airways of asthmatics was already demonstrated, 
which positively correlated with disease severity [124-126]. The role of IL-33 and its signaling 
pathway in the lung will be described more in detail below (see chapter 3.3).  
 
3.2 Chemerin  
 
Chemerin, also known as tazarotene-induced gene 2 protein (TIG2), is synthesized as a 163 
amino acid precursor, preprochemerin. During secretion, the N-terminal signal peptide is cleaved 
by a yet unknown protease to form prochemerin with low biological activity [127]. From this 
precursor, different chemerin fragments can be formed due to various serine proteases, including 
neutrophil elastase, cathepsin G and mast cell chymase/tryptase [128, 129]. Cleavage at different 
sites in the C-terminal domain can result into different chemerin peptide isoforms with pro-, anti-
inflammation actions or even inactivity [130]. Although chemerin is often described as an 
adipokine, since one of the predominant sources is the adipose tissue, chemerin was also found in 
several other tissues, including the lung. The presence of prochemerin could be clearly 
demonstrated in airway epithelial cells [120, 131] (Figure 8).  
Chemerin can bind to three G-protein coupled receptors: chemokine-like receptor 1 (CMKLR1 or 
ChemR23), G protein coupled receptor 1 (GPR1) and chemokine CC motif receptor-like 2 (CCRL2) 
[130]. Among these receptors, CCRL2 does not promote any cell signaling or receptor 
internalization upon chemerin binding. It was therefore suggested that CCRL2 increases the local 
protein concentrations and present chemerin to ChemR23 expressing cells [132]. In contrast, both 
ChemR23 and GPR1 can induce chemerin-associated signaling, but only ChemR23 will promote 
cell chemotaxis as GPR1 is not expressed on leukocytes. ChemR23 is expressed on different 
immune cells, such as immature DCs, monocytes, macrophages and NK cells, which will be 
attracted to the site of inflammation upon chemerin release, influencing innate and adaptive 
immunity [130]. Of note, the expression of ChemR23 was also found on endothelial cells [133]. 
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Interestingly, besides chemerin, a second ligand of ChemR23 was identified, resolvin E1 (RvE1), 
an anti-inflammatory lipid mediator that can promote resolution of inflammation by reducing 
leukocyte infiltration [134].  
 
 
Figure 8: Chemerin/ChemR23 axis in the lung. Preprochemerin, stored in the airway epithelial cells, is released as a 
poor bioactive precursor, prochemerin. Proteolytic cleavage of the C-terminus by extracellular proteases derived from 
neutrophils, macrophages and mast cells convert prochemerin into several chemerin variants. Bioactive chemerin is 
then able to attract and activate ChemR23 expressing cells, such as monocytes, macrophages, NK cells, conventional 
and plasmacytoid DC.  N-terminal signal peptide.  Cleavage C-terminal domain.  
 
3.2.1 Role of  Chemerin/ChemR23 signaling in the lung 
 
The chemerin/ChemR23 axis has gained interest for its multiple roles related to the onset and 
resolution of inflammation, metabolism and cancerogenesis in multiple organs, including the lung. 
Depending on the stimulus and which proteases are available in the microenvironment, chemerin 
exerts pro- or anti-inflammatory actions [130]. As different chemerin variants can be formed, each 
with their own pharmacological properties, a complex regulatory interaction and therefore 




Previously, our lab demonstrated that cigarette smoke (CS) exposure increased the chemerin 
levels in the bronchoalveolar lavage fluid (BALF). Moreover, the CS-induced airway inflammation 
was almost completely abrogated in the BALF and lung of ChemR23 knockout (KO) mice, 
indicating a pro-inflammatory role for chemerin upon CS exposure [120]. Accordingly, a positive 
correlation between plasma chemerin levels and COPD was recently demonstrated, as elevated 
chemerin levels could be measured in the serum of COPD patients compared to the control group 
[135].  
In contrast, when ChemR23 KO mice were exposed to LPS, increased inflammatory responses 
were observed, indicative for anti-inflammatory properties of chemerin [131]. Furthermore, 
ChemR23 KO mice were also more susceptible to viral pneumonia, as a delayed viral clearance, 
higher mortality and enhanced inflammatory responses were present in the absence of chemerin 
signaling [136]. In addition, administration of exogenous chemerin attenuated the ovalbumin 
(OVA)-induced allergic airway inflammation and AHR. These protective properties of chemerin 
were found to be mediated by a negative feedback mechanism on epithelial CCL2 production, 
which led to a reduced recruitment of inflammatory DCs to the airways [121]. 
 
3.3 Interleukin-33  
 
Interleukin (IL)-33 is identified as a member of the IL-1 family which is composed of 11 
cytokines, including IL-1α, IL-1β and IL-18 [137]. Under basal conditions, the IL-33 protein 
(approximately 31kDa) is constitutively stored in the cell nucleus where it will bind to chromatin, 
controlling gene expression and maintaining the cells resting state [138]. Its expression is 
widespread over multiple organs and abundantly found in various cell types, predominantly 
structural cells such as epithelial barrier tissues and endothelial cells. Although the IL-33 
expression is generally not observed in haematopoietic cells, it can be induced under 
inflammatory conditions, but still at lower levels than in structural cells [139]. Concerning the 
presence of IL-33 in the lung, important interspecies differences should however be taken into 
account, as human IL-33 is mainly observed in bronchial epithelial cells and mouse IL-33 is 
expressed by alveolar type II pneumocytes [139, 140].  
In contrast to most cytokines, IL-33 does not contain a signal sequence and will therefore not leave 
the cell via the conventional endoplasmatic reticulum-Golgi secretory pathway. Instead, IL-33 has 
been termed an alarmin that is passively released during cellular stress or injury. Recent evidence 
however suggests that IL-33 can also be actively released, without inducing cell death [139, 140].  
It was for instance demonstrated that ATP-dependent IL-33 release can occur in the absence of 
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cellular necrosis [141]. When released, full length IL-33 is already biologically active, meaning that 
processing by caspase-1 does not have to occur, in contrast to other family members, such as IL-
1β and IL-18 [138]. Of note, it was even demonstrated that IL-33 becomes inactivated after 
caspase-1 processing [142]. Moreover, also under apoptotic conditions, a programmed cell death 
where an inflammatory immune response should be avoided, nuclear IL-33 is cleaved and 
inactivated by caspase-3 and caspase-7 [143].  
During inflammation however, the expression of IL-33 can be further increased. Inflammatory 
proteases derived from neutrophils and mast cells for instance can process full length IL-33 into 
multiple shorter mature forms (18-21kDa) which possess a 10- to 30-fold greater biological 
activity than its full length form [144, 145]. Once released, IL-33 can bind with the IL-33 receptor 
(also known as IL1RL1) that consists of the specific type I transmembrane protein ST2 and 
interleukin-1-receptor accessory protein (IL-1RAcP). This IL-33R complex is highly expressed by 
a variety of immune cells, including T cells, ILC2, mast cells, eosinophils, DCs, macrophages, 
basophils, B cells and NK cells, as well as structural cells like epithelial and endothelial cells [140, 
146]. Upon IL-33 binding, signal transduction in the target cell is mediated by the recruitment of 
MyD88, IRAK and TRAF proteins. These proteins will induce the activation of different MAPK and 
NK-κB, leading to induction of pro-inflammatory immune responses (Figure 9) [137, 138, 147]. 
Interestingly, several mechanisms have been developed to limit extracellular IL-33 activity. First, 
a soluble form of ST2 (sST2) was described that functions as a decoy receptor, neutralizing free 
IL-33 and therefore preventing IL-33/ST2 signaling [139]. Secondly, shortly after release, IL-33 
can be inactivated in the extracellular environment by cysteine oxidation and formation of 
disulphide bridges, limiting the range and duration of IL-33/ST2-dependent responses [148].  
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Figure 9: Activation of 
the IL-33/ST2 axis in the 
lung. IL-33 is 
constitutively stored in the 
nucleus of lung epithelial 
cells where it controls 
gene expression and 
maintains the cells resting 
state. During mechanical 
stress and injury, nuclear 
IL-33 is passively released 
as a biological active 
alarmin. Cleavage by 
several proteases derived 
from neutrophils, 
macrophages or mast cells 
can result into multiple IL-
33 isoforms that possess a 
greater biological activity 
then its full length form. 
Once IL-33 is released, it 
can activate different cells, 
including mast cells, DCs, 
macrophages, ILC2, T and 
B cells, which express the 
ST2 receptor The 
activation of the ST2 
expressing cells can 
however be prevented by 
the presence of soluble 
ST2 (sST2), which acts as a 
decoy receptors and 
neutralizes free IL-33 
 
 
3.3.1 Role of IL-33/ST2 signaling in the lung 
 
In asthmatics, increased IL-33 expression has been observed in the serum, induced-sputum, BALF 
and bronchial epithelial cells, which positively correlates with disease severity [125, 149-151]. 
Moreover, common sequence variants in the IL-33 and ST2 gene are associated with asthma 
susceptibility [16, 17, 152, 153]. Recently, also a rare loss-of-function mutation in the IL-33 gene 
was discovered which correlated with lower eosinophil counts and protection against asthma 
[154]. Furthermore, an IL-33 splice variant without exon 3 and 4, resulting in cytosolic localization 
and facilitated IL-33 secretion, is associated with type 2 airway inflammation in patients with 
asthma [155].  
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Most murine studies have identified a critical role for IL-33/ST2 signaling during allergic airway 
inflammation. Administration of exogenous IL-33 induces goblet cell metaplasia and AHR in mice 
through type 2 cytokine production [156]. Even in the absence of an adaptive immune system, 
intranasal administration of IL-33 induced AHR with goblet cell metaplasia and eosinophil 
infiltration [157, 158]. Moreover, administration of allergens, like HDM, resulted in elevated IL-
33 levels shortly after exposure [159-161]. Functional studies using IL-33 KO, ST2 KO mice or 
recombinant soluble ST2 (r-sST2) demonstrated an attenuation of the HDM-induced allergic 
airway inflammation and AHR, implicating a critical role for the IL-33/ST2 signaling pathway 
during allergen-induced airway inflammation [159, 160, 162, 163]. These data indicate that 
targeting IL-33 could be a new promising therapeutic approach for asthma. Subcutaneous 
vaccination against IL-33 prior to HDM exposure for instance inhibited the HDM-induced airway 
inflammation and AHR in mice [164]. Interestingly, it was recently demonstrated that neutralizing 
IL-33 had the strongest preventive effect on asthma pathology in the mice neonatal period [161]. 
However, some reports demonstrate an IL-33-independent allergic lung inflammation [165-167]. 
In the absence of IL-33 for example, Li and his colleagues observed that the overall severity of the 
HDM-induced allergic airway inflammation was not affected, with the exception of an impaired 
type 2 cytokine production by ILC2 [165]. At the moment, human studies with regard to anti-IL-
33 are ongoing [37, 168]. A recent abstract stated that a human phase I study conducted with anti-
IL-33 antibody (ANB020) in healthy volunteers showed a good tolerability and safety profile, 
supporting the advancement to a phase II clinical trial in severe eosinophilic asthmatics [169].  
Mechanistically, IL-33 signaling can contribute to the pathogenesis of asthma by regulating the 
activity of different immune cells of the innate and adaptive immune system (Figure 10) [140]. 
Lung ILC2 for instance are a primary target, as they rapidly proliferate and produce typical type 2 
cytokines in response to IL-33 [158]. These IL-33-activated ILC2s can be involved in the 
proliferation and differentiation of CD4+ T cells (see chapter 4) [170]. Moreover, also IL-33-
activated DCs can induce the proliferation and differentiation of naïve CD4+ T cells into TH2 cells 
[159, 171, 172]. Of interest, IL-33 can also directly influence ST2-expressing TH2 cells, leading to 
IL-5 and IL-13 production [173, 174]. In addition, also other immune cells that regulate asthma 
pathology, including macrophages, eosinophils, basophils and mast cells, can be influenced by IL-
33 production [140, 147, 175]. For example, IL-33 contributes to the polarization towards 
alternatively activated M2 macrophages, which facilitate type 2 immune responses such as airway 
inflammation [149, 176]. IL-33 also potently enhances eosinophil survival and activation, leading 
the production and degranulation of several inflammatory mediators, responsible for airway 
inflammation [177, 178]. Moreover, IL-33 can also act on basophils and mast cells, regulating their 
adhesion, migration, activation and cytokine production [179-183]. Interestingly, IL-33 can 
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function in an autocrine fashion on structural cells which also express ST2, leading to enhanced 
IL-8 production to sustain airway inflammation [184]. 
 
 
Figure 10: IL-33 regulation of different immune cells involved in the pathogenesis of asthma. In response to IL-
33, different immune cells of the innate and adaptive immune system will release an array of cytokines and chemokines, 
contributing to airway inflammation. 
 
Besides exposure to allergens, also exposure to pollutants, such as DEPs, significantly elevated IL-
33 levels, which was associated with functional DC maturation in vitro [123]. Moreover, increased 
IL-33 production was observed when epithelial cells from severe asthmatics were treated with 
PM [185]. In addition, a critical role for IL-33 was identified during a PM-induced exacerbation in 
a murine model of chronic allergic airway inflammation [186].  
37 
 
Recently, both human and mouse studies suggested that IL-33 also has an important role in the 
pathogenesis of COPD. IL-33 expression was more abundant in peripheral blood and lung tissue 
from COPD versus non-COPD subjects, and correlated with disease severity [187-189]. 
Accordingly, IL-33 and ST2 levels were increased in CS-exposed mice, which was associated with 
a neutrophilic inflammation and release of pro-inflammatory cytokines [190]. Furthermore, IL-33 
was found to be an essential trigger of viral-induced COPD exacerbations by facilitating type I pro-
inflammatory responses via an altered ST2 expression pattern in the lungs of CS-exposed mice 
[189]. Although COPD is typically considered as a neutrophilic-driven airway inflammation, also 
increased eosinophil numbers have been described in patients with COPD [191]. Indeed, it was 
recently demonstrated that plasma IL-33 levels in patients with stable COPD positively correlated 
with the amount of eosinophils [192].  Moreover, the IL-33/ST2 signaling pathway was activated 


































Innate lymphoid cells (ILCs) are important early regulators of tissue homeostasis, immunity and 
inflammation. Although they are morphologically similar to their counterparts of the adaptive 
immune system, i.e. T and B cells, ILCs lack specific rearranged antigen receptors and are therefore 
not controlled in an antigen-specific manner. ILCs reside mainly at barrier surfaces, in peripheral 
tissues such as the lung, intestines and skin. In response to cytokines and inflammatory mediators 
that are released by epithelial, stromal and myeloid cells, they can shape several immune 
responses [194, 195]. Importantly, a low number of ILCs have also been described in secondary 
lymphoid organs, the key site for initiating adaptive immune responses. [196]. In both lymphoid 
and non-lymphoid tissue, ILCs are tissue-resident cells that are locally renewed and expanded in 
response to environmental triggers [197]. 
Analogous with T cells, ILCs are a heterogeneous population which have been classified into three 
subsets, group 1 (ILC1), group 2 (ILC2) and group 3 (ILC3) ILCs, based on their phenotype, 
function and transcriptional regulation (Figure 11) [198, 199]. Importantly, ILCs display a high 
plasticity, meaning that one subset can transdifferentiate into another, allowing them to quickly 
adapt to environmental changes [194, 200]. Similar to B and T cells, all ILCs arise from a common 
lymphoid progenitor (CLP). CLP will then develop into common helper innate lymphoid 
precursors (CHILP), which are characterized by expression of the transcription factor Id2, leading 
to the development of all non-cytotoxic ILC populations. ILCs lack common lineage markers and 
depend on IL-7Rα and the IL-2 receptor common  gamma chain (γc chain) for their development 
and maintenance [201-203].  
Although ILCs are a relatively small population of cells compared with their adaptive 
counterparts, they appear to have an important role by initiating, regulating and resolving 
inflammation [204]. ILCs are implicated in pathogen control and tissue repair in the early phases 
of infection, whereas dysregulation of ILCs can lead to the development of inflammatory diseases. 
As ILCs can promote disease pathogenesis, modulating their function could have therapeutic 
potential in several pathological diseases [194, 202]. For the purpose of this thesis, we will shortly 
discuss the different ILC subsets and subsequently elaborate on their function in lung tissue, 






Figure 11: Classification of innate lymphoid cells. Three subgroups of ILC have been defined based on the expression 
of key transcription factors and cytokines. Group 1 ILC comprise both non-cytotoxic ILC1s and natural killer (NK) cells 
that express T-bet and produce IFN-γ. ILC2s are defined by the expression of GATA-3 and production of typical type 2 
cytokines, such as IL-5 and IL-13. ILC3s are a heterogeneous population including lymphoid tissue inducers (LTi) cells 
as well as cells that are positive or negative for the natural cytotoxicity receptor (NCR). ILC3s are defined by the 




Group 1 ILCs, compromising both non-cytotoxic ILCs and natural killer (NK) cells, are defined as 
cells that are dependent on the transcription factor T-bet for their development and that produce 
IFN-γ in response to IL-12, IL-15 and IL-18 (Figure 11) [198, 199]. Although the development of 
NK cells does not strictly depend on T-bet but also on the transcription factor Eomes, they are still 
categorized as group 1 ILCs as they can rapidly produce large amounts of IFN-γ [205]. While NK 
cells recirculate between the blood and the tissue, ILC1s are presumed to be tissue resident cells 
[206]. Despite some clear developmental differences between NK cells and non-cytotoxic ILC1s, 
they are difficult to distinguish in most tissues as they share many features and their identification 
markers can be modulated under conditions of infection and inflammation [203, 205].  Moreover, 
ILC1s are a considerably heterogeneous population, including a mix of ex-ILC2s and ex-ILC3s 
[207], providing additional challenges to distinguish between the different ILC1 subsets. Besides 
the role of ILC1s in the defence against intracellular pathogens [204],  they are also considered as 
possible disease modulators since increased numbers of ILC1s are observed in several 
inflammatory diseases, including COPD, Crohn’s disease, rheumathoid arthritis, spondyloarthritis, 







ILC2s, initially termed natural helper cells or nuocytes, depend on the transcription factor GATA-
3 and ROR-α for their development and are a potent source of typical type 2 cytokines especially 
IL-5 and IL-13. They rapidly expand and become activated in response to several epithelial-
derived alarmins, including IL-25, IL-33 and TSLP, orchestrating early type 2 immune responses 
at mucosal surfaces (Figure 11) [198, 199].  To date, two ILC2 developmental pathways are being 
proposed, giving rise on the one hand to homeostatic ILC2s (natural ILC2, nILC2), sensitive to IL-
33, and on the other hand IL-25 responsive-inflammatory ILC2s (iILC2) [208]. Under 
inflammatory conditions, ILC2s can also become activated by prostaglandin D2 (PGD2) and 
cysteinyl leukotrienes (CysLTs) [201, 209-211]. Interestingly, ILC2s can also produce large 
amount of IL-9 that in an autocrine fashion potentiates type 2 cytokine production and accounts 
for ILC2s survival by inhibiting apoptosis [201, 212]. Depending on the microenvironment and 
inflammatory stimulus, ILC2s can exert both protective and pathogenic effects. ILC2s can exert 
host-protective functions against helminth infections and promote resolution of inflammation by 
restoring epithelial integrity and promoting tissue repair [201, 202, 204, 213, 214]. In contrast, 
dysregulation of the ILC2 responses can contribute to several inflammatory diseases, such as 
asthma, chronic rhinosinusitis and atopic dermatitis [202, 215]. As a consequence, ILC2s or 
pathways related to ILC2 activation have been suggested to be potential therapeutic targets in 




ILC3s are a heterogeneous population composed of at least three different subtypes, including 
natural cytotoxicity receptor (NCR)-positive ILC3s and NCR-  ILC3s which also include lymphoid 
tissue inducer cells (LTi). ILC3s express the transcription factor RORγT and can produce IL-17A, 
IL-17F and IL-22 in response to IL-23 and IL-1β (Figure 11) [198, 199]. LTi cells are a special 
subset of ILC3s which were initially described as initiators of lymphoid organogenesis. Indeed, 
during fetal development, ILC3s are required for the generation and maturation of secondary 
lymphoid structures, such as lymph nodes and Peyer’s patches. Similarly, ILC3s are important for 
lymphoid tissue formation during adult life, leading to cryptopatches (an aggregate of lymphoid 
cells located in the intestinal lamina propria) and formation of tertiary lymphoid structures, also 
known as isolated lymphoid follicles [216-218]. Considering that LTi are clustered within 
lymphoid tissues, they can orchestrate adaptive immune responses, supporting B cell class 
switching, antibody production and CD4+ T cell modulation [218, 219]. Interestingly, ILC3s are 
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also an important source of GM-CSF, promoting tolerogenic responses to commensal bacteria 
[220]. ILC3s are key regulators of mucosal barrier tissue homeostasis, inducing antimicrobial 
resistance and maintaining the epithelial barrier function by regulating tissue repair [204, 218, 
221]. Alterations of ILC3s are described in a diversity of inflammatory diseases, including 
inflammatory bowel diseases, psoriasis and rheumatoid arthritis [202].  
 
4.2 ILCs in the lung 
 
Although ILCs are a relatively rare population, all three ILC populations are present in human lung 
tissue under homeostatic conditions [194]. In pulmonary diseases however, ILC responses can 
substantially alter, contributing to the pathological processes in the lung [222]. In the next 
sections, we will elaborate on the role of ILCs in asthma and COPD. 
 
4.2.1 ILCs in asthma 
 
4.2.1.1 Activation of ILC2s 
 
In the pathogenesis of asthma, especially the involvement of ILC2s has been explored, as several 
pro-inflammatory cytokines (i.e. IL-25, IL-33 and TSLP) and lipid mediators (CysLTs and PGD2), 
which can activate ILC2s, were elevated in asthmatic airways [125, 126, 223-226]. Moreover, 
polymorphisms in genes encoding TSLP, IL-33, IL-33 receptor, IL-13 and RORα, which are 
implicated in ILC2 development or function, have been associated with asthma susceptibility [16, 
17]. Indeed, in patients with asthma a higher number of total and type 2 cytokine producing ILC2s 
were detected in the sputum, BALF and blood [227-233]. Interestingly, an association between 
activated ILC2s and asthma control status was proposed, as the number of IL-13-producing ILC2s 
rapidly decreased when the patient’s symptoms were under control, suggesting that ILC2s could 
serve as a predictor of asthma control status [231]. Moreover, recent evidence suggests that ILC2s 
could also have an important role in paediatric asthma, as ILC2s could be demonstrated in the 
BALF, induced sputum, and peripheral blood from children with severe therapy-resistant asthma 
[232].  
In murine studies, it is demonstrated that in response to various allergens, ILC2s accumulate in 
the lung and are major producers of IL-5 and IL-13 [234]. The expansion of IL-13-producing ILC2s 
is more profound in response to IL-33, compared to IL-25 [235]. Moreover, epithelial-derived 
TGF-β, which can be activated by IL-33, appears to be essential for ILC2 activation and 
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accumulation in the early allergic responses [236]. Interestingly, an optimal induction of ILC2 
activation and the subsequent inflammatory responses is proposed to depend a coordinated 
response of all epithelial cytokines [237]. Furthermore, in newborn mice, it is demonstrated that 
ILC2s spontaneously accumulate in the developing lung in an IL-33 dependent manner. Early HDM 
exposure can then further increase IL-33, leading to the activation of these ILC2s, promoting early 
life type 2 immunity [161, 238]. Of note, in addition to epithelial-derived cytokines, also mast cell 
mediators, such as PGD2 and LTD4, can drive ILC2 activation [210, 239]. Moreover, basophils can 
promote ILC2 proliferation by secreting IL-4 in response to protease allergens [240] (Figure 12). 
 
4.2.1.2 Role of ILC2s in the initiation of allergic airway inflammation 
 
The functional importance of ILC2s in asthma was first suggested by studies in RAG2 KO mice, as 
even in the absence of an adaptive immune system, ILC2s are able to mediate airway eosinophilia, 
goblet cell metaplasia and AHR in response to allergen inhalation or recombinant IL-33 [157, 158, 
241, 242]. These allergic airway responses are however abrogated in RAG2-/-IL2rg-/- mice that lack 
all ILC populations, and can be restored after adoptive transfer of lung ILC2s, enabling these mice 
to respond to allergen exposure [241, 243]. Moreover, type 2 lung inflammation is also abrogated 
in RORα-deficient mice, which lack specifically the ILC2 population [244, 245].  
ILC2s influence multiple cell types by direct cell contact or indirectly through the secretion of 
soluble cytokines, thereby promoting airway inflammation [246, 247]. Recent data indicate that 
specifically the crosstalk between ILC2s and T cells is crucial for their maintenance, proliferation 
and activation (Figure 12) [248]. ILC2s are found to be required in promoting TH2-cell-mediated 
allergic lung responses, as mice lacking ILC2 have impaired TH2 cell immunity [170, 245, 249]. A 
critical role for DCs is herein suggested, since ILC2-derived IL-13 can promote the migration of 
DCs towards the MLN, leading to TH2 differentiation [170]. Moreover, upon allergen re-challenge, 
this ILC2-DC axis is also required to recruit memory TH2 cells to the inflamed lung tissue [250]. 
Importantly, ILC2s and CD4+ T cells can also directly interact with each other via OX40 and MHCII 
expression on ILC2s, leading to T cell activation [249, 251, 252]. In turn, activated T cells can 
secrete IL-2, promoting ILC2 proliferation and cytokine production [249, 252]. However, in some 
murine models ILC2s are dispensable for the induction of adaptive immune responses. In contrast 
to local antigen exposure, systemic priming with ovalbumin for instance did not require the 
presence of ILC2s for the induction of TH2-driven lung inflammation [245]. Moreover, during 
HDM-driven allergic airway inflammation, T cell activation precedes ILC2 induction [165]. In 
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addition to the effects on T cell function, ILC2s can also promote the activation of eosinophils, 
alternatively activated macrophages and B cells [245, 253, 254].  
 
 
Figure 12: Crosstalk of ILC2s with cells of the innate and adaptive immune system. ILC2s can interact with other 
effector immune cells by direct cell contact or through the secretion of soluble mediators.  
As previously stated, in addition to allergens, also non-allergic factors, such as air pollutants, can 
initiate and exacerbate the pathogenesis of asthma [60]. To date, ILC2s have been shown to 
mediate ozone-induced airway inflammation and AHR [255, 256]. 
 
4.2.1.3 Role of ILC2s in the persistence of allergic airway inflammation  
 
Besides the role of ILC2s in the initiation of allergic airway inflammation, also the persistence of 
several asthmatic features, including lung inflammation, AHR and remodelling, can depend on 
ILC2s. Critical feedback mechanisms between epithelial cells and ILC2s for instance generate 
mechanisms for sustained IL-33 production, leading to a chronic airway inflammation [151]. 
Moreover, memory-like properties of lung ILC2s are recently demonstrated, as some ILC2s persist 
long after the resolution of allergen-mediated airway inflammation and respond more vigorously 
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upon reactivation compared to naïve ILC2s [257]. In asthmatics, type 2 inflammation can be 
sustained by ILC2-derived IL-13 which disrupt the integrity of the bronchial epithelium by 
targeting the tight junctions [258]. 
 
4.2.1.3 Suppression of ILC2s 
 
Importantly, ILC2 function can be suppressed by soluble mediators or direct cell contact. Type I 
interferons (IFN), type II IFNs and IL-27 can counter the proliferation and activation of ILC2s in a 
STAT1-dependent manner [259]. Furthermore, IFN-γ can suppress the IL-9 production of ILC2s 
in a T-bet-dependent fashion, inhibiting ILC2s survival [260]. Moreover, suppressive effects have 
been attributed to regulatory T (Tregs) cells. IL-10 for instance, produced by elevated Treg 
numbers in response to IL-2 release by IL-33 stimulated mast cells, can inactivate ILC2s and IL-
33- or papain-induced airway inflammation [243]. Moreover, the suppressive effects of Tregs on 
ILC2 activity can also be mediated through ICOS-ICOSL cell contact or TGF-β-signaling [261, 262] 
(Figure 10). Lastly, some eicosanoids, which are derived from arachidonic-acid, can negatively 
regulate ILC2 function. Prostaglandin I2 (PGI2) for example exerts predominantly anti-
inflammatory effects, leading to an inhibition of ILC2 function. Administration of a PGI2 analog 
(cicoprost) inhibits IL-33-induced ILC2 proliferation in mice and decreases type 2 cytokine 
production in humans [263]. Moreover, also lipoxin A4 (LXA4) functions as a negative regulator 
of ILC2s, inhibiting their type 2 cytokine production [264].  
 
4.2.1.4 ILC2s as therapeutic targets 
 
Considering the growing evidence on the importance of ILC2s in asthma pathogenesis, ILC2s or 
ILC2-releated pathways are considered as potential therapeutic targets [202]. By targeting lipid 
mediators and their receptors for instance, ILC2 function can be modulated [194, 202, 215]. 
Prostaglandin D2 receptor (CRTH2) or leukotriene receptor antagonists (montelukast) can 
reduce eosinophilic airway inflammation, improve lung function or prevent ILC2 activation 
respectively [265-267]. Moreover, strategies that negative regulate ILC2 function, such as LXA4, 
PGI2 and Tregs, could be employed to inhibit ILC2-driven inflammatory responses [263, 264, 
268]. As severe asthmatics can have a LXA4 deficiency [269], LXA4 supplementation could be 
beneficial for these patients. Intriguingly, in severe non-allergic eosinophilic asthma, which is 
often insensitive to corticosteroid treatment and is associated with exposure to air pollutants, 
microbes and glycolipids, the hypothesis was raised that especially ILC2s will be of interest, rather 
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than TH2 immune cells [270]. Although there is still some controversy, it is indeed suggested that 
ILC2s are insensitive to steroids, as ILC2s numbers were still increased in the airways of severe 
asthmatics despite high doses of oral corticosteroids [230]. Drugs that target TSLP or STAT5 have 
been proposed to overcome the resistance to corticosteroid treatment [271]. Interestingly, in a 
phase II clinical trial, anti-TSLP was recently demonstrated to be very effective in severe 
uncontrolled asthmatics, leading to significant fewer asthma exacerbations compared to placebo 
[50]. Strategies that target TSLP and other epithelial-derived cytokines, i.e. IL-25 and IL-33, need 
further investigation [194, 202, 215] and combinatorial blockage of all epithelial-cytokines may 
be necessary to effectively inhibit ILC2-mediated lung inflammation [272]. Lastly, as described 
earlier (see chapter 1.2.3), blocking downstream cytokines, such as IL-5, has proven to be 
therapeutically effective in the treatment of severe eosinophilic asthma [45].  Further studies are 
however required to elucidate the direct effects of these treatments on ILC2s since they can also 
target other inflammatory cells.  
 
4.2.1.5 Other ILC subsets in asthma 
 
Emerging studies have unravelled a possible association between asthma and the presence of 
ILC3s. In severe asthmatics, an increased amount of IL-17-expressing ILC3s was found in the BALF 
compared to mild asthmatics and healthy volunteers [273]. Moreover, IL-17-expressing ILC3s 
were increased in paediatric severe therapy resistant asthma [274]. In a murine study, IL-22-
producing ILC3s were proposed to modulate allergic responses in the lung, limiting airway 
inflammation and contributing to the maintenance of homeostasis [275]. Whereas for the moment 
no data are available concerning non-cytotoxic ILC1s in the pathogenesis of asthma, the role of NK 
cells has been better studied [276]. It was for instance suggested that NK cells could be critical for 
the development of allergen-induced AHR [277].   
 
4.2.2 ILC in COPD 
 
To date, limited studies are performed to assess the abundance and functions of ILCs in COPD. In 
GOLD stage IV patients, a lower amount of ILC2s were detected, whereas significantly more ILC1s 
and ILC3s were present compared to healthy subjects or patients with less-severe COPD (GOLD I 
and II). It was here suggested that the decrease in ILC2s was due to the transdifferentiation into 
ILC1s [278]. Moreover, the augmented ILC1 responses correlated with disease severity and 
susceptibility to exacerbations [279]. In accordance, CS silences murine ILC2 function, which 
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facilitated an exaggerated type 1 anti-viral response, leading to exacerbating disease [189]. 
Recently, ILC3s were detected in inflammatory aggregates in lungs of smokers and COPD patients, 














CHAPTER 5: TRANSLATIONAL RESEARCH – 






5.1 Translational Research 
 
Translational research refers to the process of applying discoveries generated through laboratory 
research into the development of new drugs and treatments which will be tested in clinical trials 
(from bench to bedside) (Figure 13). Applying the obtained findings into medical practice is the 
ultimate goal of translational research.  
 
 
Figure 13: Translational Research. The translation of laboratory discoveries to the clinic (bench to bedside) and new 
therapies applying to clinical practice, populations based studies (bedside to community).  
 
In our lab, we have optimized 3 different approaches, which will be discussed in detail in this 
thesis, to elucidate several research questions. In basic research, murine models are a valuable 
tool to test hypotheses and give more insights into the molecular and cellular mechanisms. 
Considering that murine models of asthma closely mimic important features of the disease, such 
as airway inflammation, remodeling and hyperresponsiveness, they are often employed in asthma 
research. Availability of genetic manipulated mouse strains allows researchers to investigate the 
involvement of specific genes or molecules in vivo. Moreover, mice are relatively easily bred, 
housed and handled which make them an ideal in vivo research model. Although the mouse 
genome is completely sequenced and is highly homologue with the human genome, there are 
several limitations that have to be taken into account when working with animal models. 
Especially the differences in the respiratory anatomy, physiology and immune system could have 
implications on the outcome, making the translation of murine findings to the human disease 
difficult [23]. Moreover, ethical concerns are being raised towards animal experimentation. 
Therefore, in addition to our murine model, an in vitro approach with primary human bronchial 
epithelial cell (HBEC) cultures can be employed. These in vitro cell cultures allow to investigate 
specific mechanisms of action concerning the human epithelium. It has to be acknowledged 
however that observations made in these in vitro settings could differ from the in vivo situation, 
since these cells grow in an artificial milieu without cell to cell interactions which differs from 
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what they encounter in an in vivo situation. In a third approach, knowledge that has been obtained 
in basic research can be validated on ex vivo human lung samples from patients. These samples 
can be used to characterize different human cell populations and study gene and protein 
expression. 
In this thesis, we are interested in the aggravating effects of DEPs on allergic airway inflammation. 
Therefore, we have optimized an in vivo murine model where DEPs were given simultaneously 
with a clinical relevant allergen, house dust mite (HDM) (see 5.2.2). Moreover, to characterize the 
recently described innate lymphoid cells populations in human lung, we have used ex vivo human 
lung samples from patients with COPD, smokers without airflow limitation and never smokers 




 5.2 Murine models 
 
5.2.1 Murine model of acute DEPs exposure 
 
To investigate the mechanisms of DEPs on the respiratory system, Provoost S et al. established an 
acute DEPs model in our lab wherein the acute effects of DEPs on the innate immune responses 
are closely mimicked. DEPs (SRM 2975) were purchased from the National Institute for Standards 
and Technology (NIST, Gaithersburg, MD) and suspended in saline containing 0,05% tween 80. 
Ketamine/xylazine anaesthetized mice are intratracheally instilled with saline or 100µg DEPs in 
a 50µL volume on day 1, 4 and 7. On day 9, the inflammatory mediator release and cell recruitment 
are assessed. Tween 80 (0.05%) was used as a vehicle in all conditions [94].  
 
5.2.2 Murine model of DEPs-enhanced allergic airway inflammation 
 
To unravel the mechanisms underlying the enhanced effects of DEPs on allergic airway 
inflammation, a clinical relevant combination model of DEPs with HDM was developed. HDM 
(Dermatophagoides pteronyssinus) was obtained from Greer laboratories (Lenoir,NC). This 
DEPs+HDM combination model was developed from hands-on experience with an in-house 
CS+HDM that had been established earlier [281]. First of all, dose titration experiments were 
performed since the enhancing capacity of DEPs on allergic airway inflammation can no longer be 
observed when mice are exposed to too high or low doses of both DEPs and HDM [96, 98]. 
Ultimately, intranasal application of saline, 25µg DEPs, 1µg HDM dissolved in saline and combined 
DEPs+HDM is performed in isoflurane anaesthetized mice by using a continuous flow vaporizer 
on day 1, 8 and 15. Experimental endpoints are performed on day 17. Tween 80 (0.05%) was used 
as a vehicle in all conditions. 
 
5.2.3 Endpoints and analyses 
 
48 hours after the last exposure, mice are anaesthetized for lung function measurements or 
sacrificed with a lethal dose of intraperitoneal (IP) pentobarbital. Murine blood, brochoalveolar 
lavage fluid (BALF), lung tissue and mediastinal lymph nodes (MLN) are collected to assess the 
inflammatory responses (Figure 14). All in vivo manipulations were approved by the local ethical 





Figure 14: Overview experimental techniques on DEPs+HDM exposed mice. C57BL/6 mice are intranassaly 
instilled with DEPs+HDM on day 1, 8 and 15. 2 days later endpoints are performed to examine the airway responses. 
Bronchoalveolar lavage is assessed by cytospin and FACS analyses. The airway hyperresponsiveness is evaluated with 
the forced oscillation technique. Cytokine responses are analyzed in the lungs and lymph nodes that are restimulated 
with HDM in vitro. The inflammatory responses in the lung are also analyzed with FACS and RNA extraction is performed 
to perform RT-PCR. Moreover, peribronchial eosinophils and goblet cells are detected by histological analyses.  
 
5.2.3.1 Lung function measurements 
 
Lung function measurements are assessed using the forced oscillation technique (Flexivent 
system, SCIREQ, Montreal, QC, Canada) (Figure 15). Airway hyperresponsiveness (AHR) is 
assessed in mice using carbachol, which provokes bronchoconstriction by directly activating the 
airway smooth muscle cells. In brief, neuromuscular blockade is induced by intravenously (IV) 
injecting pancuronium bromide (1mg/kg) to anaesthetized and tracheostomized mice. The 
airway resistance of the whole respiratory system (airways, lungs and chest wall) is measured 
during a “snapshot perturbation” manoeuvre, while mice are challenged with increasing doses of 
carbachol (0-640 µg/kg). For each concentration, 12 “snapshot perturbations” are performed and 




Figure 15: Flexivent system for lung function measurements. 
 
5.2.3.2 Bronchoalveolar lavage fluid (BALF) 
 
Inflammatory cells from the bronchial and alveolar spaces of the lung are withdrawn by 
performing a bronchoalveolar lavage (BAL). Therefore, a tracheal cannula is inserted and a salt 
solution is gently instilled and withdrawn. The cell-free supernatants are stored to assess 
cytokines by ELISA (see 5.2.3.7). The cell pellet is used for flow cytometric analyses (see 5.2.3.3) 
and cell differentiation on a cytospin using a May-Grünwald Giemsa staining. The use of cytospins 
allows discrimination of monocytes/macrophages, neutrophils, eosinophils and lymphocytes 






Figure 16: Cytospins of bronchoalveolar lavage cells stained with May-Grünwald Giemsa. Representative 
photomicrographs of BALF cells of A) saline, B) DEPs, C) HDM or D) DEPs+HDM-exposed mice.                                                               
1= monocyte/macrophage, 2= neutrophil, 3= eosinophil, 4 = lymphocyte.  
 
5.2.3.3 Flow cytometry 
 
BALF cells and single cell suspensions from the major lobe of the right lung are used for flow 
cytometry. This technique allows the characterization of multiple cell types based on the 
combination of specific surface and intracellular markers. Therefore, antibodies conjugated to 
different fluorescent dyes are used. Excitation of these fluorescent dyes by a laser will transmit 
characteristic emission spectra which will be measured by the flow cytometer. The cells that are 

















Figure 17: Gating strategy inflammatory cells in mice (lung tissue). Representative dot plots of WT mice that were 
exposed to combined DEPs+HDM. A) Selection of single cells, Fixable Viability Dye (FVD) negative cells and CD45+cells 
was made for all cell types. B) DCs were identified as CD11c+, Siglec-F-, MHCII+ and CD11b+. Eosinophils were 
characterized as CD11c-; CD11b+ and Siglec-F+. Neutrophils were gated as CD11c-, CD11b+, Ly6G+ and Ly6C+. Monocytes 
were CD11c-, CD11b+, Ly6G- and Ly6C+. C) T lymphocytes were identified as CD3+ cells. A distinction was made between 
CD4+ and CD8+ T cells. CD69 was used as an activation marker. Intracellular IL-5 and IL-13 in CD4+ T cells was 
investigated. D) Innate lymphoid cells (ILC) type 2 were characterized as Lin- (CD3, CD5, TCRβ, NK1.1, CD11c, CD11b 




5.2.3.4 Mediastinal lymph node (MLN) culture 
 
MLN single cell suspensions are cultured in vitro to assess the cytokine expression within the 
draining lymph nodes. Therefore, 200.000 cells/well are cultured in 96 well plates, either alone 
or supplemented with 3.75µg/well HDM. After 5 days in a humidified 37°C incubator and 5% CO2 
atmosphere, supernatant is harvested for cytokine measurements with ELISA (see 5.2.3.7). 
  
5.2.3.5 Histological evaluation 
 
To quantify peribronchial eosinophils and goblet cell metaplasia, paraffin sections of the left lung 
are subjected to a chemical staining, Congo Red and Periodic acid-Schiff (PAS) respectively. 
Quantitative measurements are performed in a blinded fashion on a Zeiss Axioimager running 
Axiovision software. Periobronchial eosinophils are determined as the total number per mm2 
bronchial wall area (WAt), whereas PAS-positive cells are expressed per millimeter perimeter of 
the basement membrane (Pbm) (Figure 18).  Airways with a basement membrane < 800 µm or > 
2000 µm are excluded. Measurements from at least 10 airways per mouse are performed. 
 
Figure 18: Quantification of peribronchial eosinophils and goblet cell metaplasia. Representative 
photomicrographs of A) congo and B) PAS stained lungs of DEPs+HDM-exposed mice. WAt = total bronchial wall area, 








Quantitative real time polymerase chain reaction (qRT-PCR) is a powerful tool to quantify gene 
expression profiles. Briefly, lung mRNA is extracted using the miRNeasy Mini kit (Qiagen) and 
cDNA is prepared with the Transcriptor Universal cDNA Master kit (Roche) following the 
manufacturer’s instructions. The gene of interest relative to housekeeping genes is analysed using 
Taqman Gene Expression Assays (Life Technologies). qRT-PCR is performed on a LightCycler 96 




Enzyme-linked Immunosorbent Assay (ELISA) is an effective method which allows the 
quantification of proteins in serum, lung homogenate, BALF and MLN supernatants. 
Immunoglobulin levels are determined on serum collected by retro-orbital bleeding. Total IgE is 
measured using LO-ME-3 coated plates and biotinylated polyclonal rabbit anti-mouse IgE (S. 
Florquin, Universite´ libre de Bruxelles). For detection of HDM-specific IgG1, plates are coated 
with 25µg/ml HDM extract. Serum is added, followed by a horseradish peroxidise (HRP)–
conjugated polyclonal goat anti-mouse IgG1 antibody (Bethyl Laboratories, Montgomery, Tex). Ig 
levels are reported in optical densities (ODs). Other ELISAs performed in this thesis are 





5.3 Human Studies  
 
5.3.1 Human lung tissue 
 
Lung tissue is obtained from patients who undergo a surgical lung resection at Ghent University 
Hospital for solitary pulmonary tumours. Patients are excluded from the study when a treatment 
with neo-adjuvant chemotherapy, recent COPD exacerbation or pulmonary infection occurred. 
COPD diagnosis and severity was defined using pre-operative spirometry according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) classification [52]. Written informed 
consents were obtained from all subjects, according to the protocol approved by the medical 
ethical committee of Ghent University Hospital. 
Tissue is collected by a pathologist at maximum distance from the lung lesion, showing no signs 
of retro-obstructive pneumonia or tumour invasion. Single cell suspension (Figure 19) is prepared 
for flow cytometric analyses (see 5.1.3.3).  
 
Figure 19: Protocol for the characterization of innate lymphoid cells in human lung tissue. Lung tissue is collected 
by a pathologist from patients who underwent a lobectomy. The lung tissue is cut into fine pieces and digested for 45 
minutes at 37°C in digestion medium. Cells are resuspended in EDTA and filtered through a 40-μm cell strainer. 
Mononuclear cells are isolated using a ficoll gradient and subjected to red blood cell lysis. These cells are then 
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Asthma is a prevalent disorder of the conducting airways with a high socio-economic impact. 
Besides a genetic predisposition, also environmental exposures are important determining 
factors in the development of asthma. Multiple epidemiological and experimental studies 
provided evidence that inhalation of air pollutants greatly contributes to the induction as well as 
exacerbation of asthma. The underlying mechanisms remain however largely unknown. 
Considering that the current treatment options are predominantly symptomatic, novel treatments 
and therefore a better understanding in the asthma pathogenesis are urgently needed. 
In a first part, we focused on the role of the airway epithelium in pollutant-induced airway 
inflammation, and more specifically investigated some specific epithelial-derived mediators, i.e. 
chemerin and IL-33.  
 From our previous work it was clear that there is an important role for dendritic cells 
(DCs) at the frontline of diesel exhaust particles (DEPs)-modulated immune 
responses. The recruitment of these DCs towards the pulmonary tissue is regulated by 
diverse chemokine/cytokine interactions wherein the airway epithelium plays an 
important role. As chemerin, an epithelial-derived chemokine, induces cell chemotaxis 
of ChemR23 expressing cells, i.e. DCs and monocytes, towards the site of inflammation, 
we hypothesized that chemerin/chemR23 signaling is involved in pollutant-
induced inflammatory lung responses. For this purpose, both the acute 
inflammatory effects of DEPs exposure and the enhancing effects of DEPs on allergic 
airway inflammation were evaluated in ChemR23 KO mice (Chapter 7).  
 Inhalation of both DEPs and house dust mite (HDM) stimulates the airway epithelium 
to induce the production of innate pro-type2 cytokines, including IL-33. This IL-33 
release is implicated in allergic airway inflammation as well as in functional DC 
maturation towards sole DEPs exposure. Hence, we hypothesized that IL-33/ST2 
signaling is crucial in DEPs-enhanced allergic airway inflammation. To examine 
this, a recombinant decoy receptor (r-sST2) that neutralizes IL-33 activity was 
administrated to mice that were exposed to combined DEPs+HDM (Chapter 8).  
 
In a second part, we were interested in the contribution of ILCs in pollutant-aggravated 
inflammatory lung responses 
 Allergic asthma is typically considered as a TH2-mediated disease. For many allergens 
an important contribution of ILC2s in allergic airway inflammation has been identified. 
Because DEPs aggravate the allergic airway inflammation, we hypothesized a role 
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for ILC2s in DEPs-enhanced allergic airway inflammation. In a first step, we 
investigated the presence and activation of ILC2s upon combined DEPs+HDM 
exposure. In a second step, we investigated whether the DEPs-enhanced responses 
were dependent on a GATA-3-mediated activation. Finally, the contribution of both 
ILC2s and TH2 cells was evaluated in RAG2 KO and ILC2-deficient mice (Chapter 9).  
 ILCs have been extensively studied over the years, as dysregulation of these cells can 
lead to the development of several inflammatory diseases. Whereas human ILC 
subsets have been predominantly studied in the intestines or skin, limited data was 
available concerning ILCs in the human respiratory system. We hypothesized that all 
ILC subsets are present in human lung tissue and altered during lung pathology. 
We first analysed the different ILC subsets in human lung tissue based on specific 
surface markers, transcriptional expression and cytokine production. Next, we tried to 

















CHAPTER 7: PRO- AND ANTI-INFLAMMATORY ROLE OF 
CHEMR23 SIGNALING IN POLLUTANT-INDUCED 
INFLAMMATORY LUNG RESPONSES 
 
Chemerin is an epithelial-derived chemokine that attracts ChemR23 expressing cells (i.e. monocytes, 
macrophages and DCs) to the site of inflammation. The role of the chemerin/chemR23 axis during 
respiratory diseases is however quite controversial. A pro-inflammatory role for ChemR23 signaling 
in response to cigarette smoke was already clearly demonstrated, whereas anti-inflammatory 
properties were observed during allergen exposure. In this study, we aimed to investigate the 
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Rationale: Inhalation of traffic-related particulate matter (such as diesel exhaust particles, ‘DEP’) 
is associated with acute inflammatory responses in the lung and promotes the development and 
aggravation of allergic airway diseases. We previously demonstrated that exposure to DEP was 
associated with increased recruitment and maturation of monocytes and conventional dendritic 
cells (DC), resulting in TH2 polarization. Monocytes and immature DC express the G-protein 
coupled receptor chemR23, which binds the chemoattractant chemerin.  
Methods: Using chemR23 knockout (KO) and corresponding wild-type (WT) mice, we determined 
the role of chemR23 signaling 1) in response to acute exposure to DEP and 2) in response to DEP-
enhanced house dust mite (HDM)-induced allergic airway inflammation.  
Results: Exposure to DEP alone, as well as combined exposure to DEP + HDM, elevated the levels 
of chemerin in the bronchoalveolar lavage fluid of WT mice. In response to acute exposure to DEP, 
monocytes and monocyte-derived DC accumulated in the lungs of WT mice but this response was 
significantly attenuated in chemR23 KO mice. Concomitant exposure to DEP + HDM resulted in 
allergic airway inflammation with increased eosinophilia, goblet cell metaplasia and TH2 cytokine 
production in WT mice, which was further enhanced in chemR23 KO mice.  
Conclusion: In conclusion, we demonstrated an opposing role for chemR23 signaling depending 
on the context of DEP-induced inflammation: the chemR23 axis showed pro-inflammatory 
properties in a model of DEP-induced acute lung inflammation, in contrast to anti-inflammatory 





It is well accepted that inhalation of traffic-related particulate matter, of which diesel exhaust 
particles (DEP) are a main component, is associated with acute inflammatory responses in the 
lung. In addition, traffic-related particulate matter can contribute to new-onset asthma as well as 
to exacerbations of pre-existing asthma [60]. Experimental studies in mice showed that exposure 
to DEP can enhance allergic airway responses, including eosinophilia, goblet cell metaplasia and 
TH2 production [23]. In addition, in controlled human exposure studies, combined DEP + allergen 
exposure increased allergen-specific immunoglobulin levels and induced a TH2 cytokine pattern 
[23, 100]. The mechanistic basis of the inflammatory response in the lung to DEP inhalation as 
well as the adjuvant response to DEP on allergen-induced airway inflammation remain 
incompletely known.  
Using a mouse model of DEP-induced acute lung inflammation, we previously demonstrated that 
exposure to DEP was associated with increased expression of pro-inflammatory 
cytokines/chemokines and with the accumulation of neutrophils and monocytes in lung tissue 
[91]. Furthermore, we showed that DEP had a great impact on the biology of conventional 
dendritic cells (DC) [94], which are crucial in the induction of asthma. We demonstrated that 
exposure to DEP induced the recruitment of monocytes and DC towards the lung via the G-protein 
coupled receptors CCR2 and CCR6, increased DC maturation and enhanced DC-induced allergen 
transport towards the draining lymph nodes, resulting in TH2 polarization. This modulation of DC 
function could be the mechanistic basis underlying DEP-enhanced allergic airway responses [94, 
95]. 
ChemR23 (also known as chemokine-like receptor 1, CMKLR1) is a seven-transmembrane G-
protein coupled receptor that is expressed on monocytes, macrophages, natural killer cells, 
conventional and plasmacytoid DC in humans and mice [128, 282, 283]. Its ligand, chemerin, is 
secreted as a weakly active precursor protein (i.e. prochemerin) that is converted into bioactive 
chemerin by proteolytic cleavage of its C-terminal [284]. This maturation step is mediated by 
extracellular proteases released by activated macrophages, mast cells and neutrophils [129, 285, 
286]. In addition to chemerin, resolvin E1 (RvE1, an anti-inflammatory lipid, derived from the 
omega-3 fatty acid eicosapentaenoic acid) is reported as a second putative ligand of chemR23 
[134]. 
Intriguingly, the role of the chemerin/chemR23 axis in inflammation is controversial and seems 
to have pro- and anti-inflammatory properties depending on the model that is investigated. 
Previous work from our lab demonstrated that exposure to cigarette smoke was associated with 
increased chemerin levels in the bronchoalveolar lavage fluid (BALF). Moreover, chemR23 
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knockout (KO) mice were almost completely protected against cigarette smoke-induced lung 
inflammation [120]. In contrast to this pro-inflammatory role of chemR23 signaling in response 
to cigarette smoke, chemR23 KO mice showed an increased inflammatory response in a LPS-
induced model of acute lung injury [131] and were more susceptible to viral pneumonia [136]. In 
addition, intranasal administration of exogenous chemerin was associated with attenuated 
allergic airway inflammation and airway hyperresponsiveness [121]. 
Here, we studied the role of chemR23 signaling in the context of DEP-induced lung responses. 
First, we examined the chemR23 axis in the murine model of DEP-induced lung inflammation. 
Next, we investigated the contribution of chemR23 signaling to the adjuvant capacity of DEP in 
enhancing allergic airway inflammation, using a model of concomitant exposure to DEP and a 
clinically relevant allergen (i.e. house dust mite, HDM). We demonstrated that the functional role 
of chemR23 signaling is dependent upon the background inflammatory conditions, which explains 




MATERIAL AND METHODS 
 
Animals 
Female C57BL/6 mice (6-8 weeks old) were purchased from Harlan. Female ChemR23 KO mice 
(6-9 weeks old) and corresponding C57BL/6 WT mice (6-9 weeks old) were obtained from 
Deltagen and bred in our animalarium. All in vivo manipulations were reviewed and approved by 
our local ethical committee (Animal Ethical Committee of the Faculty of Medicine and Health 
Sciences, Ghent University, Ghent, Belgium).  
 
DEP and HDM administrations  
DEP (SRM 2975) was obtained from the National Institute for Standards and Technology. For the 
mouse model of DEP-induced acute lung inflammation, DEP were suspended in saline (B. Braun 
Melsungen) containing 0.05% Tween 80 (Invitrogen). Mice were anesthetized with an 
intraperitoneal ketamine/xylazine injection (Ketamine 1000 CEVA (70 mg/kg), Ceva Sante 
Animale; Rompun 2% (7 mg/kg), Bayer) prior to instillation. The anesthetized mice were 
intratracheally instilled with 50 µl saline or DEP solution (i.e. 100 µg) on day 1, 4 and 7. On day 9, 
the animals were sacrificed by a lethal dose of intraperitoneal pentobarbital (Ceva Sante Animale) 
(4-6). For the mouse model of DEP-enhanced allergic airway inflammation, HDM 
(Dermatophagoides pteronyssinus; Greer Laboratories) was suspended in saline. Mice were 
anesthetized with isoflurane (Abbott Laboratories) prior to instillation. The anesthetized mice 
were intranasally instilled with 50 µl saline, DEP (i.e. 25 µg), HDM (i.e. 1 µg) or combined DEP plus 
HDM solution on day 1, 8 and 15. On day 17, the animals were sacrificed by a lethal dose of 
intraperitoneal pentobarbital (Ceva Sante Animale). Tween 80 (0.05%) was used as a vehicle in 
both murine models and in all conditions. 
 
BALF 
A tracheal cannula was inserted and BALF was recovered by instillation of 3 x 300 µl HBSS w/o 
Ca2+ or Mg2+ (BioWittaker) supplemented with 1 % BSA (for cytokine and chemokine 
measurements; Sigma-Aldrich) and 6 x 500 µl HBSS w/o Ca2+ or Mg2+ supplemented with 0.6 
mM sodium EDTA (Sigma-Aldrich). The lavage fractions were pooled and total cell counts were 
performed using a Bürcker chamber (Brand GMBH). 
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Lung and mediastinal LN single cell suspensions 
Pulmonary circulation was rinsed with saline, supplemented with EDTA, to remove the 
intravascular pool of cells. Lungs or mediastinal LN were minced and incubated in digestion 
medium (RPMI 1640 supplemented with 5% FCS, 2 mM L-glutamine, 0.05 mM 2-
mercaptomethanol (all Invitrogen), 100 U/ml penicillin - 100 µg/ml streptomycin (Sigma-
Aldrich), 1 mg/ml collagenase type 2 (Worthington Biochemical) and 0.02 mg/ml DNase I (grade 
II from bovine pancreas; Boehringer Ingelheim)) for 45 minutes at 37°C and 5% CO2. Red blood 
cells were lysed using ammonium chloride buffer. Cell counting was performed with a Z2TM 
coulter counter (Beckman Coulter). 
 
Flow cytometry 
All staining procedures were performed in PBS w/o Ca2+ or Mg2+ containing 5 mM EDTA and 1% 
BSA. To minimize non-specific bindings, BALF cells and lung single cell suspensions were 
incubated with anti-CD16/CD32 (clone 2.4G2). Cells were labeled with combinations of CD11c 
(HL3), MHCII (2G9), CD11b (M1/70), Ly6C (AL-21), Ly6G (1A8), Siglec-F (e50-2440), CD4 
(GK1.5), CD8 (53-6.7), CD69 (H1.2F3), CD3 (145-2C11) (all BD Biosciences). Data acquisition was 
performed on a FACSCaliburTM flow cytometer running CELLQuestTM software or on a 
LSRFortessaTM cell analyser running FACSDivaTM software (BD Biosciences). FlowJo software 
was used for data analysis. 
 
Cell culture 
Mediastinal LN cells were cultured in culture medium (RPMI 1640 supplemented with 10% FCS, 
2 mM L-glutamine, 0.05 mM 2-mercaptomethanol (all Invitrogen), 100 U/ml penicillin - 100 
µg/ml streptomycin (Sigma-Aldrich)) either alone or supplemented with 3.75 µg/well HDM in 
round bottom 96-well plates, and incubated in a humidified 37°C incubator with 5% CO2. After 5 








Lungs were fixed in 4% paraformaldehyde and embedded in paraffin (Klinipath). 3 µm transversal 
sections were cut, treated with Ultra V Block (Thermo Scientific) and incubated with polyclonal 
anti-mouse chemerin antibody (R&D Systems). The goat HRP-Polymer Kit (Biocare Medical) and 
diaminobenzidine (DakoCytomation) were used for detection. Prochemerin staining was 
quantified within the airway epithelium in a marked area between the airway lumen and the 
basement membrane, using KS400 Software (Zeiss) [120]. The area with positive staining for 
prochemerin was normalized to the basement membrane perimenter (Pbm) (nomenclature 
described in [287]). All airways with Pbm >2000 µm were excluded. For the visualisation of 
eosinophils or goblet cells, lungs were stained with Congo-Red or Periodic Acid Schiff (Klinipath). 




Chemerin, CCL2, CCL20, interleukin (IL)-4, IL-5 and IL-13 levels in BALF or mediastinal LN culture 
supernatant were measured using commercially available ELISA kits (R&D Systems). Ig were 
determined on serum that was collected by retro-orbital bleeding. Total IgE was measured using 
coated plates and biotinylated polyclonal rabbit anti-mouse IgE (S. Florquin, Université libre de 
Bruxelles). For detection of HDM-specific IgG1, plates were coated with HDM extract. Serum was 
added, followed by a HRP-conjugated polyclonal goat anti-mouse IgG antibody (Bethyl 
Laboratories). Ig values were reported in optical densities (OD). 
 
RT-PCR 
Hematopoietic (CD45+) cells and non-hematopoietic (CD45-) lung cells were sorted using an 
OctoMACS separator and CD45 MicroBeads (according to manufacturer’s instructions; Miltenyi 
Biotec). The sorted populations showed >95 % purity (data not shown). Next, RNA extraction was 
performed (miRNeasy Mini Kit; Qiagen) and cDNA (Transcriptor First Strand cDNA synthesis kit; 
Roche Diagnostics) was obtained following manufacturer’s instructions. SYBR Green-based RT-
PCR reactions (LightCycler 480 SYBR Green I Master; Roche) were performed using a LightCycler 
96 system (Roche). Chemerin primer sequences were previously described in (15). Data was 
processed using the standard curve method. Expression of chemerin mRNA was normalized based 




Statistical analysis was performed with SPSS, version 22.0. Groups were compared using 
nonparametric tests (Kruskall-Wallis and Mann-Whitney U) according to standard statistical 






Role of chemR23 signaling in a model of DEP-induced lung inflammation 
Chemerin levels in BALF are increased in WT mice exposed to DEP 
We previously identified airway epithelial cells as the major source of (pro)-chemerin in lung 
tissue [120]. To examine the localisation and expression of (pro)-chemerin in response the DEP, 
we exposed WT mice to saline or DEP (experimental protocol in Fig. 1A), sorted hematopoietic 
(CD45+) versus structural non-hematopoietic (CD45-) cells from lung tissue, and examined the 
chemerin mRNA expression. Chemerin was mainly expressed in the CD45- cell population, 
whereas minimal chemerin mRNA expression was observed in the CD45+ cell population. 
Chemerin mRNA expression in CD45- cells significantly increased in response to exposure to DEP 
(Fig. 1B). Using immunohistochemistry, we confirmed that the epithelium was the predominant 
source of (pro)chemerin in the lung. We quantified the (pro)chemerin staining and observed that 
exposure to DEP was associated with decreased (pro)chemerin staining in the epithelium when 
compared to control mice (Fig. 1C). To assess whether this was due to increased secretion, we 
determined (pro)chemerin levels in BALF using ELISA, and found that exposure to DEP elevated 
the secreted levels of (pro)chemerin (Fig. 1D). RvE1 is a second putative ligand of chemR23 [134]. 
Using ELISA, we assessed the RvE1 levels in the BALF and found that these were decreased in 
response to DEP exposure (Fig 1E). 
 
ChemR23 is required for DEP-induced monocyte and alveolar DC recruitment 
Chemerin/chemR23 signaling can mediate the recruitment of monocytes and (immature) DC 
[284]. To assess the contribution of the chemR23 pathway to the accumulation of monocytes and 
DC in response to DEP, we exposed WT and chemR23 KO mice to saline or DEP. Upon exposure to 
DEP, the number of total BALF cells increased in WT mice. This increase was smaller in chemR23 
KO mice (Fig. 2A). Exposure to DEP was associated with an accumulation of monocytes in the 
BALF and lung, and monocyte-derived DC in lung of WT mice, which was severely reduced or 
absent in chemR23 KO mice (Fig. 2B-D). In addition, DEP exposure increased the number of 
alveolar DC and their maturation, as demonstrated by increased expression of CD86. These 
responses were significantly attenuated in chemR23 KO mice compared to WT mice (Fig. 2E and 
F). In contrast, the DEP-induced increase in lung CD11b+ conventional DC and neutrophils in BALF 
and lung were similar between WT and chemR23 KO mice (Fig. 2G-I). Lung macrophage counts 
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FIGURE 1: Chemerin levels in BALF are increased in WT mice exposed to DEP. Mice were intratracheally exposed 
to saline (white bar) or 100 µg DEP (black bar). A, schematic overview of the model of DEP-induced acute lung 
inflammation. EP = endpoints. B, chemerin mRNA expression in hematopoietic (CD45+) and structural non-
hematopoietic (CD45-) lung cells was determined using RT-PCR. C, photomicrographs of prochemerin staining in the 
airway epithelium of mice that were exposed to saline or DEP and quantification of prochemerin staining. D-E, chemerin 
(D) and RvE1 (E) RvE1 protein levels in BALF were determined by ELISA.  Results are expressed as mean ± SEM. n = 8 
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FIGURE 2: ChemR23 is required for DEP-induced monocyte and alveolar DC recruitment. WT and chemR23 KO 
mice were exposed to saline (white bars) or DEP (black bars). A, total cell number in BALF. B-J, monocytes numbers in 
BALF (CD11clow, CD11b+, Ly6C+ and Ly6G-) (B);  % monocytes in lung tissue (CD11clow, CD11b+, Ly6C+ and Ly6G-) (C); 
% lung monocyte-derived DC (CD11chigh, low autofluorescent, CD11b+ and Ly6C+) (D); DC numbers in BALF (CD11chigh, 
low autofluorescent and MHCII+) (E); mean fluorescence intensity (MFI) of CD86 on alveolar DC (F); % lung CD11b+ 
conventional DC (CD11chigh, low autofluorescent, CD11b+ and Ly6C-) (G); neutrophils numbers in BALF (CD11clow, 
CD11b+, Ly6C+ and Ly6G+) (H); % lung neutrophils (CD11clow, CD11b+, Ly6C+ and Ly6G+) (I); and % lung macrophages 
(CD11chigh, high autofluorescent) (J) were determined by flow cytometry. Results are expressed as mean ± SEM. n = 7-
8 mice per group. *p < 0.05. Representative flow cytometric density plots and gating strategy can be found in the 







ChemR23 is required for DEP-induced CCL2 and CCL20 production 
CCL2 and CCL20 are important chemokines for the DEP-induced recruitment of monocytes and 
monocyte-derived DC [95]. DEP exposure elevated the levels of CCL2 and CCL20 in the BALF in 
both WT and chemR23 KO mice. However, the levels of these chemokines were significantly 
reduced in DEP-exposed chemR23 KO mice (Fig. 3A and B). The level of the chemR23 ligand, 
chemerin, in BALF was elevated in WT mice that received DEP as described above. Independent 
of the exposure, all chemR23 KO mice had increased chemerin levels when compared to WT 
controls (Fig. 3C).  
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FIGURE 3: ChemR23 is required for DEP-induced CCL2 and CCL20 production. WT and chemR23 KO mice were 
exposed to saline (white bars) or DEP (black bars). A-C, CCL2 (A); CCL20 (B); and chemerin (C) protein levels in BALF 
were determined by ELISA. Results are expressed as mean ± SEM. n = 7-8 mice per group. *p < 0.05. 
 
Role of chemR23 signaling in a model of DEP-enhanced allergic airway inflammation 
Chemerin levels are increased in WT mice co-exposed to DEP + HDM 
Exposure to DEP promotes sensitization towards co-inhaled allergens and aggravates asthma 
[23]. To investigate the molecular mechanisms, we set up a model wherein we exposed mice to 
saline, DEP or HDM alone, or combined DEP and HDM (experimental protocol in Fig. 4A). In order 
to examine the adjuvant capacity of DEP optimally, we administered low doses of DEP and HDM, 
that elicited almost no inflammatory or allergic response on their own. In this model, the chemerin 
levels in BALF were elevated in WT mice concomitantly exposed to DEP + HDM, compared to all 
control groups (Fig. 4B). Levels of RvE1 were decreased in WT mice exposed to DEP or HDM 
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FIGURE 4: Absence of chemR23 aggravates allergic responses in BALF upon combined DEP + HDM exposure. 
WT and chemR23 KO mice were intranasally exposed to saline (white bar), 25 µg DEP (striped bar), 1µg HDM (checked 
bar) or 25 µg DEP + 1 µg HDM (black bar). A, schematic overview of the model of DEP-enhanced allergic airway 
inflammation. EP = endpoints. B-C, chemerin (B) and RvE1 (C) protein levels in BALF were determined by ELISA. D-I, 
monocyteS numbers (CD11clow, CD11b+, Ly6C+ and Ly6G-) (D); neutrophils numbers (CD11clow, CD11b+, Ly6C+ and 
Ly6G+) (E); eosinophils (F); DC numbers (CD11chigh, low autofluorescent and MHCII+) (G); CD4+ T-cell numbers (CD3+, 
CD8- and CD4+) (H); and CD8+ T-cell numbers (CD3+, CD4- and CD8+) (I) in BALF were determined by flow cytometry, 
except eosinophils which were determined on cytospins. J-K, CCL2 (J); and chemerin (K) protein levels in BALF were 
determined by ELISA. Results are expressed as mean ± SEM. n = 7-12 mice per group. *p < 0.05. Lines with branches 
represent significant differences between DEP + HDM versus saline, DEP alone or HDM alone, except in (C) were the 
line with braches represents differences between saline versus DEP alone, HDM alone and DEP +HDM.  
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Absence of chemR23 aggravates allergic responses in BALF upon combined DEP + HDM 
exposure 
To elucidate the role of chemR23 signaling in DEP-enhanced allergic airway inflammation, we 
exposed WT and chemR23 KO mice to saline, DEP or HDM alone, or combined DEP + HDM. In this 
protocol, exposure to sole DEP in WT mice was associated with marginal increases in monocytes 
and neutrophils in BALF, when compared to WT mice that were exposed to saline (Fig. 4D and 
E). Sole HDM slightly increased the amount of BALF eosinophils, CD4+ T-cells and CD8+ T-cells 
compared to the saline WT group (Fig. 4F, H and I). In contrast, concomitant exposure to DEP + 
HDM greatly enhanced the inflammatory and allergic response in WT mice, with increased 
numbers of monocytes, eosinophils, DC, CD4+ T-cells and CD8+ T cells in the BALF, when compared 
to the three WT control groups. This was further increased in chemR23 KO mice that were 
exposed to combined DEP + HDM (Fig. 4D, F-I). Of interest, chemR23 KO mice seemed more 
susceptible to allergic airway inflammation, since chemR23 KO receiving sole HDM had increased 
monocytes and eosinophils when compared to HDM-exposed WT mice (Fig. 4D and F). In line 
with the data from the model of DEP-induced lung inflammation, the number of BALF monocytes 
were attenuated in chemR23 KO mice that were exposed to DEP alone, when compared to DEP-
exposed WT mice (Fig. 4D). Levels of CCL2 in BALF were elevated in WT mice exposed to DEP, 
and increased further in mice that received concomitant DEP + HDM. In contrast, chemR23 KO 
mice had decreased CCL2 levels when compared with their WT controls (Fig. 4J). The levels of 
chemerin were increased in mice that were co-exposed to DEP + HDM as described above. 
Independent of the exposure, all chemR23 KO had increased chemerin levels when compared to 





Absence of chemR23 aggravates allergic responses in lung upon combined DEP + HDM 
exposure 
Similarly to the data in the BALF, eosinophils, DC and CD4+ T-cells accumulated in the lungs of 
mice that were concomitantly exposed to DEP + HDM, when compared to WT control groups. 
Again, this response was further increased in ChemR23 KO mice that received combined DEP + 
HDM (Fig. 5A-C). ChemR23 KO mice that received sole HDM had slightly increased eosinophils 
and DC when compared to HDM-exposed WT mice (Fig. 5A and B). Histological analysis revealed 
peribronchial eosinophilic inflammation and increased goblet cells in WT mice that were exposed 
to combined DEP + HDM. In chemR23 KO mice that received DEP + HDM, this was further 
increased (Fig. 5D and E respectively). While low dose HDM on its own had no significant effect 
on eosinophilia or goblet cell metaplasia in WT mice, numbers of peribronchial eosinophils and 
goblet cells were elevated in chemR23 KO that received sole HDM (Fig. 5D and E). 
 
Absence of chemR23 increases type 2 cytokine production upon combined DEP + HDM 
exposure 
To assess type 2 cytokine production in the model of DEP-enhanced allergic inflammation, 
mediastinal LN were cultured with HDM and analysed for cytokine production. LN cells from WT 
mice that were previously exposed to saline, sole DEP or low dose HDM showed no production of 
type 2 cytokines. However, combined exposure to DEP + HDM was associated with increased 
production of IL-4, IL-5 and IL-13 in WT mice. Production of type 2 cytokines was amplified in 
chemR23 KO mice that received DEP + HDM (Fig. 6 A-C). Exposure to HDM alone was also 
associated with increased IL-5 and IL-13 levels in chemR23 KO mice in comparison with HDM-
exposed WT mice (Fig. 6 B-C). Total serum IgE and HDM-specific IgG1 were elevated in WT mice 
that received combined DEP + HDM. The levels tended to increase in chemR23 KO mice that were 
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FIGURE 5:  Absence of chemR23 aggravates allergic responses in lung upon combined DEP + HDM exposure. WT and chemR23 
KO mice were exposed to saline (white bars), DEP (striped bars), HDM (checked bars) or DEP + HDM (black bars). A-C, % eosinophils 
(CD11clow, CD11b+ and Siglec-F+) (A); % CD11b+ conventional DC (CD11chigh, low autofluorescent, CD11b+ and MHCII+) (B); and % 
CD4+ T-cells (CD3+, CD8-, CD4+ and CD69+) (C) in lung tissue were determined by flow cytometry. Representative flow cytometric 
density plots and gating strategy can be found in the materials & methods section (Figure 15, p.54). D-E, photomicrographs and 
quantification of Congo Red (D) and Periodic Acid Schiff (E) stained sections of the airways of mice that were exposed to saline, DEP, 
HDM or DEP + HDM. Representative photomicrographs from WT mice are shown. Results are expressed as mean ± SEM. n = 7-12 mice 
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FIGURE 6: Absence of chemR23 increases type 2 cytokine production and immunoglobulins upon combined 
DEP + HDM exposure. WT and chemR23 KO mice were exposed to saline (white bars), DEP (striped bars), HDM 
(checked bars) or DEP + HDM (black bars). A-C, IL-4 (A); IL-5 (B); and IL-13 (C) protein levels in the supernatant of 
HDM-restimulated LN cells were determined by ELISA. D-E, Total IgE (E); and HDM-specific IgG1 (E) in serum were 
determined by ELISA. Results are expressed as mean. n = 7-12 mice per group. *p < 0.05. Lines with branches represent 






In this study, we showed that the response to modulation of the chemerin/chemR23 axis is 
contingent upon the specific conditions of DEP-induced airway inflammation. In the model of DEP-
induced lung inflammation, chemR23 KO mice had decreased numbers of monocytes and DC upon 
DEP-exposure compared to WT mice, suggesting a pro-inflammatory role for chemR23 signaling. 
In contrast, in the model of DEP-enhanced allergic airway inflammation, chemR23 KO mice had 
increased lung eosinophilia, goblet cell metaplasia and TH2 cytokine production in response to 
DEP + HDM compared to WT mice, suggesting an anti-inflammatory role for the chemR23 axis.  
In the lung, epithelial cells are the first to encounter inhaled particles and allergens. In response 
to immunostimulatory antigens, the epithelium can release cytokines and chemokines that direct 
the recruitment and/or activation of innate and adaptive immune cells [288]. Upon exposure to 
DEP, we observed decreased (pro)chemerin protein staining in the airway epithelium, which was 
associated with an increased (pro)chemerin release in the BALF. Similar observations were 
previously made in our model of cigarette-smoke induced inflammation [120], suggesting that 
exposure to pollutants can trigger the epithelium to release (pro)-chemerin in the alveolar lumen. 
In addition, we demonstrated a synergistic response between DEP and HDM to induce (pro)-
chemerin secretion in the BALF.  
After proteolytic activation, chemerin attracts chemR23-expressing immune cells, including 
monocytes and monocyte-derived DC [284]. In chemR23 KO mice the accumulation of pulmonary 
monocytes and monocyte-derived DC was decreased in the model of DEP-induced lung 
inflammation, suggesting a pro-inflammatory role for chemR23 signaling, which is similar to 
previous observations reported by our group in a model of cigarette smoke-induced inflammation 
[120].  
Monocyte-derived DC are known to stimulate TH2 immunity in response to inhaled allergens [95, 
289]. Since we observed decreased monocyte and monocyte-derived DC numbers in chemR23 KO 
mice that were exposed to DEP alone, we were interested in the role of chemR23 signaling in a 
model of allergic inflammation enhanced by DEP. Intriguingly, we found an increased allergic 
airway inflammation in chemR23 KO mice that were exposed to concomitant DEP + HDM, 
suggesting an anti-inflammatory role of the chemR23 axis in DEP-enhanced allergic airway 
inflammation. Despite the modest response towards HDM alone in our model, chemR23 KO mice 
were also more susceptible to (exclusively) HDM-induced allergic airway inflammation, with 
enhanced eosinophilia and TH2 cytokine production compared to WT mice. Interestingly, in 
independent models of HDM- or OVA-induced airway inflammation, exogenously administered 
chemerin was reported to be associated with an anti-inflammatory response [121, 290], 
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suggesting that chemerin mediates its anti-inflammatory properties in models of allergic airway 
inflammation by signaling via chemR23. The chemerin/chemR23 axis was also found to mediate 
anti-inflammatory responses in models of viral pneumonia and LPS-induced lung inflammation 
[131, 136]. 
Although a direct effect of active chemerin on monocytes has been described [284], it is of interest 
that chemR23 KO mice had impaired levels of CCL2 and CCL20. We previously showed that 
monocyte and monocyte-derived DC recruitment in response to DEP is attenuated in mice 
deficient for CCR2 and CCR6, which are the receptors for CCL2 and CCL20 respectively [95]. 
Possibly, the reduced monocytic response in DEP-exposed chemR23 KO mice is therefore a 
consequence from the reduced levels of CCL2 and CCL20, rather than representing a direct role 
for the chemR23 axis in monocyte recruitment, per se. Moreover, the reduced CCL2 and CCL20 
levels in the chemR23 KO mice could suggest that chemR23 signaling is required for the 
upregulation in CCL2 and CCL20 in response to DEP. The fact that chemR23 KO mice receiving 
concomitant DEP + HDM also had decreased CCL2 levels compared to WT mice supports the 
suggestion that chemR23 signaling modulates the production of CCL2. Furthermore, it suggests 
that the enhanced allergic inflammation and monocyte recruitment that is elicited in the lungs of 
chemR23 KO mice by DEP + HDM is independent of CCL2, which is in contrast to the findings of a 
previous report [121]. 
The underlying basis of these opposing activities of chemerin/chemR23 signaling remains unclear 
[132]. Various proteases can process prochemerin to bioactive chemerin. Thus, depending on the 
proteases that are present in the microenvironment, diverse chemerin fragments may be 
produced with distinct pharmacological properties. Serine proteases (i.e. neutrophil elastase and 
cathepsin G) that are released upon neutrophil degranulation generate chemerin-157 and 
chemerin-156 (i.e. prochemerin lacking the last six and seven amino acids, respectively) that are 
associated with the recruitment of chemR23-expressing antigen presenting cells [129, 284]. Since 
exposure to DEP and cigarette smoke is associated with neutrophil recruitment to the lung and 
increased expression of neutrophil-derived proteases [91, 120], one can speculate that inhalation 
of air pollutants promotes a microenvironment that generates pro-inflammatory peptides of 
chemerin. On the other hand, mast cell chymase can convert these chemerin-157 and -156 
peptides into chemerin-154, which is associated with anti-inflammatory actions on chemR23 
[285, 286]. Thus, chemerin may be cleaved into diverse anti-inflammatory peptides in response 
to allergic airway inflammation wherein the activation of mast cells is a prominent feature. A 
limitation of our study is that we could not distinguish between prochemerin and the bioactive 
isoforms of chemerin in the 2 models. To our knowledge, there are no commercially available 
antibodies that efficiently discriminate between prochemerin or the various chemerin isoforms. 
86 
 
Nevertheless, such tools are necessary to get more insights in the complex biology of chemerin 
signaling, since prochemerin and the multiple chemerin isoforms can act as antagonists for each 
other’s activity, and can all compete for chemR23 binding and ultimate biological response [291]. 
To overcome this, we have attempted to measure chemerin bioactivity in our samples using an 
aequorin-based calcium assay [136] (data not shown). Unfortunately, the chemerin levels were 
too low to detect any bioactivity, yet this does not exclude that local lung chemerin levels 
contribute to leukocyte recruitment.  
Recently, chemR23 expression was also demonstrated on endothelial cells [133]. To explain the 
opposing roles of the chemerin/chemR23 axis, it was alternatively suggested that chemerin 
exerted its anti-inflammatory properties via chemR23 that was expressed on non-leukocytic (i.e. 
endothelial or epithelial) cells [121, 136]. In support of this, we observed that the pro-
inflammatory activity of chemR23 signaling in the model of DEP-induced acute lung inflammation 
was restricted to hematopoietic cells that were reported to express chemR23 (i.e. monocytes and 
DC [284]), while no effects were seen on non-chemR23 expressing cells such as neutrophils. In 
contrast, in the model of DEP-enhanced allergic airway inflammation, we observed anti-
inflammatory activity for both chemR23 expressing and non-expressing cells. Although one could 
suggest that these anti-inflammatory actions could be mediated through release of chemokines 
by the endothelium or epithelium, experiments with chimeric mice or conditional chemR23 KO 
should be performed to definitively resolve this issue. 
RvE1 is a second putative ligand of chemR23 [134]. In models of experimental asthma, exogenous 
administration of RvE1 could both impair the development and promote the resolution of OVA-
induced airway inflammation [292-294]. One can therefore speculate that the opposing role of 
chemR23 signaling in our experiments was due to preferential binding of chemR23 to chemerin 
(in the model of acute DEP-induced inflammation) or RvE1 (in the model of DEP-enhanced allergic 
airway inflammation). Although a confounding role for RvE1 cannot be excluded, the decreased 
RvE1 levels in both the models suggest that the pro- and anti-inflammatory properties of the 
chemR23 axis in the models is not attributable to RvE1. Indeed, (exogenously administered) 
chemerin on itself is reported to have both pro- and anti-inflammatory activities [121, 131]. 
Given the anti-inflammatory role of the chemerin/chemR23 axis in diverse lung disease models, 
including models of allergic airway inflammation, chemerin or chemR23 agonists are proposed as 
novel candidate therapeutics for treatment of asthma [121, 290]. On the other hand, blocking 
chemR23 is also suggested as therapeutic intervention in disease models were the chemR23 axis 
has pro-inflammatory properties [120]. Our data highlight the complexity of chemerin/chemR23 
signaling and the opposing activities depending on the inflammatory conditions. To consider the 
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chemerin/chemR23 axis as therapeutic target for lung diseases, further research is needed into 











CHAPTER 8: IL-33 SIGNALING CONTRIBUTES TO 
POLLUTANT-INDUCED ALLERGIC AIRWAY 
INFLAMMATION  
 
IL-33 is an important epithelial-derived cytokine that has been implicated in the pathogenesis of 
asthma.  Recently, an increased IL-33 production was observed in airway epithelial cells derived from 
severe asthmatics that were exposed to particulate matter. In this study, we aimed to investigate the 
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Background: Clinical and experimental studies have identified a crucial role for IL-33 and its 
receptor ST2 in allergic asthma. Inhalation of traffic-related pollutants, such as diesel exhaust 
particles (DEP), facilitates the development of asthma and can cause exacerbations of asthma. 
However, it is unknown whether IL-33/ST2 signaling contributes to the enhancing effects of air 
pollutants on allergic airway responses. 
Objective: We aim to investigate the functional role of IL-33/ST2 signaling in DEP-enhanced 
allergic airway responses, using an established murine model. 
Methods: C57BL/6J mice were exposed to saline, DEP alone, house dust mite (HDM) alone, or 
combined DEP+HDM. To inhibit IL-33 signaling, recombinant soluble ST2 (r-sST2) was given 
prophylactically (i.e. during the whole experimental protocol) or therapeutically (i.e. at the end of 
the experimental protocol). Airway hyperresponsiveness and the airway inflammatory responses 
were assessed in bronchoalveolar lavage fluid (BALF) and lung. 
Results: Combined exposure to DEP+HDM increased IL-33 and ST2 expression in lung, elevated 
inflammatory responses and bronchial hyperresponsiveness compared to saline, sole DEP or sole 
HDM exposure. Prophylactic interference with the IL-33/ST2 signaling pathway impaired the 
DEP-enhanced allergic airway inflammation in the BALF, whereas effects on lung inflammation 
and airway hyperresponsiveness were minimal. Treatment with r-sST2 at the end of the 
experimental protocol did not modulate the DEP-enhanced allergic airway responses.  
Conclusion: Our data suggest that the IL-33/ST2 pathway contributes to the onset of DEP-




Asthma is one of the most common chronic airway diseases and is a serious global health problem 
[3, 4]. It is generally characterized by a chronic airway inflammation of the conducting airways, 
causing reversible airway obstruction, excessive mucus production, airway hyperresponsiveness 
(AHR) and remodeling. Asthma has been defined as a heterogeneous disease, with multiple 
phenotypes that are distinguished based on the patient’s clinical characteristics and inflammatory 
profile [6]. The best characterized phenotype is allergic asthma, a type 2 mediated immune 
disorder caused by exposure to common inhaled allergens, such as house dust mite (HDM) [6, 7]. 
The airway epithelium is continuously exposed to inhaled environmental triggers. It acts not only 
as a passive barrier but is also actively involved in respiratory defense through pro-inflammatory 
cytokine production [117]. Interleukin (IL)-33 plays a key role in bridging innate and adaptive 
immune responses and contributes to the regulation of tissue homeostasis, injury and repair. IL-
33 has multiple bioactive forms: a full-length and several more potent cleaved forms. Both forms 
can bind the ST2 transmembrane receptor that is expressed on various immune cells, including 
mast cells, basophils, dendritic cells (DC), macrophages, eosinophils, iNKT cells, innate lymphoid 
cells type 2 (ILC2), CD4+ T-cells and CD8+ T-cells. Besides the transmembrane form, ST2 also exists 
as a soluble form, sST2, which acts as a decoy receptor to prevent IL-33-mediated cellular 
activation [139, 140, 295]. 
Several genome wide association studies have shown that IL-33 and its receptor ST2 are 
associated with asthma susceptibility [16, 17, 296]. In patients with asthma, elevated IL-33 
protein levels were observed in serum, induced-sputum, bronchoalveolar lavage fluid (BALF) and 
bronchial epithelial cells, which all correlated positively with the severity of the disease [125, 149-
151]. Moreover, most murine studies using IL-33 or ST2 knockout (KO) mice, anti-IL-33 or 
recombinant sST2 (r-sST2) showed a critical role for IL-33/ST2 signaling in allergen-induced 
airway inflammation [158-160, 163, 172, 235, 297, 298]. Targeting IL-33 could therefore be a new 
promising therapeutic approach for asthma.  
Over the years, substantial epidemiological evidence has linked exposure to traffic-related 
particulate matter, such as diesel exhaust particles (DEP), with the onset, progression and 
exacerbation of asthma [77]. Studies with controlled human exposures to DEP + allergen 
demonstrated augmented allergen-specific responses, including increased airway eosinophilia, 
type 2 cytokine production and allergen-specific immunoglobulin (Ig) E levels [99, 101]. The 
underlying mechanisms are however incompletely known. To elucidate these, we and others 
developed and characterized murine models that mimic DEP-enhanced allergic airway responses 
[23, 299, 300]. We demonstrated that combined exposure to DEP+HDM was associated with AHR, 
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increased inflammatory cells in the airways, type 2 cytokine responses, increased 
immunoglobulin production and mucus metaplasia [299, 300]. Moreover, we observed elevated 
IL-33 protein levels in lungs of mice that received combined DEP+HDM [300]. In vitro, an 
increased IL-33 production was also observed in PM-exposed epithelial cells derived from severe 
asthmatics [185]. However, whether IL-33 signaling contributes to the aggravating effect of DEP 
on allergic airway inflammation remains unknown. 
Here, we aim to investigate the role of IL-33/ST2 signaling in DEP-enhanced allergic airway 
inflammation. For that, r-sST2, which neutralizes IL-33 activity, was administered in our 
established DEP+HDM mouse model. We demonstrate that interfering with the IL-33/ST2 
pathway prophylactically (i.e. during the whole experimental protocol) results in an impaired 
DEP-enhanced allergic airway inflammation, whereas r-sST2 administration at the end of the 




MATERIAL & METHODS  
 Mice 
Female 6-8 weeks old wild-type (WT) C57BL/6J mice (4-8 mice/group) were obtained from the 
Jackson Laboratory. All in vivo manipulations were approved by the Animal Ethical Committee of 
the Faculty of Medicine and Health Sciences of Ghent University. 
 
Exposure protocol 
DEP (SRM 2975) was obtained from the National Institute for Standards and Technology. HDM 
(Dermatophagoides pterynossinus) was obtained from Greer Laboratories. On day 1, 8 and 15, 
isoflurane-anesthetized mice were intranasally instilled with saline, 25 µg DEP suspended in 
saline + 0.05 % tween 80, 1 µg HDM in saline, or the combination of DEP and HDM as described 
previously [299, 300]. On day 17, the animals were sacrificed by a lethal dose of intraperitoneal 
pentobarbital (Fig. 1A). Tween 80 (0.05%) was used as a vehicle in all conditions. 
For the prophylactic inhibition of IL-33, mice received PBS or 25 µg r-sST2 in PBS intranasally on 
day 1, 8 and 15. This instillation was performed 8 minutes after the exposure to saline, DEP, HDM 
or DEP+HDM (Fig. 1B) [301]. For the therapeutic approach, mice were treated with PBS or 25 µg 
r-sST2 in PBS on day 14, 15 and 16 (Fig. 1C).  
 
 








Figure 1: Exposure protocols. A) C57BL/6J mice 
were intranasally (IN) exposed to saline, 25 µg DEP, 1 
µg HDM or combined DEP+HDM on day 1, 8 and 15. 48 
hours after the last exposure, endpoints (EP) were 
performed. B) To prophylactically inhibit IL-33, mice 
received PBS or 25 µg r-sST2 intranasally 8 minutes 
after the exposure to saline,DEP, HDM or DEP+HDM. C) 
For the therapeutic approach, mice were treated with 























A tracheal cannula was inserted and BALF was recuperated by instillation of 3 x 300 µl 1% HBSS 
supplemented with 1% BSA and 6 x 500 µl HBSS supplemented with EDTA. The lavage fractions 
were pooled and total cell counts were measured using a Bürker chamber.  
 
Lung and mediastinal lymph nodes (MLN) single cell suspensions  
The pulmonary circulation was rinsed with saline supplemented with EDTA to remove the 
intravascular pool of cells. Lungs and MLN were minced and incubated for 45 minutes in digestion 
medium (Roswell Park Memorial Institute medium-1640 supplemented with 5% fetal calf serum, 
2 mM L-glutamine, 0.05 mM 2-mercaptomethanol, 100 U/ml penicillin, 100 mg/ml streptomycin, 
1 mg/ml collagenase type 2, and 0.02 mg/ml DNase I) at 37°C and 5% CO2. Red blood cells were 
lysed using ammonium chloride buffer. Total cell counts were performed with a Z2 Coulter 
Counter. 
 
MLN cell culture 
MLN single cells were cultured in culture medium alone or supplemented with 3.75 µg/well HDM 
in round bottom, 96-well plates and incubated in a humidified 37°C incubator with 5% CO2. After 
5 days, supernatants were harvested for cytokine measurements.  
 
Flow cytometry and cell sorting 
To minimize non-specific binding, BALF cells and lung single cell suspensions were incubated with 
anti-CD16/CD32 (clone 2.4G2). Cells were further labeled with a combination of anti-mouse 
fluorochrome-conjugated monoclonal antibodies against: CD4 (GK1.5), CD8 (53-6.7), CD11b 
(M1/70), Ly6C (AL-21), Ly6G (1A8), MHCII (2G9), SiglecF (E50-2440), CD3 (145-2C11), CD90.2 
(30.H12), CD5 (53-7.3), CD11c (N418), CD25 (PC61.5), CD45R (RA3-6B2), NK1.1 (PK136), TCRβ 
(H57-597) and ST2 (DJ8). For cytoplasmatic IL-13 (eBio13A) or matched isotype staining, cells 
were stimulated with ionomycin and phorbol 12-myristate 13-acetate, supplemented with 
brefeldin A and monensin at 37°C for 4 hours. Data acquisition was performed on a LSR Fortessa 
cytometer. Cell subsets were analyzed using FlowJo software.  
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CD45+ and CD45- lung cells were sorted using an OctoMACS separator and CD45 microbeads 
following the manufacturer’s instructions (Miltenyi). 
 
Histology 
The left lung was fixated with 4% PFA and embedded in paraffin. Transversal sections (3 µM) 
were cut and treated with Ultra V Block. To identify eosinophils and goblet cells, lung sections 
were stained with congo red or periodic acid-Schiff staining respectively. Quantitative 
measurements were performed on an Axioimager running Axiovision software 
 
Lung homogenates 
The lung was homogenized in T-PER tissue protein extraction reagent containing Halt Protease 
Inhibitor Cocktail Kit using a TissueRuptor. The homogenates were centrifuged and the middle 




IL-13 levels in BALF and MLN and IL-1β in lung homogenate were measured using commercially 
available ELISA kits (R&D systems).  
HDM-specific IgG1 was determined on serum that was collected by retro-orbital bleeding. Briefly, 
plates were coated with HDM extract. Serum was added, followed by a horseradish-conjugated 
polyclonal goat anti-mouse IgG1 Ab. IgG1 values were reported in optical density (ODs). 
 
Western Blotting 
Protein extracts of lung tissue homogenates were loaded on a 15% Tris/HCl gel (25 µg/slot), 
separated by SDS PAGE and blotted onto a nitrocellulose membrane. Murine IL-33 was detected 
by mouse IL-33 antigen affinity-purified polyclonal goat IgG antibody in combination with the 
donkey anti-goat horseradish peroxidase (HRP) antibody. As a loading control, rabbit anti–
glyceraldehyde-3-phosphate dehydrogenase antibody in combination with donkey anti-rabbit 
HRP antibody were used. Positive bands were visualized with Immobilon Western 
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Chemiluminescence HRP substrate and detected by Chemidoc Touch Imaging System. Semi-
quantitative analysis of band intensities was performed by measuring the area under the peak of 
plotted lanes with ImageJ software. 
 
qRT-PCR 
RNA from total lung tissue or from CD45+/- sorted lung cells was extracted using the miRNeasy 
mini kit (Qiagen) and cDNA synthesis (Transcriptor Universal cDNA Master, Roche) was 
performed following the manufacturer’s instructions. IL-33 and ST2 expression was analyzed 
with TaqMan Gene Expressions assays using a LightCycler 96 system. IL-33 and ST2 expression 
was normalized based on the expression of the HPRT reference gene.  
 
Airway Hyperresponsiveness 
Airway hyperresponsiveness (AHR) in response to increasing doses carbachol (0, 20, 40, 80, 160, 
320, 640 µg/kg) was measured 48 hours after the last intranasal instillation of DEP and/or HDM 
using the forced oscillation technique (Flexivent System). Mice were anaesthetized with a 1/10 
dilution pentobarbital and neuromuscular blockade was induced by injecting 1 mg/kg 
pancuronium bromide intravenously. A “snapshot perturbation” maneuver was imposed to 
measure the resistance (R) of the whole respiratory system (airways, lung and chest wall).   
 
Statistical analysis 
Statistical analysis was performed with SPSS, version 24.0. Non parametric tests (Kruskal-Wallis 
and Mann-Whitney-U) were used to compare different groups, according to the standard 






Combined DEP+HDM exposure increases IL-33 and ST2 expression in the murine lung 
C57BL/6J mice were exposed to saline, DEP alone, HDM alone, or combined DEP+HDM (Fig. 1A). 
To optimally investigate the enhancing capacity of DEP on HDM-induced allergic airway 
responses, we have previously optimized doses of both DEP and HDM that elicit limited 
inflammatory responses on their own [299, 300]. 
Compared to the three control groups (i.e. saline, DEP alone and HDM alone), combined exposure 
to DEP+HDM increased the mRNA expression of IL-33 and ST2 in total lung tissue (Fig. 2A, B). To 
further investigate their origin, we sorted hematopoietic (CD45+) versus non-hematopoietic 
(CD45-) cells from lung tissue. IL-33 mRNA was predominantly expressed in CD45- non-
hematopoietic cells, while it was barely detectable in CD45+ hematopoietic cells (Fig. 2C). 
Contrary to this, ST2 mRNA was preferentially expressed in the CD45+ cell population, whereas it 
was minimally expressed in the CD45- cell fraction (Fig. 2D). Similar to the data from total lung 
tissue, combined exposure to DEP+HDM increased expression of IL-33 in the sorted CD45- cells 
and ST2 mRNA in the sorted CD45+ cells, when compared with the three control groups (Fig. 2C 
and D).  
We previously showed that IL-33 protein levels in lung homogenates increased upon combined 
DEP+HDM-exposure compared to saline, DEP and HDM exposure [300]. To identify which protein 
form of IL-33 was increased, we performed western blot analysis. Both full-length IL-33 (~30kDa) 
and cleaved IL-33 (~18kDa) were significantly increased in WT mice that received combined 
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Figure 2: Combined DEP+HDM exposure increases IL-33 and ST2 expression in the murine lung. C57BL/6J WT 
mice were intranasally exposed to saline (white bars), 25 µg DEP (striped bar), 1 µg HDM (checked bar) or combined 
DEP+HDM (black bar). A-B, IL-33 (A) and ST2 (B) mRNA expression in total lung tissue was determined using qRT-
PCR. C-D, IL-33 (C) and ST2 (D) mRNA expression in sorted non-hematopoietic (CD45-) and hematopoietic (CD45+) 
lung cells was determined with qRT-PCR. E-G, Full-length and cleaved murine IL-33 in lung homogenates were 
examined by western blot and relative band-intensities were measured. Results are expressed as mean ± SEM. n = 4-8 
mice per group. * P < 0.05. 
A. B. 





Prophylactic administration of recombinant soluble ST2 attenuates DEP-enhanced allergic 
airway inflammation in BALF 
To evaluate the functional role of the IL-33/ST2 axis in the model of DEP-enhanced allergic airway 
inflammation, we inhibited IL-33/ST2 signaling by administering r-sST2 or PBS control 
prophylactically (i.e. from the start of the exposure protocol) to C57BL/6J mice (Fig. 1B).  
Combined exposure to DEP+HDM in PBS-treated mice vastly increased the numbers of DC, 
neutrophils, eosinophils, ILC2 and CD4+ T cells in the BALF (Fig. 3A-E), whereas exposure to sole 
DEP or sole HDM elicited minimal inflammation. Moreover, elevated IL-13 protein levels and 
increased numbers of IL-13+ ILC2 and IL-13+ CD4+ T cells were observed in the BALF of combined 
DEP+HDM-exposed mice, when compared to saline-, DEP- or HDM-exposed mice (Fig. 3F-H). 
Concomitant exposure to DEP+HDM modestly increased the IL-1β levels compared with the 
controls (Fig. 3I).  
Upon prophylactic administration of r-sST2, the DEP-enhanced allergic airway inflammation was 
significantly reduced. r-sST2-treated mice had reduced numbers of DC, neutrophils, eosinophils, 
ILC2 and CD4+ T cells in BALF on exposure to combined DEP+HDM, when compared with the PBS-
treated mice that received DEP+ HDM (Fig. 3A-E). In addition, IL-13 protein levels as well as IL-
13+ ILC2 and IL-13+ CD4+ T-cells in BALF were decreased in DEP+HDM-exposed mice that were 
treated with r-sST2, in comparison with the PBS-treated DEP+HDM group (Fig. 3F-H). Moreover, 
administration of r-sST2 lowered the IL-1β levels in the DEP+HDM-exposed mice compared with 
the PBS-treated DEP+HDM controls (Fig. 3I). It has to be acknowledged however that r-sST2 
treatment did not completely abolish the allergic airway inflammation, since combined 
DEP+HDM-exposed mice treated with r-sST2 still had higher inflammatory responses in the BALF 
when compared to saline-, DEP- or HDM-exposed mice treated with r-sST2 (Fig. 3A-H). Of 
interest, in mice that were exposed to sole HDM, prophylactic treatment with r-sST2 also reduced 
the number of ILC2 and IL-13+ ILC2 in the BALF when compared to the PBS-treated HDM group 
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Figure 3: Prophylactic administration of recombinant soluble ST2 attenuates DEP-enhanced allergic airway 
inflammation in BALF. C57BL/6J mice were intranasally exposed to saline (white bars), 25 µg DEP (striped bars), 1 
µg HDM (checked bars) or combined DEP+HDM (black bars). 8 minutes after each exposure, the mice were treated with 
PBS or 25 µg r-sST2. A-E, DC (CD45+, CD11chigh, and MHCII+) (A), neutrophils (CD45+, CD11c-, CD11b+, Ly6G+, and Ly6C+) 
(B), eosinophils (CD45+, CD11c-, CD11b+, and Siglec-F+) (C), ILC2 (CD45+, Lin- (CD3-, CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- 
and CD45R-), CD25+, CD90+, and ST2+) (D) and CD4+ T cells (CD45+, CD3+, CD4+, and CD8-) (E) in BALF were determined 
by flow cytometry. F, IL-13 protein levels in BALF were determined by ELISA. G-H, BALF cells were stimulated for 4 
hours with PMA/ionomycin + protein transport inhibitors, intracellularly labeled and analyzed using flow cytometry. 
Number of IL-13 expressing ILC2 (CD45+, Lin-, CD25+, and CD90+) (G) or CD4+ T cells (CD45+, CD3+, and CD4+) (H).  I, 
IL-1β levels in lung homogenate were determined by ELISA. Results are expressed as mean ± SEM. n = 8 mice per group. 
* P < 0.05. 
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Prophylactic r-sST2 administration does not prevent tissue inflammation, type 2 
sensitization and airway hyperresponsiveness upon combined DEP+HDM exposure 
Combined DEP+HDM-exposed mice that were treated with PBS showed a significant higher 
amount of peribronchial eosinophils and goblet cell metaplasia in lung tissue, compared to saline-
, sole DEP- or sole HDM-exposed mice (Fig. 4A, B). Moreover, concomitant DEP+HDM exposure 
in PBS-treated animals was associated with increased IL-13 production in the mediastinal lymph 
nodes (MLN) and elevated serum HDM-specific IgG1 levels (Fig. 4C-D).  
Prophylactic interference with the IL-33/ST2 pathway had no significant effect on peribronchial 
eosinophilic inflammation, goblet cell metaplasia, IL-13 levels in MLN and HDM-specific IgG1 
levels in serum since similar levels were observed in DEP+HDM-exposed mice that were treated 
with r-sST2 in comparison with DEP+HDM group that was treated with PBS (Fig. 4A-D). Of note, 
although r-sST2 lowered the amount of peribronchial eosinophils and goblet cells in HDM-
exposed mice compared to their PBS controls, this was not statistically significant (Fig. 4A, B). 
Interestingly, mice that were concomitantly exposed to DEP+HDM showed airway 
hyperresponsiveness (AHR) compared to sole HDM-exposed mice. Prophylactivally 
administering r-sST2 to DEP+HDM-exposed mice led to a slight reduction – although not 
significantly – in AHR (Fig. 4E). 
 
Therapeutic r-sST2 administration does not modulate the DEP-enhanced allergic airway 
inflammation 
To investigate the therapeutic potential of r-sST2 in DEP-enhanced allergic airway inflammation, 
we administered r-sST2 only at the end of the exposure protocol (Fig. 1C).  
Combined DEP+HDM-exposed mice that were therapeutically treated with r-sST2 had a similar 
increase in BALF DC, neutrophils, eosinophils, ILC2 and CD4+ T cells, compared with the PBS-
treated DEP+HDM group (Fig. 5A-E). Moreover, the increased IL-13 protein levels and total 
number of IL-13+ ILC2 and CD4+ T cells in the BALF did not differ between DEP+HDM-exposed 
mice that were treated with PBS or r-sST2 (Fig. 5F-H). A similar increase in IL-1β levels was 
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Figure 4: Prophylactic r-sST2 administration does not prevent tissue inflammation, type 2 sensitization and 
airway hyperresponsiveness upon combined DEP+HDM exposure. C57BL/6J mice were intranasally exposed to 
saline (white bars), 25 µg DEP (striped bars), 1 µg HDM (checked bars) or combined DEP+HDM (black bars). 8 minutes 
after each exposure, the mice were treated with PBS or 25 µg r-sST2. A-B, Representative photomicrographs and 
quantification of congo red-stained peribronchial eosinophils (A) or periodic acid-Schiff-stained mucus-producing 
goblet cells (B). C-D, IL-13 levels in the supernatants of MLN restimulated with HDM (C) and HDM-specific IgG1 levels 
in serum (D) were determined by ELISA. E, Airway resistance (R) of HDM-exposed mice treated with PBS (black line), 
combined DEP+HDM-exposed mice treated with PBS (green line), HDM-exposed mice treated with r-sST2 (red line) 
and DEP+HDM-exposed mice treated with r-sST2 (blue line) was measured in response to increasing doses of carbachol. 
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Figure 5: Therapeutic r-sST2 administration does not modulate the DEP-enhanced allergic airway 
inflammation in the BALF. C57BL/6J mice were intranasally exposed to saline (white bars), 25 µg DEP (striped bars), 
1 µg HDM (checked bars) or combined DEP+HDM (black bars). On day 14, 15 and 16, mice were treated with PBS or 25 
µg r-sST2. A-F, DC (CD45+, CD11chigh, and MHCII+) (A), neutrophils (CD45+, CD11c-, CD11b+, Ly6G+, and Ly6C+) (B), 
eosinophils (CD45+, CD11c-, CD11b+, and Siglec-F+) (C), ILC2 (CD45+, Lin- (CD3-, CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- and 
CD45R-), CD25+, CD90+, and ST2+) (D) and CD4+ T cells (CD45+, CD3+, CD4+, and CD8-) (E) in BALF were determined by 
flow cytometry. F, IL-13 protein levels in BALF were determined by ELISA. G-H, BALF cells were stimulated for 4 hours 
with PMA/ionomycin + protein transport inhibitors, intracellularly labeled and analyzed using flow cytometry. Number 
of IL-13 expressing ILC2 (CD45+, Lin-, CD25+, and CD90+) (G) or CD4+ T cells (CD45+, CD3+, and CD4+) (H). I, IL-1β levels 
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Histological analyses further revealed a comparable peribronchial eosinophilia and goblet cell 
metaplasia in the lungs of DEP+HDM-exposed mice that were treated with PBS or r-sST2. Despite 
the fact that r-sST2 lowered the amount of peribronchial eosinophils and goblet cells in HDM-
exposed mice compared to their PBS controls, this could not be statistically confirmed (Fig. 6A, 
B).  
 
                               
                          
                                     
Figure 6: Therapeutic r-sST2 administration does not modulate the DEP-enhanced allergic lung inflammation. 
C57BL/6J mice were intranasally exposed to saline (white bars), 25 µg DEP (striped bars), 1 µg HDM (checked bars) or 
combined DEP+HDM (black bars). On day 14, 15 and 16, mice were treated with PBS or 25 µg r-sST2. A-B, 
Representative photomicrographs and quantification of congo red-stained peribronchial eosinophils (A) periodic acid-
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In this paper, we focused on the functional role of IL-33/ST2 signaling in the aggravating effect of 
DEP on HDM-induced airway responses. We demonstrate that a prophylactic neutralization of IL-
33 activity with r-sST2 attenuates allergic airway inflammation upon combined DEP+HDM 
exposure. In contrast, in a therapeutic setting, in which r-sST2 is given only at the end of the 
exposure protocol, the DEP-enhanced allergic airway response is not affected. 
IL-33 is an important epithelial-derived cytokine that has been implicated in the pathogenesis of 
asthma. Indeed, increased IL-33 expression was already demonstrated in asthmatic patients 
which correlated with asthma severity  [125]. Also in murine models of asthma, a rapid IL-33 
increase in BALF and lung tissue was observed upon allergen exposure [159, 161, 297].  Although 
in our model no increase in lung IL-33 levels was observed in response to suboptimal HDM doses, 
concomitant DEP+HDM exposure vastly increased the pulmonary IL-33 mRNA and protein levels.. 
In accordance, in vitro exposure of human bronchial epithelial cells from severe asthmatics to PM 
resulted in increased IL-33 production [185]. Although under inflammatory conditions IL-33 can 
be induced in immune cells [140], we identified non-hematopoietic cells as the major IL-33 
producers in the model of DEP-enhanced allergic airway inflammation, whereas ST2 was 
predominantly present on the hematopoietic cells. Moreover, although this should be further 
examined, the increase in cleaved IL-33 that was seen upon combined exposure to DEP+HDM 
could have important implications, as cleaved IL-33 can be up to 30-fold more potent than the full-
length IL-33 form [139, 295]. 
To assess the functional role of the IL-33/ST2 pathway in DEP-enhanced allergic airway 
responses, r-sST2 was intranasally administered from the start of the exposure protocol. We 
demonstrated that this prophylactic administration of r-sST2 in DEP+HDM-exposed mice 
decreased numbers of eosinophils, TH2 cells and ILC2 and IL-13 levels in the BALF. In contrast, r-
sST2 had no significant effect on the DEP+HDM-induced responses in lung tissue, HDM-specific 
IgG1 levels and AHR. Considering that only a local response towards r-sST2 was observed, 
whereas the effects in lung tissue and draining LN were limited, it could be that the half-life of r-
sST2 was too short or dosing was suboptimal due to the intranasal administration route. In a 
model of SplD-induced asthma however, intratracheal administration of r-sST2 also minimally 
affected the inflammatory responses in the lung tissue [301]. Furthermore, an i.p. injection of r-
sST2 at the time of HDM sensitization showed also no apparent differences in type 2 immune 
response in the lymph nodes and amount of goblet cells [161]. Finally, it should be mentioned that 
– at least in murine models of asthma – discrepant results have been reported concerning the 
functional role of IL-33 signaling. Although a reduction of the HDM- or OVA-induced allergic 
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airway inflammation and AHR was shown in most studies with IL-33 KO mice, ST2 KO mice or 
mice that were treated with anti-IL-33 or r-sST2 [159, 160, 163, 298, 302], some studies found no 
differences [165, 166]. Of note, with exception of the total number and cytokine-producing ILC2 
in the BALF, also in our model, r-sST2 did not significantly affect allergic airway responses 
towards suboptimal doses of sole HDM. 
As it was previously demonstrated that anti-IL-33 treatment could decrease a PM-induced asthma 
exacerbation in mice [186], we were interested if r-sST2 could be therapeutically beneficial during 
the aggravating effects of DEP on allergic airway inflammation. When r-sST2 was administered 
only at the end of the exposure protocol, no differences in airway immune responses could be 
observed, suggesting that signaling via the IL-33/ST2 pathway is more important during the onset 
of DEP-enhanced allergic airway inflammation. Our observations are in line with data from mouse 
models of HDM-induced asthma, in which it was shown that administration of r-sST2 during the 
challenge phase had no effect on airway eosinophilia [161], whereas IL-33 neutralization at the 
time of sensitization attenuated the HDM-induced eosinophil and lymphocytic inflammation in 
the BALF [161, 162]. We can however not exclude that the lack of efficacy in this therapeutic 
setting could be due to the half-life of r-sST2 or intranasal application route . In this regard, other 
approaches could give additional insights concerning the potential therapeutic effect of IL-33 
blockage. 
The mechanisms underlying the discrepant results of IL-33 during the prophylactic and 
therapeutic setting should be further investigated. As decreased IL-1β levels were observed in 
DEP+HDM-exposed mice that were prophylactically treated with r-sST2, but not therapeutically, 
this could be a potential mechanism of the observed discrepancy in inflammatory airway 
responses since IL-1β was previously found to be involved in type 2 promoting responses [303, 
304].  
At the moment, human studies with regard to anti-IL-33 are ongoing [37, 168] and still have to 
prove their beneficial effect in asthmatic patients. Moreover, it would be interesting to examine 
the functional role of other epithelial type 2 promoting cytokines, i.e. IL-25 and TSLP, during DEP-
enhanced allergic airway inflammation, as it was suggested that combinatorial blockage of these 
cytokine could be necessary to effectively inhibit lung inflammation [272].  
In conclusion, our preclinical data suggest that signaling through the IL-33/ST2 pathway has a 
functional role during the onset of DEP-enhanced allergic airway inflammation, whereas 








CHAPTER 9: DYSREGULATION OF TYPE 2 INNATE 
LYMPHOID CELLS AND TH2 CELLS IMPAIRS 
POLLUTANT-INDUCED ALLERGIC AIRWAY RESPONSES  
 
Although allergic asthma is typically considered as a TH2-mediated disease, an important 
contribution of ILC2s in allergic airway inflammation has been identified. Besides allergen exposure, 
it has been well accepted that exposure to pollutants can induce and exacerbate the allergic 
inflammatory responses. The underlying mechanisms remain however largely unknown. In this 
study, we aimed to investigate the role of both ILC2s and TH2 cells during DEP-enhanced allergic 
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Background: Whereas the prominent role of T helper 2 (TH2) cells in type 2 immune responses is 
well established, the newly identified type 2 innate lymphoid cells (ILC2) can also contribute to 
the orchestration of allergic responses. Several experimental and epidemiological studies have 
provided evidence that allergen-induced airway responses can be further enhanced upon 
exposure to environmental pollutants, such as diesel exhaust particles (DEP). However, the 
components and pathways responsible remain incompletely known.  
Objective: To investigate the relative contribution of ILC2 and adaptive TH2 cell responses in a 
murine model of DEP-enhanced allergic airway inflammation. 
Methods: Wild-type (WT), Gata3+/nlslacZ (Gata-3 haploinsufficient), RORαfl/flIL7RCre (ILC2-deficient) 
and Rag2-/- mice were challenged with saline, DEP or house dust mite (HDM), or combined 
DEP+HDM. Airway hyperresponsiveness as well as inflammation and intracellular cytokine 
expression in ILC2 and TH2 cells in the bronchoalveolar lavage fluid and lung tissue were assessed.  
Results: Concomitant DEP+HDM exposure significantly enhanced allergic airway inflammation, 
characterized by increased airway eosinophilia, goblet cell metaplasia, accumulation of ILC2 and 
TH2 cells, type 2 cytokine production and airway hyperresponsiveness, compared to sole DEP or 
HDM. Reduced Gata-3 expression decreased the number of functional ILC2 and TH2 cells in 
DEP+HDM exposed mice, resulting in an impaired DEP-enhanced allergic airway inflammation. 
Interestingly, whereas the DEP-enhanced allergic inflammation was marginally reduced in ILC2-
deficient mice that received combined DEP+HDM, it was abolished in DEP+HDM-exposed Rag2-/- 
mice.  
Conclusion: These data indicate that dysregulation of ILC2 and TH2 cells attenuates DEP-
enhanced allergic airway inflammation. In addition, a crucial role for the adaptive immune system 





Asthma is a chronic disorder of the conducting airways that is associated with a reversible airway 
obstruction, chronic airway inflammation, airway remodeling, and airway hyperresponsiveness 
[10]. It is a heterogeneous disease where multiple phenotypes can be distinguished based on 
clinical characteristics and inflammatory profile. Asthma that originates during childhood (early-
onset asthma) mostly has an atopic component [6, 270] and is typically considered as mainly a T 
helper 2 (TH2) driven disease [305].  
In addition to the adaptive immune system, the airway epithelium has gained great importance 
during the initiation and maintenance of the allergic and asthmatic cascade. In particular, it has 
been shown that upon allergen exposure, several epithelial cytokines – such as interleukin (IL)-
25, IL-33 and thymic stromal lymphopoietin (TSLP) – are involved in the pathogenesis of asthma 
[102, 306]. Moreover, several genes discovered in genome wide association studies (i.e. IL-33, IL-
1RL1, TSLP) support a key role for these cytokines [16, 17]. On the one hand, these epithelial-
derived cytokines have the capability to activate the adaptive immune system by stimulating TH2 
polarizing dendritic cells (DC) [102]. On the other hand, the recently identified type 2 innate 
lymphoid cells (ILC2) also become activated by these cytokines [307-309]. Analogous with the 
TH2 cells, ILC2 require the transcription factor Gata-3 and are a potent source of the type 2 
cytokines IL-5 and IL-13, which are able to induce lung eosinophilia and mucus hypersecretion 
[170, 199, 234, 235, 310]. Studies in Rag-/- mice have shown that these ILC2 are crucial players in 
allergic airway responses [311]. Even in the absence of the adaptive immune system, ILC2 were 
able to mediate eosinophilia, goblet cell metaplasia, type 2 cytokine production and airway 
hyperresponsiveness (AHR) [241, 242, 312]. In addition, mice that were ILC2-deficient due to the 
targeting of the transcription factor RORα had decreased type 2 immune responses [170, 245, 
249]. Interestingly, it was reported that ILC2 and T cells interact with each other and that this 
crosstalk could contribute to the maintenance, proliferation and activation of both ILC2 and TH2 
cells [248, 249, 252].  
Besides allergen exposure, it has become well accepted that traffic-related particulate matter, 
such as diesel exhaust particles (DEP), also contributes to the development and exacerbation of 
asthma [23, 60, 313]. For instance, epidemiological studies reported a correlation between high 
DEP levels and the frequency of symptomatic episodes in allergic children [314]. In addition, 
combined allergen + DEP administration during controlled human exposure studies resulted in 
increased allergen-specific immunoglobulins and type 2 cytokine responses [99]. Furthermore, 
concomitant DEP + house dust mite (HDM) exposure in murine models enhanced eosinophilia, 
immunoglobulin production, AHR and remodelling [96].  However, the mechanisms underlying 
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the enhanced effects of DEP on allergen-induced airway inflammation remain largely unknown. 
Several studies suggested that the airway epithelium could be an important player since 
particulate matter was also able to stimulate the release of several epithelial-derived cytokines, 
such as TSLP and IL-33, which can lead to enhanced DC maturation and TH2 responses [94, 95, 
122, 186]. However, whether this also activates ILC2 is unknown.  
In this paper, we investigate the relative contribution of ILC2 and the adaptive immune system in 
the enhancing effects of DEP on allergen-induced airway inflammation. We show in a murine 
model that concomitant exposure to a clinically relevant allergen (i.e. HDM) and DEP enhances 
several allergic airway responses, including airway eosinophilia, goblet cell metaplasia, increased 
ILC2 and TH2 cells, type 2 cytokine production and AHR. Since Gata-3 is an important transcription 
factor during the development and function of both ILC2 and TH2 cells [315], we used 
haploinsufficient  Gata3+/nlslacZ mice – which have a reduced expression of Gata-3 [316] – to 
demonstrate that the enhancing effects of DEP on allergic airway inflammation depend on Gata-3 
mediated regulation of ILC2 and TH2 cells. Moreover, to examine the specific contribution of ILC2 
in the model of DEP-enhanced allergic airway inflammation, we used a conditionally targeted 
RORαfl/fl mouse that, when intercrossed with IL-7 receptor (IL7R)-Cre mice, yields an ILC2-
deficient mouse strain in which other lineages are unaffected [249]. Finally, to investigate the 
functional role of the adaptive immune system in this model, we used RAG2-/- mice which lack 
mature T and B cells [317]. We demonstrated that ILC2 marginally contributed to DEP-enhanced 
allergic airway responses, whereas the adaptive immune system appeared critical to orchestrate 




MATERIAL & METHODS 
Mice 
Female C57BL/6 mice (6-8 weeks old) were obtained from the Jackson Laboratory. C57BL/6 
Gata3+/nlslacZ and their WT littermates were a kind gift of Dr. R. Hendriks (Department of 
pulmonary medicine, Erasmus MC, Rotterdam, The Netherlands) [316] and bred in our animal 
facility of Ghent University. RORαfl/flIL7RCre mice and RORαfl/flIL7R+/+ controls were on a C57BL/6 
background [249]. C57BL/6 Rag2-/- mice [317] and their wild-type (WT) controls were purchased 
from Taconic. All in vivo manipulations were approved by the Animal Ethical Committee of the 
Faculty of Medicine and Health Sciences of Ghent University. 
 
Intranasal instillation of reagents 
DEP (SRM 2975) was purchased from the National Institute for Standards and Technology (NIST). 
HDM (Dermatophagoides pteronyssinus) was obtained from Greer laboratories. Saline, 1µg HDM 
extract dissolved in saline, 25µg DEP suspended in saline or a combination of DEP+HDM were 
delivered intranasally to isoflurane anesthetized mice using a continuous flow vaporizer on day 
1, 8 and 15. Two days after the last challenge, mice were sacrificed with a lethal dose 
intraperitoneal pentobarbital. Tween 80 (0.05%) was used as a vehicle in all conditions. 
 
Bronchoalveolar lavage fluid (BALF) 
A tracheal cannula was inserted and BALF was recuperated by instillation of 3 x 300µl 1% Hank’s 
balanced salt solution (HBSS) supplemented with 1% bovine serum albumin (BSA) and 6 x 500µl 
HBSS supplemented with ethylenediaminetetraacetic acid (EDTA). The lavage fractions were 
pooled and total cell counts were measured using a Bürker chamber.  Differential cell counts were 
performed on cytospin after a May-Grünwald-Giemsa staining.  The remaining cells were used for 
flow cytometry. 
 
Lung and mediastinal lymph node single cell suspensions  
The pulmonary circulation was rinsed with saline supplemented with EDTA to remove the 
intravascular pool of cells. Lungs and mediastinal lymph nodes (MLN) were minced and incubated 
for 45 minutes in digestion medium (roswell park memorial institute medium (RPMI)-1640 
supplemented with 5% foetal calf serum (FCS), 2 mM L-glutamine, 0.05 mM 2-mercaptomethanol, 
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100 U/ml penicillin, 100 mg/ml streptomycin, 1 mg/ml collagenase type 2, and 0.02 mg/ml DNase 
I) at 37°C and 5% CO2.  Red blood cells were lysed using ammonium chloride buffer. Total cell 
counts were performed with a Z2 Coulter Counter. 
 
Mediastinal lymph node cell culture 
MLN were harvested and digested as described above. Cells were cultured in culture medium 
either alone or supplemented with 3.75µg/well HDM in round bottom, 96-well plates and 
incubated in a humidified 37°C incubator with 5% CO2. After 5 days, supernatants was harvested 
for cytokine measurements.  
 
Flow cytometry 
BALF cells and single lung suspensions were stained with a combination of anti-mouse 
fluorochrome-conjugated monoclonal antibodies against: CD4 (GK1.5), CD8 (53-6.7), CD11b 
(M1/70), CD69 (H1.2F3), Ly6C (AL-21), Ly6G (1A8), MHCII (2G9), Siglec-F (E50-2440) (all BD 
Biosciences); CD3 (145-2C11), CD90.2 (30.H12) (all Biolegend); CD5 (53-7.3), CD11c (N418), 
CD25 (PC61.5),  CD127 (A7R34), CD45R (RA3-6B2), NK1.1 (PK136), TCRβ (H57-597) (all 
eBioscience). For cytoplasmatic cytokine staining, cells were stimulated for 4 hours with 
ionomycin and phorbol 12-myristate 13-acetate (PMA), supplemented with brefeldin A and 
monensin at 37°C for 4h. The intracellular fixation and permeabilization buffer set (eBioscience) 
was used for fixation and cell permeabilization. The following antibodies were used: PE-
conjugated anti-IL-5 (TRFK5), anti-IL-13 (eBio13A) and isotype-matched controls (eBioscience). 
Data acquisition was performed on a FACSCalibur flow cytometer running CellQuest software or 
a LSR II cytometer running DiVa software. 250.000 events were collected. Cell subsets were 
analyzed using FlowJo software. Representative flow cytometric density plots and gating strategy 
of all analyzed cell populations in BALF and lung tissue can be found in the materials & methods 
section (Figure 15, p.54).  
 
Histology 
The left lung was fixated with 4% paraformaldehyde (PFA) and embedded in paraffin. 3µm 
transversal sections were stained with a Congo Red staining to identify eosinophils or with a 
Periodic Acid‐Schiff (PAS) staining to analyze goblet cells. Quantitative measurements were 





IL-4, IL-5 and IL-13 levels in BALF or MLN supernatants were measured by commercially available 
ELISA kits (R&D systems). In lung homogenates, IL-25 and IL-33 were measured with ELISA (R&D 
systems) following the manufacturer’s instructions. HDM-specific IgG1 was determined on serum 
collected by retro-orbital bleeding. For detection, plates were coated with HDM extract. Serum 
was added, followed by an HRP-conjugated polyclonal goat anti-mouse IgG1 antibody (Bethyl 
Laboratories). The plate was read at 490nm. HDM-IgG1 levels were reported in optical densities 
(OD). All samples were on the same plate and experimental data from different plates are not co-
presented. 
 
Airway hyperresponsiveness (AHR) 
Airway hyperresponsiveness in response to increasing doses carbachol (0, 20, 40, 80, 160, 320, 
640 µg/kg) was measured 48 hours after the last intranasal instillation using the forced oscillation 
technique (Flexivent System, SCIREQ, Montreal, QC, Canada). Neuromuscular blockade was 
induced by injecting 1mg/kg pancuronium bromide intravenously. A “snapshot perturbation” 
maneuver was imposed to measure the resistance (R) of the whole respiratory system (airways, 
lung and chest wall).   
 
Statistical analysis 
Statistical analysis was performed with SPSS, version 22.0. Non parametric tests (Kruskal-Wallis 
and Mann-Whitney-U) were used to compare different groups, according to the standard 






Exposure to diesel exhaust particles enhances house dust mite-induced airway 
inflammation 
C57BL/6 mice were exposed to saline, DEP or HDM alone, or combined DEP+HDM (Fig. 1A). In 
order to have a model wherein we could optimally examine the potential adjuvant capacities of 
DEP on HDM-induced airway inflammation, mice were exposed to doses of DEP and HDM that 
elicited almost no inflammatory response on their own (dose titrations for HDM are shown in Fig. 
S1, BALF inflammation to low versus high doses of DEP was previously shown [94]). Exposure to 
DEP alone slightly increased the amount of DC, neutrophils and CD4+ T cells in the BALF, in 
comparison with saline-exposed mice (Fig. 1D, E and G). Administration of HDM induced a 
modest increase of DC, CD4+ T cells, CD8+ T cells and eosinophils in the BALF when compared with 
the saline group (Fig. 1D, G, H and I). In contrast, combined exposure to DEP+HDM greatly 
enhanced the allergic airway immune responses. Concomitant exposure to DEP+HDM elicited a 
marked increase in the epithelial-derived cytokines IL-25 and IL-33 (Fig. 1B, C). Moreover, the 
numbers of DC, neutrophils, ILC2, CD4+ T cells, CD8+ T cells and eosinophils were significantly 
increased in the BALF of WT mice that received combined DEP+HDM compared with the three 
control groups (Fig. 1D-I). Of note, all ILC2 expressed ST2 (data not shown), resembling natural 
ILC2 [208]. Co-exposure of DEP+HDM was also associated with a significant enhancement of 
inflammatory cells in the lung tissue (Fig. S2). Furthermore, histological examination revealed 
increased peribronchovascular eosinophilic inflammation and goblet cell metaplasia upon 
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Figure 1: Exposure to diesel exhaust particles enhances house dust mite-induced airway inflammation in the 
BALF. WT mice were exposed to saline (white bar), 25µg DEP (striped bar), 1µg HDM (checked bar) or DEP+HDM (black 
bar) on day 1, 8 and 15. A, Schematic overview of our model of DEP-enhanced allergic airway inflammation. B-C, IL-25 
(B) and IL-33 (C) protein levels in lung were determined by ELISA. D-I, DC (CD11chigh, low autofluorescent, MHCII+) 
(D), neutrophils (E), ILC2 (Lin- (CD3-, CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- and CD45R-) CD25+ CD90+) (F), CD4+ T cells 
(CD3+ CD4+ CD8-) (G), CD8+ T cells (CD3+ CD8+ CD4-) (H) and eosinophils (I) in BALF were determined by flow 
cytometry except neutrophils and eosinophils that were determined on cytospin. Results are expressed as mean ± SEM. 
n = 7-8 mice per group. * p < 0.05. Data are representative of three independent experiments. Representative flow 
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Figure 2: Exposure to diesel exhaust particles enhances house dust mite-induced airway inflammation in the 
lung. WT mice were exposed to saline (white bar), 25µg DEP (striped bar), 1µg HDM (checked bar) or DEP+HDM (black 
bar) on day 1, 8 and 15. A-B, Representative photomicrographs and quantification of peribronchovascular eosinophils 
(A) and PAS-stained lung specimen (B). Results are expressed as mean ± SEM. n = 7-8 mice per group. * p < 0.05. Data 
are representative of three independent experiments.  
 
Combined exposure to DEP+HDM increases type 2 cytokine production, HDM-specific IgG1 
and induces airway hyperresponsiveness 
Typical type 2 cytokines were evaluated in the BALF and supernatant of HDM-restimulated MLN 
that were obtained from WT mice exposed to saline, DEP or HDM alone, or combined DEP+HDM. 
In the BALF of mice exposed to DEP+HDM, elevated IL-5 and IL-13 levels were found compared 
to the three control groups, whereas HDM or DEP alone elicited no response (Fig. 3A, B). In the 
supernatant of HDM-restimulated MLN, concomitant DEP+HDM exposed mice had marked higher 
levels of IL-4, IL-5 and IL-13, compared to the control groups (Fig. 3C-E). In contrast, exposure to 
DEP alone was associated with a modest increase in IL-4 and IL-13 in comparison with the saline 
group (Fig. 3C, E). Sole HDM administration slightly increased IL-5 and IL-13 levels in the MLN 
compared with the saline-exposed group (Fig. 3D, E). Furthermore, combined DEP+HDM exposed 
mice had significantly elevated HDM-specific IgG1 titers in serum, when compared to saline-, DEP- 
and HDM-exposed control groups (Fig. 3F). Additionally, mice that were concomitantly exposed 
to DEP+HDM showed AHR in comparison with the three control groups (Fig. 3G). 
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Figure 3: Combined exposure to DEP+HDM increases type 2 cytokine production, HDM-specific IgG1 and 
induces airway hyperresponsiveness. WT mice were exposed to saline (white bar), 25µg DEP (striped bar), 1µg HDM 
(checked bar) or DEP+HDM (black bar) on day 1, 8 and 15. A-B, IL-5 (A) and IL-13 (B) protein levels in BALF were 
determined by ELISA. C-E, IL-4 (C), IL-5 (D), IL-13 (E) protein levels in the supernatants of HDM-restimulated MLN 
were determined by ELISA. F, HDM-specific IgG1 titers in serum were determined by ELISA. G, Airway resistance (R) of 
saline (black line), DEP (blue line), HDM (green line) and DEP+HDM (red line) exposed mice was measured in response 
to increasing doses of carbachol. Results are expressed as mean ± SEM. n = 7-8 mice per group. * p < 0.05. Data are 
representative of two independent experiments. 
 
Reduced Gata-3 expression impairs airway eosinophilia and mucus metaplasia upon 
combined DEP+HDM exposure 
Gata-3 is an important transcription factor for the development of ILC2 and TH2 cells [315]. Since 
the Gata-3 gene copy number is positively correlated with both ILC2 and TH2 function [318-320], 
we evaluated the effect of reduced Gata3 expression in our model of DEP-enhanced allergic airway 








galactosidase reporter [316], and WT littermates were exposed to saline, DEP or HDM alone, or 
the combination of DEP+HDM. Concomitant DEP+HDM exposure in Gata3+/nlslacZ mice resulted in 
DC, neutrophil, CD4+ T cell and CD8+ T cell numbers that were comparable to those in WT 
littermates, whereas ILC2 and eosinophil numbers in the BALF were significantly reduced (Fig. 
4A-F). Moreover, histological analyses in DEP+HDM exposed Gata3+/nlslacZ mice revealed a 
diminished peribronchial eosinophilic inflammation and goblet cell metaplasia compared to their 
littermate controls (Fig. 5A, B). Also upon sole HDM exposure, a reduced eosinophilia (Fig. 5A) 
and goblet cell metaplasia (Fig. 5B) was observed in the Gata3+/nlslacZ mice in comparison with 
littermates. Comparable HDM-specific IgG1 levels in the serum were found in WT and Gata3+/nlslacZ 
mice that were exposed to DEP+HDM (Fig. 5C). Moreover, concomitant exposure to DEP+HDM 
led to a similar increase in airway responsiveness in Gata3+/nlslacZ mice and  WT littermates, when 
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Figure 4: Reduced Gata-3 expression impairs BALF eosinophilia upon combined DEP+HDM exposure. WT and 
Gata3+/nlslacZ mice were exposed to saline (white bar), 25µg DEP (striped bar), 1µg HDM (checked bar) or DEP+HDM 
(black bar). A-F, DC (CD11chigh, low autofluorescent, MHCII+) (A), neutrophils (B), ILC2 (Lin- (CD3-, CD5-, NK1.1-, TCRβ-
, CD11c-, CD11b- and CD45R-) CD25+ CD90+) (C), CD4+ T cells (CD3+ CD4+ CD8-) (D), CD8+ T cells (CD3+ CD8+ CD4-) (E) 
and eosinophils (F) in BALF were determined by flow cytometry except neutrophils and eosinophils that were 
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Figure 5: Reduced Gata-3 expression impairs airway eosinophilia and mucus metaplasia upon combined 
DEP+HDM exposure. WT and Gata3+/nlslacZ mice were exposed to saline (white bar), 25µg DEP (striped bar), 1µg HDM 
(checked bar) or DEP+HDM (black bar). A-B, Representative photomicrographs and quantification of congo red stained 
lungs (A) or PAS-stained mucus producing goblet cells (B) of DEP+HDM exposed WT and Gata3+/nlslacZ mice. C, HDM-
specific IgG1 levels in serum were determined by ELISA. D, Airway resistance (R) in WT (full line) and Gata3+/nlslacZ 
(broken line) mice was measured in response to increasing doses of carbachol. Results are expressed as mean ± SEM. 
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Reduced Gata-3 expression decreases type 2 cytokine production by ILC2 and CD4+ T cells 
upon combined DEP+HDM exposure 
We further assessed the type 2 cytokine production in Gata3+/nlslacZ mice and WT littermates in 
response to combined DEP+HDM. Exposure to DEP+HDM led to reduced IL-13 levels in BALF of 
Gata3+/nlslacZ mice, compared to littermates (Fig. 6A). In addition, intracellular type 2 cytokine 
production in both ILC2 and CD4+ T cells was investigated in BALF and lung tissue. The increased 
numbers of IL-13 positive ILC2 and CD4+ T cells that were observed in BALF of DEP+HDM WT 
mice were significantly decreased in DEP+HDM exposed Gata3+/nlslacZ mice (Fig. 6B, C). Moreover, 
IL-5 and IL-13 expressing ILC2 were significantly diminished in lung single cell suspensions of 
Gata3+/nlslacZ mice independent of the exposure, compared to littermates (Fig. 6D, E). The 
increased percentages of IL-5 and IL-13 positive CD4+ T cells that were observed in the co-exposed 
DEP+HDM Gata3+/nlslacZ mice did not significantly differ from their WT controls. In contrast, 
Gata3+/nlslacZ mice exposed to sole HDM had significant lower IL-5 and IL-13 positive CD4+ T cells 
in comparison with the littermates (Fig. 6F, G). 
 
ILC2 marginally contribute to DEP-enhanced allergic airway inflammation 
Since Gata-3 haploinsufficiency affects both the innate and adaptive component, we next 
examined the specific contribution of ILC2 in the enhancing effects of DEP on allergic airway 
inflammation. For that, we exposed RORαfl/flIL7RCre (ILC2-deficient) mice [249] and their 
corresponding  RORαfl/flIL7R+/+ controls to HDM and DEP+HDM. As expected, ILC2 numbers in the 
BALF were abolished in RORαfl/flIL7RCre mice, independent of the exposure (Fig. 7A). Concomitant 
DEP+HDM exposed RORαfl/flIL7RCre mice had significant reduced DC in the BALF (Fig. 7B), 
whereas the BALF neutrophils, CD4+ T cells, CD8+ T cells and eosinophils tended to decrease 
compared to RORαfl/flIL7R+/+ controls (Fig. 7C-F). Histological analyses further revealed a similar 
peribronchial eosinophilia and goblet cell metaplasia between DEP+HDM exposed RORαfl/flIL7RCre 
mice and controls (Fig. 8A, B). Moreover, the increased BALF IL-5 (data not shown) and IL-13 
levels found upon DEP+HDM exposure in the BALF and supernatants of restimulated MLN did not 
differ between RORαfl/flIL7RCre mice and RORαfl/flIL7R+/+ controls (Fig. 8C, D). Levels of HDM-
specific IgG1 were also comparable between DEP+HDM exposed RORαfl/flIL7RCre mice and their 
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Figure 6: Reduced Gata-3 expression decreases cytokine production by ILC2 and CD4+ T cells upon combined 
DEP+HDM exposure. WT and Gata3+/nlslacZ mice were exposed to saline (white bar), 25µg DEP (striped bar), 1µg HDM 
(checked bar) or DEP+HDM (black bar). A, IL-13 protein levels in BALF were determined by ELISA. B-G, BALF or lung 
cells were stimulated for 4 hours with PMA/iomycin, intracellular labeled for cytokine production and analyzed using 
flow cytometry. Percentage IL-13 expressing ILC2 (Lin- (CD3-, CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- and CD45R-) CD25+ 
CD90+) (B) or CD4+ T cells (CD3+  CD4+) (C) in BALF. Proportion of IL-5 (D) and IL-13 (E) producing ILC2 (Lin- (CD3-, 
CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- and CD45R-) CD25+ CD90+) in the total lung tissue. Percentages IL-5 (F) and IL-13 
(G) positive T cells (CD3+ CD4+) of total lung. Results are expressed as mean ± SEM. n = 7-8 mice per group. * p < 0.05. 
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Figure 7: ILC2 marginally contribute to DEP-enhanced allergic airway inflammation. RORαfl/flIL7RCre mice and 
RORαfl/flIL7R+/+ WT controls were exposed to 1µg HDM (checked bar) or DEP+HDM (black bar). A-F, ILC2 (Lin- (CD3-, 
CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- and CD45R-) CD25+ CD90+) (A), DC (CD11chigh, low autofluorescent, MHCII+) (B), 
neutrophils (C),  CD4+ T cells (CD3+ CD4+ CD8-) (D), CD8+ T cells (CD3+ CD8+ CD4-) (E) and eosinophils (F) in BALF were 
determined by flow cytometry except neutrophils and eosinophils that were determined on cytospin. Results are 
expressed as mean ± SEM. n = 8 mice per group. * p < 0.05. 
 
The adaptive immune system has a crucial role in DEP-enhanced allergic airway 
inflammation 
To investigate how the adaptive immune system contributes to the DEP-enhanced allergic airway 
inflammation, we exposed WT and Rag2-/- mice – which lack an adaptive immune system [317] – 
to saline, DEP or HDM alone, or combined DEP+HDM. As expected, Rag2-/- mice had no mature 
CD4+ T cells in the lung, whereas the proportion of lung ILC2 was increased, independent of the 
exposure (Fig. 9A, B). Rag2-/- mice and WT controls that were co-exposed to DEP+HDM had 
similar ratios of DC and neutrophils in the BALF (Fig. 9C, D). However, combined DEP+HDM 
exposure resulted in a complete abolishment of BALF eosinophils compared to the WT controls 
(Fig. 9E). Histological analyses further revealed a severely reduced eosinophilia and abolished 
goblet cell metaplasia in the Rag2-/- mice that received combined DEP+HDM in comparison with 
WT controls (Fig. 10A, B). Additionally, combined DEP+HDM exposure failed to increase BALF 
IL-5 (data not shown) and IL-13 levels in BALF and supernatants of restimulated MLN in Rag2-/- 
mice compared with their WT controls (Fig. 10 C, D). The modest inflammation that was seen in 
the WT mice upon sole HDM exposure was also completely abolished in the Rag2-/- mice. 
D. E. F. 
A. B. C. 
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Independent of the exposure, there was no HDM-specific IgG1 production in Rag2-/- mice, 
compared to WT controls (data not shown). Furthermore, RAG2-/- mice had no increase in airway 
responsiveness in response to DEP + HDM (Fig. 10E).  
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Figure 8: ILC2 marginally contribute to DEP-enhanced allergic airway inflammation. RORαfl/flIL7RCre mice and 
RORαfl/flIL7R+/+ WT controls were exposed to 1µg HDM (checked bar) or DEP+HDM (black bar). A-B, Representative 
photomicrographs and quantification of congo red stained lungs (A) or PAS-stained mucus producing goblet cells (B). 
C-E, BALF IL-13 protein levels (C), IL-13 levels in the supernatants of HDM-restimulated MLN (D) and HDM-specific 
IgG1 levels in serum (E) were determined by ELISA. Results are expressed as mean ± SEM. n = 8 mice per group. * p < 
0.05.  
A. B. 
C. D. E. 
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Figure 9: The adaptive immune system has a crucial role in DEP-enhanced allergic airway inflammation. WT 
and Rag2-/- mice were exposed to saline (white bar), 25µg DEP (striped bar), 1µg HDM (checked bar) or DEP+HDM 
(black bar). A-E, Percentage CD4+ T cells (CD3+ CD4+ CD8- CD69+) of total lung (A), percentage lung ILC2 (Lin- (CD3-, 
CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- and CD45R-) CD25+ CD127+) (B), number of BALF DC (CD11chigh, low 
autofluorescent, MHCII+) (C), number of BALF neutrophils (D) and number of BALF eosinophils (E) were determined 
by flow cytometry except neutrophils and eosinophils that were determined on cytospin. Results are expressed as mean 
± SEM. n = 7-8 mice per group. * p < 0.05. 
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Figure 10: The adaptive immune system has a crucial 
role in DEP-enhanced allergic airway inflammation. WT 
and Rag2-/- mice were exposed to saline (white bar), 25µg 
DEP (striped bar), 1µg HDM (checked bar) or DEP+HDM 
(black bar. A-B, Representative photomicrographs and 
quantification of congo red stained lungs (A) or PAS-stained 
mucus producing goblet cells (B) of DEP+HDM exposed WT 
and Rag2-/- mice. C-D, BALF IL-13 protein levels (C) and IL-
13 levels in the supernatants of HDM-restimulated MLN (D) 
were determined by ELISA. E, airway resistance (R) in WT 
(full line) and Rag2-/- (broken line) mice was measured in 
response to increasing doses of carbachol. Results are 
expressed as mean ± SEM. n = 7-8 mice per group. * p < 0.05. 












In this paper, we demonstrated that dysregulation in ILC2 and TH2 cell numbers and function by 
targeting Gata-3 was associated with an attenuated airway inflammation upon concomitant 
DEP+HDM exposure. Moreover, we showed a critical role of the adaptive immune system to DEP-
enhanced allergic responses and AHR, whereas ILC2 only marginally contribute to DEP-enhanced 
allergic airway inflammation.  
 
The immunological mechanisms by which DEP can promote allergen-induced airway 
inflammation are largely unknown. To unravel these cellular and molecular mechanisms, we set 
up a mouse model with concomitant exposure to a clinical relevant allergen (i.e. HDM) and DEP. 
To have an optimal model wherein the potential adjuvant effects of DEP on HDM-induced allergic 
airway inflammation can be evaluated, we downtitrated the dose of DEP and HDM until they 
elicited minimal inflammatory responses on their own. We demonstrated that concomitant 
exposure to DEP+HDM markedly enhanced multiple features of allergic inflammation, 
characterized by an eosinophilic response, goblet cell metaplasia, ILC2 and TH2 cell accumulation, 
type 2 cytokine production, elevated HDM-specific IgG1 levels and AHR. In accordance with our 
findings, several experimental and epidemiological studies already provided evidence regarding 
the synergistic ability of DEP on allergic airway inflammation [23, 96, 99, 314]. Although these 
studies already demonstrated the enhanced effects on airway remodeling, AHR, eosinophilic 
inflammation and immunoglobulin production, insights concerning the number and function of 
the recently identified ILC2s in response to concomitant exposure to DEP+HDM were lacking. 
 
Epithelial cells are the first barrier to encounter several inhaled allergens and particles. In 
response to these particulates, the epithelium can release cytokines and chemokines to direct the 
recruitment and activation of several innate and adaptive immune cells [102, 306]. Upon HDM for 
instance, it was shown that IL-25 and IL-33 levels were upregulated, contributing to the observed 
airway and lung inflammation [159, 321]. Although we observed no increased IL-25 and IL-33 
response upon sole DEP or HDM, combined DEP+HDM exposure elicited an increase of IL-25 and 
IL-33 in particular, suggesting that DEP works synergistically with HDM to induce release of 
epithelial cytokines in the environment. 
 
These epithelial-derived cytokines share the capacity to stimulate TH2 development by polarizing 
DC on the one hand [102] and to activate ILC2 on the other hand [307, 308]. Whereas the role of 
TH2 cells in the pathogenesis of asthma is well established [5], it was recently shown that ILC2 can 
also substantially contribute to allergic airway inflammation [311]. Moreover, ILC2 can mediate 
AHR, independent of the adaptive immune system [242, 312]. Importantly, we found that 
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exposure to DEP+HDM increased the number of cytokine expressing ILC2 and TH2 cells in the 
alveolar space, suggesting that type 2 cytokine production of both cell types contributes to the 
adjuvant effects of DEP on allergic airway inflammation. Although the numbers of type 2 
expressing ILC2 in the lung did not increase upon combined DEP+HDM exposure, ILC2 could still 
be critical in initiating and maintaining the DEP-enhanced type 2 immune responses. At least in 
response to the pollutant ozone, it was suggested that the increased activation of ILC2 was 
associated with an enhanced eosinophilic inflammation towards Aspergillus fumigates [255]. 
 
Since Gata-3 is an important transcription factor during the development and function of ILC2 as 
well as TH2 cells [315], we investigated the effects of Gata-3 modulation in our model of DEP-
enhanced allergic airway inflammation. At baseline, Gata3+/nlslacZ mice[4] had lower functional 
ILC2 in the lung, while effects on TH2 cells were limited. In response to DEP+HDM, both IL-13 
expressing ILC2 and TH2 cells were attenuated in BALF of Gata3+/nlslacZ mice, suggesting that the 
observed reduction in type 2 airway inflammation could be the result of diminished functional 
ILC2 and TH2 cells in the bronchoalveolar space. In addition, considering that co-exposure of 
DEP+HDM only tended to decrease the type 2 cytokine expressing TH2 cells in the lung whereas 
the ILC2 were abolished, the imbalance of functional ILC2 and TH2 cells in the lung could 
contribute to the reduced eosinophilic inflammation. Importantly, the reduction of type 2 
expressing ILC2 and TH2 cells in Gata3+/nlslacZ mice had no effect on the development of AHR in 
response to DEP+HDM[5]. Interestingly, the modest inflammation that was observed in response 
to only HDM was also greatly reduced in the Gata3+/nlslacZ mice. In line, exposure of Gata-3 mutant 
mice to ovalbumin inhibited the allergic airway inflammation [322]. Moreover, therapeutic 
targeting of Gata-3 in a clinical trial involving allergic asthmatics also attenuated both late and 
early allergen-induced asthmatic responses [323].  
 
To further assess the relative contribution of the innate (i.e. ILC2) and adaptive (i.e. TH2 cells) arm 
in our model of DEP-enhanced allergic airway inflammation, we used RORαfl/flIL7RCre (ILC2-
deficient) mice and Rag2-/- mice respectively. Intriguingly, we found that the DEP-enhanced 
allergic airway inflammation only tended to decrease in RORαfl/flIL7RCre mice, whereas typical type 
2 immune responses such as eosinophilia, mucus metaplasia and type 2 cytokine production were 
completely abolished in Rag2-/- mice that received combined DEP+HDM. In addition, Rag2-/- mice 
exposed to DEP+HDM failed to develop AHR. This suggests that the presence of an adaptive 
immune system or at least an adequate interaction of adaptive immune cells with ILC2 is required 
in mediating the adjuvant capacity of DEP on HDM-enhanced allergic airway inflammation and 
AHR. Of note, depletion of CD4+ or CD8+ T cells in a murine model with intraperitoneal exposure 
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to DEP+ovalbumin was associated with abrogated cytokine production and ovalbumin-specific 
immunoglobulin responses in the peritoneal exudate fluid [324]. Interestingly, whereas it was 
previously shown that ILC2 were critical in T-cell independent allergic lung inflammation [241], 
the modest inflammation in response to HDM in our model was completely abolished in the Rag2-
/- mice. The amount of administered HDM could therefore be important, suggesting that doses of 
HDM that elicit limited biological inflammation on their own are unable to activate ILC2 and to 
drive the allergic airway inflammation in absence of an adaptive immune system. Furthermore, it 
could be that ILC2 are of less importance in subchronic responses than during the acute phases of 
an inflammatory response. This was supported by research performed in a papain model, where 
the secondary responses were more likely TH2 dependent [170]. Moreover, it was suggested that 
the communication between ILC2 and TH2cells by a MHCII-mediated dialog or specific cytokine 
secretion could be crucial to substantiate their effects on allergic airway inflammation [248, 249, 
252]. It seemed however that upon concomitant DEP+HDM exposure activation of TH2 cells 
appeared relatively independent of ILC2, opposed to previous reports where ILC2 were crucial 
for the initiation of TH2 responses towards (relatively high) doses of HDM and papain [170, 245]. 
 
Taken together, although a significant role for ILC2s has been demonstrated in several models of 
allergen-induced inflammation, our findings suggest that co-exposure to multiple environmental 
factors, such as particulate pollutants and allergens (i.e. HDM), modulate the contribution of ILC2 





Figure S1: Titration of the HDM dose for the combined DEP+HDM model. C57BL/6 mice were 
exposed to decreasing doses of sole HDM (i.e. 12.5µg, 2.5µg, 1µg, 250ng, 25ng HDM) or combined 
25µg DEP + decreasing doses of HDM on day 1, 8 and 15. On day 17, BALF eosinophils were 
determined on cytospin. Data presented on the different graph represent separate experiments. 
The red box represents the selected dose for the experiments in the manuscript. Results are 
expressed as mean ± SEM. n = 8 mice per group. * p < 0.05.  
 
 

















































































































































































Figure S2: Adjuvant effect of DEP on HDM induced airway inflammation in the lung. WT mice 
were exposed to saline (white bars), 25µg DEP (striped bars), 1µg HDM (checked bars) or 
DEP+HDM (black bars) on day 1, 8 and 15. A-F, DC (CD11c+ MHCII+ CD11b+) (A), neutrophils 
(CD11c- CD11b+ Ly6G+ Ly6C+) (B), eosinophils (CD11c- CD11b+ Siglec-F+) (C), ILC2 (Lin-  (CD3-, 
CD5-, NK1.1-, TCRβ-, CD11c-, CD11b- and CD45R-) CD25+ CD90+) (D), CD4+ T cells (CD3+ CD4+ CD8- 
CD69+) (E) and CD8+ T cells (CD3+ CD8+ CD4- CD69+) (F) in lung tissue were determined by flow 
cytometry. Results are expressed as the mean percentages of total lung ± SEM. n = 7-8 mice per 
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CHAPTER 10: CHARACTERIZATION AND 
QUANTIFICATION OF INNATE LYMPHOID CELLS 
SUBSETS IN HUMAN LUNG  
 
Innate lymphoid cells (ILCs) are important regulators of tissue homeostasis, injury and 
inflammation. Whereas human ILC have been extensively studies in the intestines and skin, limited 
data are available concerning ILCs in the human respiratory system. The aim of this study was to 
characterize the different ILC subsets in human lung tissue and to investigate their relative 
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Background: Innate lymphoid cells (ILC) are a new family of innate immune cells that have 
emerged as important regulators of tissue homeostasis and inflammation. However, limited data 
are available concerning the relative abundance and characteristics of ILC in the human lung.  
 
Methods: The aim of this study was to characterize and enumerate the different ILC subsets in 
human lung by multi-color flow cytometry.  
 
Results: Within the CD45+ Lin- CD127+ pulmonary ILC population, we identified group 1 (ILC1), 
group 2 (ILC2) and group 3 (ILC3) innate lymphoid cells using specific surface markers (i.e. 
IL12Rβ2, CRTH2 and CD117 respectively) and key transcription factors (i.e. T-bet, GATA-3 and 
RORγT respectively). Based on the presence of NKp44, ILC3 were further subdivided in natural 
cytotoxicity receptor (NCR)+ and NCR- ILC3. In addition, we demonstrated the production of 
signature cytokines IFN-γ, IL-5, IL-17A, IL-22 and GM-CSF in the pulmonary ILC population. 
Interestingly, we observed a tendency to a higher frequency of NCR- ILC3 in lungs of patients with 
chronic obstructive pulmonary disease (COPD) compared with controls.  
 
Conclusions: We show that the three main ILC subsets are present in human lung. Importantly, 






Innate lymphoid cells (ILC) are a newly characterized heterogeneous family of the innate immune 
system, which have emerged as important regulators of tissue homeostasis, immunity and 
inflammation. ILC are morphologically similar to their counterpart of the adaptive immune 
system, T- and B-cells. Although they lack specific rearranged antigen receptors, which is a 
hallmark of the adaptive immune system, these innate immune cells can produce an array of 
cytokines in response to various danger signals and changes in homeostasis [199, 325]. Analogous 
with T-cells, ILC have been classified into three subsets – group 1 (ILC1), group 2 (ILC2) and group 
3 (ILC3) innate lymphoid cells – depending on their phenotype, function and transcriptional 
regulation. The ILC1 subset includes both natural killer (NK) cells and non-toxic ILC1. These non-
toxic ILC1 are characterized by the expression of the transcription factor T-bet and production of 
IFN-γ in response to interleukin (IL)-12. ILC2 depend on the transcription factor GATA-3 for their 
function and development and produce the type 2 cytokines, IL-5 and IL-13, in response to IL-25 
and IL-33. Finally, the ILC3 subset is divided into natural cytotoxicity receptor (NCR, i.e. NKp44, 
NKp46 and NKp30)+ ILC3 and NCR- ILC3. The latter group is a heterogeneous population which 
also encompasses lymphoid tissue inducers (LTi) cells. These ILC3 express the transcription 
factor RORγT and are capable to produce IL-17A, IL-22 or granulocyte-macrophage colony-
stimulating factor (GM-CSF) in response to IL-23 and IL-1β [198, 326].  
 
Over the last few years, human ILC subsets have been studied in several tissues, including the skin 
and intestines [326].  To characterize these ILC, several surface markers have been proposed 
based on studies in the gut [198]. To our knowledge, research into ILC in the human respiratory 
system is currently limited to ILC2 [264, 327-331]. Recently, one study showed the presence of 
ILC subsets in human lung tissue in the context of lung cancer [332]. However, the relative 
abundance of ILC1, NCR+ ILC3 and NCR- ILC3 in human lung tissue under inflammatory conditions 
such as chronic obstructive pulmonary disease (COPD) has not yet been characterized. COPD is a 
chronic inflammatory lung disease that is associated with the development of emphysema and 
lymphoid follicles. It has been shown that besides the adaptive immune system also innate 
immune cells substantially contribute to the pathogenesis of COPD [53].  
 
In this manuscript, we identified and quantified non-toxic ILC1, ILC2, NCR+ ILC3 and NCR- ILC3 
subsets in human lung by flow cytometry based on several phenotypical markers and signature 
transcription factors. Further, we examined the expression of specific cytokines in the pulmonary 
ILC population. Finally, we compared the relative abundance of the ILC subsets in control subjects 




MATERIAL AND METHODS  
Lung tissue 
Lung tissue was obtained from patients who underwent a surgical lung resection at Ghent 
University Hospital for solitary pulmonary tumors. Tissue was collected by a pathologist at 
maximum distance from the lung lesion, and showed no signs of retro-obstructive pneumonia or 
tumor invasion. Sixteen subjects were enrolled in our study and classified into 2 groups: 5 control 
subjects and 11 patients with COPD stage I or II. COPD diagnosis and severity was defined using 
pre-operative spirometry according to the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) classification: all control subjects had a post-bronchodilator ratio of forced expiratory 
volume in 1 second (FEV1) to forced vital capacity (FVC) above 70%, whereas all COPD patients 
had a FEV1/FVC ratio below 70%. Patients were diagnosed with COPD GOLD I when FEV1≥ 80%, 
patients with COPD GOLD II had a FEV1 between 50 and 80% predicted [333]. Written informed 
consents were obtained from all subjects, according to the protocol approved by the medical 
ethical committee of Ghent University Hospital. Patient characteristics are shown in Table 1. 
 
Single cell suspensions from lung tissue 
Lung resection specimens were processed as described previously to obtain single cell 
suspensions [334]. In brief, lung tissue was rinsed with physiological water (0.9 % NaCl) to 
remove residual blood. The lung tissue was cut into fine pieces and digested for 45 minutes at 
37°C in digestion medium (Roswell Park Memorial Institute medium (RPMI) 1640 supplemented 
with 5% fetal calf serum (FCS), 2 mM L-glutamine, 0.05 mM 2-mercaptomethanol (all Invitrogen), 
100 U/ml penicillin, 100 mg/ml streptomycin (Sigma-Aldrich), 1 mg/ml collagenase type 2 
(Worthington Biochemical), and 0.02 mg/ml DNase I (grade II from bovine pancreas; Boehringer 
Ingelheim)). Cells were resuspended in 10 mM ethylenediaminetetraacetic acid (EDTA) for 5 
minutes at room temperature on a shaker. Next, cells were filtered through a 40-µm cell strainer 
and mononuclear cells were isolated with Ficoll-PaqueTM plus (GE Healthcare). Finally, cells were 








Table 1: Subject Characteristics 
Characteristics  Controls 
n = 5 
COPD 
n = 11 
Gender (male/female)  3/2 10/1 
Age, years 1 
60 ± 11 67 ± 9 
BMI 1, 2 
25 ± 5 26 ± 5 
Smoking history, Pack Years 1 
8 ± 13 36 ± 11 
Smoking Status (never /current/ex smoker)  
3/2/0 0/5/6 
COPD GOLD Stage 
na3 I / II 
FEV1 % predicted, post-bronchodilator 1, 4 
99 ± 9 89 ± 16 
FVC % predicted, post-bronchodilator 1, 5 
107 ± 12 102 ± 18 
FEV1/FVC, post-bronchodilator 1, 4, 5 
77 ± 5 64 ± 5 
 
1 Data are expressed as mean ± standard deviation. 
2 BMI: body mass index. 
3 na: not applicable. 
4 FEV1: forced expiratory volume in 1 s. 
5 FVC: forced vital capacity. 
 
Flow cytometry  
Single cell suspensions were pre-incubated with human IgG to reduce nonspecific binding. For 
surface staining, the following human monoclonal antibodies were used: fluorescein 
isothiocyanate (FITC)-conjugated anti-CD45 (HI30), peridinin chlorophyll protein-cyanine 5.5 
(PerCP)-conjugated anti-CD3 (OKT3), anti-CD19 (HIB19), anti-CD11c (3.9), anti-CD11b (M1/70), 
allophycocyanin (APC)-conjugated anti-NKp44 (P44-8), PE/indotricarbocyanine (Cy7)-
conjugated anti-CD117 (104D2), brilliant violet 421TM-conjugated anti-CD127 (A019D5), 
brilliant violet 605TM-conjugated anti-CD56 (HCD56) (all from Biolegend); phycoerythrin (PE)-
conjugated anti-IL12Rβ2 (305719; R&D systems), biotinylated anti-CRTH2 (BM19; Miltenyi 
Biotec) in combination with streptavidin (SAV)-APC or SAV-APC-Cy7 (BD Biosciences). For 
cytoplasmatic cytokine staining, cells were simulated for 15 hours with phorbol myristate acetate 
(PMA) and ionomycin, supplemented with brefeldin A and monensin (eBioscience) at 37°C. The 
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intracellular fixation and permeabilization buffer set (eBioscience) was used for fixation and cell 
permeabilization. The following antibodies were used: PE-conjugated anti-IL-17A 
(eBio64CAP17), anti-IFN-γ (4S.B3), anti-IL-22 (22URTI), anti-IL-5 (TRFK5), anti-GM-CSF 
(GM2F3), and isotype-matched control antibodies (all eBioscience). For nuclear staining, 
Foxp3/transcription factor staining buffer (eBioscience) set was used in combination with the 
following antibodies: PE-conjugated anti-T-bet (eBio4B10), anti-GATA-3 (TWAJ), anti-RORγT 
(AFKJS-9), and isotype-matched control antibodies (all eBioscience).  
 
Data acquisition and analysis 
Data acquisition was performed on a LSRFortessa running DiVa software (BD Biosciences). Cell 
subsets were analyzed using FlowJo Software. Statistical analysis was performed with SPSS, 
version 22.0 (SPSS, Chicago, USA). A non-parametric test (Mann-Whitney-U) was used to compare 
the different ILC subsets in the control versus COPD group, according to the standard statistical 
criteria. P-values < 0.05 were considered as significant. Patient characteristics are expressed as 
the mean ± standard deviation (SD). Flow cytometric data are expressed as the mean ± standard 




Characterization of innate lymphoid cell subsets in human lung 
In humans, the presence of ILC subsets has been studied in blood, gut and skin. In order to 
characterize ILC subsets in human lung tissue, we analyzed surgical lung resection specimens        
(n = 16; patient characteristics are shown in table 1). Single cell suspensions were stained to 
identify the different ILC subsets. Fluorescence-minus-one controls were used to set flow 
cytometric gates (Fig. S2). ILC were characterized as CD45+ cells, a marker that is present on all 
hematopoietic cells. In addition, ILC lack the expression of specific lineage (Lin) markers (i.e. CD3 
(T-cells), CD19 (B-cells), CD11b (neutrophils/eosinophils) and CD11c (dendritic 
cells/macrophages)), but express CD127 (IL-7Rα), the receptor for IL-7. We further refer to these 
CD45+ Lin- CD127+ cell population as the pulmonary ILC population (Fig. 1A).  
 
To make a distinction between the different ILC subsets within the pulmonary ILC population, we 
used specific surface markers. Since NK cells could contaminate the ILC1 subset, we used the CD56 
marker to exclude NK cells and characterized the non-toxic ILC1 subset as CD56- IL12Rβ2+ 
pulmonary ILC (Fig. 1B). The ILC2 subset was identified as pulmonary ILC that express the 
chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), in analogy with 
ILC2 that previously were detected in the upper airways (Fig. 1C). Both ILC3 subsets, NCR+ ILC3 
and NCR- ILC3, were gated as CD117+ (c-kit) pulmonary ILC and a further distinction was made 
by NKp44, a natural cytotoxicity receptor (Fig. 1D). Using these staining combinations, we were 
able to discriminate between the three ILC subsets in human lung tissue. Moreover, we 
demonstrated that our staining combination was specific, since the surface markers that were 
used to characterize a specific ILC subset, were not expressed on other ILC subsets (Fig. S3). 
Interestingly, inclusion of extra lineage markers (i.e. CD1a, CD14, CD34, CD123, TCRαβ, TCRγδ, 





Figure 1: Characterization of innate lymphoid cell subsets in human lung. ILC subsets were identified by flow 
cytometry on single cell suspensions of digested human lung (n = 16). Fluorescence-minus-one controls were used to 
set gates (Fig. S2). A, The pulmonary ILC population was characterized as CD45+, Lin- (i.e. CD3, CD19, CD11c, CD11b) 
and CD127+ cells. Subsets were further defined based on specific surface markers. B, Non-toxic ILC1 were further gated 
as CD56-, IL12Rβ2+ cells. C, The ILC2 subset expresses CRTH2. D, NCR+ ILC3 were CD117+, NKp44+, whereas NCR- ILC3 
were characterized as CD117+, NKp44- cells.  
 
Intracellular staining of transcription factors in pulmonary ILC subsets 
Besides characterization based on surface markers, also specific transcription factors can be used 
to characterize ILC subsets. For that purpose, we assessed the expression of key transcription 
factors within the different ILC subsets using intracellular flow cytometry. T-bet expression was 
detectable within the non-toxic ILC1 subset and – interestingly – also in the ILC3 subset, but not 
in the ILC2 subset (Fig. 2A). The transcription factor GATA-3 was clearly expressed in the ILC2 
subset, whereas no to limited GATA-3 levels were found in the ILC1 and ILC3 subsets (Fig. 2B). 
Finally, specific expression of RORγT was demonstrated in the ILC3 subset; which contrasts with 






Figure 2: Intracellular staining of transcription factors in pulmonary ILC subsets. The developmental 
transcription factors were determined in the specific ILC subsets on single cell suspensions of digested human lung. A, 
Expression of T-bet (black line) versus isotype control (grey line) in the ILC1 (CD45+, Lin- CD127+, CD56-, CRTH2-, 
CD117-), ILC2 (CD45+, Lin-, CD127+, CRTH2+), ILC3 (CD45+, Lin-, CD127+, CD117+) population. B, GATA-3 expression 
(black line) versus isotype control (grey line) in the different ILC subsets. C, Expression of RORγT (black line) versus 
isotype control (grey line) in ILC1, ILC2 and ILC3 population.  
 
Intracellular cytokine production in the pulmonary ILC population 
To assess signature cytokines via intracellular flow cytometry, we stimulated lung single cell 
suspensions for 15 hours with PMA/ionomycin (+ protein transport inhibitors). Due to the 
scarcity of individual ILC subsets in human lung, signature cytokines where examined in the total 
pulmonary ILC population (i.e. CD45+ Lin- CD127+ cells). Additionally, since NK cells are able to 
produce type 1 cytokines, CD56 was used as an extra exclusion marker during the analyses of IFN-
γ. We observed production of IFN-γ, indicative for ILC1 in the human lung tissue (Fig. 3A). 
Similarly, we could identify type 2 cytokine production, specifically IL-5 expression, which 
suggested the presence of pulmonary ILC2 in the human lung tissue (Fig. 3B). Finally, also 
cytokines produced by ILC3 such as IL-17A (Fig. 3C), IL-22 (Fig. 3D) and GM-CSF (Fig. 3E) were 
seen within the pulmonary ILC population. Fig. 3F shows the frequency of cytokine positive cells 
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in the ILC population. Of note, unstimulated pulmonary ILC had no to limited basal cytokine 
expression (data not shown). 
 
 
Figure 3: Intracellular cytokine production in the pulmonary ILC population. Several signature cytokines in 
pulmonary ILC (gated as CD45+, Lin- CD127+ cells) were determined on single cell suspensions of digested human lung 
(n = 8). Since NK cells could contaminate the non-toxic ILC1 subset, CD56+ cells were excluded to investigate the IFN-γ 
production.  For the production of these cytokines, lung cells were first stimulated for 15 hours with PMA/ionomycin 
(+ transport inhibitors). A, IFN-γ production in ILC. B, Production of IL-5 in the pulmonary ILC population. C, IL-17 
production in ILC. D, ILC production of IL-22. E, Production of GM-CSF in the ILC population. The bottom panels 
represent the isotype controls of the specific cytokine staining. F, Frequency of IFN-γ, IL-5, IL-17A, IL-22 and GM-CSF 
positive cells within the ILC (CD45+, Lin- CD127+) population (n = 8, mean ± SEM).  
 
ILC subsets in control subjects versus patients with COPD 
Using the above described surface markers, we quantified the percentages of ILC1, ILC2, NCR+ 
ILC3 and NCR- ILC3 subsets in lung single cell suspensions. Since the relative abundance of 
pulmonary ILC subsets could be altered in diseases such as COPD, we investigated the frequency 
of the different ILC subsets in control subjects (n=5) and in patients with COPD (n=11). Although 
there were no significant differences observed in the relative abundance of the specific ILC subsets 
between the control and COPD group (probably due to low patient numbers) (Fig. 4A), some 
interesting findings were found. In the control group, both ILC2 and NCR- ILC3 were the most 
abundant ILC subsets. Interestingly, in patients with COPD the distribution of ILC tended to shift 
to a greater presence of NCR- ILC3 compared with the other ILC subsets (Fig. 4B). Moreover, when 
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analysing cytokine positive ILC, we observed that IL-17A and IL-22 expressing ILC tended to 
increase in patients with COPD compared with controls, whereas IFN-γ and IL-5 expressing ILC 
were similar (Fig. S5).  
 
 
Figure 4: ILC subsets in control subjects versus patients with COPD. A, The frequency of ILC1 (CD45+, Lin-, CD127+, 
CD56-, IL12Rβ2+), ILC2 (CD45+, Lin-, CD127+, CRTH2+), NCR+ ILC3 (CD45+, Lin-, CD127+, CD117+, NKp44+) and NCR- ILC3 
(CD45+, Lin-, CD127+, CD117+, NKp44-) in digested human lung from control (n = 5) and COPD patients (n = 11) was 
determined by flow cytometry. ILC numbers were expressed as percentages (%) of the CD45+ population (mean ± SEM). 
B, Pie chart of the relative abundance of ILC1, ILC2, NCR+ ILC3 and NCR- ILC3 subsets in control subjects and patients 






We demonstrate the presence of all ILC subsets in human lung (Fig. 5). Using specific surface 
markers and key transcription factors, we characterized the ILC1, ILC2, NCR+ ILC3 and NCR- ILC3 
subsets in human lung single cell suspensions by multi-color flow cytometry. In addition, we 
assessed the production of signature cytokines in the pulmonary ILC population. Furthermore, 
our data suggest that the frequency of NCR- ILC3 tended to increase in patients with COPD. 
 
 
Fig. 5. Overview of innate lymphoid cell subsets in human lung tissue. The presence of CD45+, Lin- (i.e. CD3, CD19, 
CD11c, CD11b) and CD127+ ILC in pulmonary tissue was demonstrated. These ILC were further subdivided in a CD56- 
IL12Rβ2+ ILC1 subset, CRTH2+ ILC2 subset, CD117+ NKp44+ (NCR+) ILC3 subset and CD117+ NKp44- (NCR-) ILC3 subset. 
Further, expression of signature transcription factors (i.e. T-bet, GATA-3 and RORγT) within the specific ILC subset and 




To characterize ILC subsets in human tissues, specific surface markers have been proposed in the 
literature. In gut mucosal tissue, a higher fraction of the IL12Rβ2 transcript could be detected in 
the ILC1 population [335]. Using this specific marker, as well as CD56 to exclude contaminating 
NK cells [198, 336], we identified lung ILC1 as CD45+ Lin- CD127+ CD56- IL12Rβ2+ cells. However, 
it should be noted that some controversy still exists in the characterization of the (human and 
mouse) ILC1 subset. At least in the gut, an additional intraepithelial CD127low CD103+ ILC1 subset 
has been discovered, that would be the equivalent of cytotoxic CD8+ T-cells [326]. Recently, such 
a CD127low CD103+ ILC1 subset was also found in human lung tissue [332]. Compatible with 
research findings in the gut and nasal polyps [331], we identified pulmonary ILC2 as CRTH2+ cells 
within the pulmonary ILC population. ILC3 subsets in the gut and skin were distinguished based 
on NCR (NKp44) [337, 338]. Accordingly, in human lung specimens, we show the presence of both 
NCR+ ILC3 and NCR- ILC3 within the CD117+ pulmonary ILC. One should however be aware that 
the NCR- ILC3 subset remains a heterogeneous population that also contains LTi-cells. 
 
In addition to the characterization based on surface markers, the expression of developmental 
transcription factors is an important feature to identify ILC subsets. We demonstrated a clear 
expression of GATA-3 in the ILC2 subset and RORγT in the ILC3 subset, which suggests that our 
staining based on surface markers adequately discriminates between the ILC subsets. Of interest, 
besides T-bet expression in the ILC1 subset, we also demonstrated a high T-bet expression in the 
ILC3 subset. It was previously shown that, upon stimulation with IL-12, intestinal NCR- ILC3 could 
lose their RORγT expression and upregulate T-bet, suggesting that ILC3 can differentiate into ILC1 
[335, 339]. Our observed T-bet signal in the ILC3 subset could therefore indicate a plasticity of 
human pulmonary ILC3, although this requires further investigation. 
 
Upon stimulation, ILC are able to produce several effector cytokines. We observed expression of 
IFN-γ, IL-5, IL-17A and IL-22 in the pulmonary ILC population, indicative for the presence of 
activated ILC1, ILC2, NCR+ ILC3 and NCR- ILC3. In addition, we also observed GM-CSF production 
which would be interesting to explore further, since RORγT+ ILC3 were able to produce GM-CSF 
in the mouse intestine which contributed to T-cell homeostasis [220, 340]. However, it should be 
emphasized that the cytokine expression was investigated in the total pulmonary ILC population. 
Assessment of cytokine production by the specific pulmonary ILC subsets could provide 
additional functional insights. Furthermore, it would be worthwhile to investigate the production 
of amphiregulin by human pulmonary ILC2 in future experiments. At least in mice, it has been 
shown that besides type 2 cytokines, ILC2 can produce amphiregulin, an epidermal growth factor 




Depending on the tissue, the composition of human ILC subsets can differ [326]. In healthy skin, 
for instance, higher numbers of ILC2 and NCR- ILC3 were found [337], whereas NCR+ ILC3 are the 
most abundant ILC subset in the gut [341]. The number of ILC subsets in our control subjects is 
relatively low, but is in line with the number of ILC2 that was previously observed in non-inflamed 
nose tissue [331]. Further, it has been shown that the relative abundance of the ILC subsets can 
depend on the disease state, such as in Crohn’s disease, psoriasis and chronic rhinosinusitis [331, 
335, 337]. Although there were no statistical differences between the control and COPD group, a 
trend to a higher relative abundance of NCR- ILC3 could be observed in patients with COPD. It 
should however be noted that a small number of patients was investigated, and that our findings 
need to be confirmed in a larger study population.  
 
In COPD patients, a higher number of lymphoid follicles was found compared to controls that 
correlated with disease severity [342, 343].  Importantly, IL-17A and IL-22, which are produced 
by NCR- ILC3, are crucial in the formation of lymphoid follicles [344, 345]. It would therefore be 
interesting to investigate the role of the increased NCR- ILC3 subset in lymphoid follicle formation 
in patients with COPD. Furthermore, as lymphoid follicles are also observed in other chronic 
pulmonary diseases (i.e. pulmonary fibrosis, bronchiectasis, follicular bronchiolitis, lymphoid 
interstitial pneumonia) [343], it would be worthwhile to also examine the relative abundance of 
NCR- ILC3 in these disease settings. Besides being involved in the formation of lymphoid follicles, 
NCR- ILC3 could also contribute to the persistent inflammation in COPD patients by pro-
inflammatory cytokine production. Alternatively, it could be that the accumulation of NCR- ILC3 
in COPD is associated with host protective immunity, in response to bacterial respiratory tract 
infections which occur frequently in patients with COPD [343]. Further functional studies that 
address the role of NCR- ILC3 in COPD are therefore warranted. Very little is known about the 
(protective and pathological) role of ILC3 in lung homeostasis as well as in the context of disease. 
Recently, NCR- ILC3 were found to accumulate in human non-small cell lung cancer tissue, where 
they might contribute to the formation of protective tumour-associated tertiary lymphoid 
structures [332]. 
 
Until now, studies in the respiratory system have mainly focused on the ILC2 subset. Although 
several animal studies have described an important role for ILC2 in helminth infections [214], 
allergic airway inflammation [158, 234, 241, 346] and airway hyperresponsiveness [242, 312], 
the function of ILC2 in the human lung remains incompletely studied. To date, increased numbers 
of ILC2 in nasal polyps from patients with chronic rhinosinusitis have been demonstrated [330, 
331], suggesting a role for ILC2 in eosinophilic inflammation in the upper airways. In addition, 
genes discovered in genome-wide association studies of asthma (RORα, IL-13, IL-33, IL-1RL1; 
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which are all related to ILC2) suggest a key role for ILC2 in asthma [16]. We recently hypothesized 
that ILC2 could have an important role in non-allergic eosinophilic airway inflammation [270]. In 
support of this, research in an experimental model of asthma has shown that ILC2 are highly 
corticosteroid resistant [271], which could explain why severe eosinophilic asthmatics are 
relatively corticosteroid resistant [270].  
 
In summary, based on expression of surface markers and key transcription factors, we 
demonstrated that ILC1, ILC2, NCR+ ILC3 and NCR- ILC3 subsets are present in the human lung. In 
addition, pulmonary ILC were able to produce signature cytokines upon stimulation. Of interest, 
we showed that pulmonary NCR- ILC3 tended to accumulate in the lung of COPD patients, although 
this should be confirmed in a larger study population. The functional role of ILC subsets in lung 
homeostasis and pulmonary diseases however remains to be fully elucidated. Further research on 
the function of ILC subsets is therefore needed to address whether ILC are possible targets for 






Fig. S1: Process of making single cell suspensions of lung resection specimen. Lung tissue 
was obtained from patients who underwent a surgical lung resection. Tissue was cut into fine 
pieces and digested for 45 minutes at 37°C in digestion medium supplemented with collagenase 
type 2 and DNase I. Next, EDTA was added to stop the digestion and the lung cells were filtered 
through a 40-µm cell strainer. Pulmonary mononuclear cells were isolated with Ficoll-PaqueTM 






Fig. S2: Fluorescence minus one (FMO) controls to set up an adequate ILC gating strategy. 
FMO controls were used on single cell suspensions of digested human lung and analyzed by flow 
cytometry. FMO controls contain every stain in the ILC panel except for that specific fluorochrome 
that was investigated. This figure shows how the gate for the specific ILC subsets (Fig. 1) was set 














Fig. S3: Specificity of ILC staining combination. A, Expression of CRTH2, CD117 in the 
pulmonary ILC1 population. B, Analyses of the surface markers IL12Rβ2, CD117 in the ILC2 









Fig. S4: Inclusion of extra lineage markers in the ILC cocktail. Inclusion of additional lineage 
markers in the ILC cocktail was assessed by flow cytometry on single cell suspensions of digested 
human lung. Frequencies of ILC1, ILC2 and ILC3 in digested human lungs using our ‘classical’ 
lineage mix (i.e. CD3, CD19, CD11c, CD11b) (filled symbols) and the lineage mix with extra 
markers (i.e. CD3, CD19, CD11c, CD11b, CD1a, CD14, CD34, CD123, TCRαβ, TCRγδ, BDCA2 and 




Fig. S5: Frequency of cytokine positive ILC in control subjects and patients with COPD. 
Frequency of IFN-γ, IL-5, IL-17A, IL-22 positive ILC (gated as CD45+, Lin-, CD127+ cells) in digested 
human lung of control subjects (n=2) and COPD patients (n=6) was determined by intracellular 
































11.1 Diesel exhaust particles aggravate allergic airway inflammation 
 
Exposure to air pollution is associated with many health problems, ranging from respiratory 
diseases, such as asthma, COPD and lung cancer, to cardiovascular illness and all-cause mortality 
[60]. In the lung, exposure to DEPs causes acute inflammation and augments allergen-induced 
immune responses. To study the aggravating effects of DEPs on allergic airway inflammation, we 
developed a murine model wherein a clinical relevant allergen, i.e. HDM, was administered 
simultaneously with DEPs. Whereas exposure to sole DEPs or HDM elicited minimal responses, 
concomitant DEPs+HDM exposure greatly enhanced several features of allergic airway 
inflammation, characterized by an excessive inflammatory cell recruitment, mucus metaplasia, 
type 2 cytokine production, HDM-specific IgG1 and AHR. These observations were in line with 
other experimental models wherein the enhancing effect of DEPs on allergic airway inflammation 
was also present [96, 314]. Although we can conclude that we have developed a murine model 
wherein simultaneous exposure to DEPs and HDM aggravated the allergic inflammatory 
responses, the exposure of these environmental factors could also occur at different time points 
in real life. Therefore, it would be worthwhile to repeat the experiment where DEPs and HDM are 
administered separately and investigate if the effects of DEPs on allergic responses may vary. At 
least in an OVA-model it was suggested that allergic sensitization and/or challenge prior to DEPs 
led to exaggerated airway responses [347-349]. In contrast, when DEPs was administered prior 
OVA sensitization an attenuated OVA-induced airway inflammation was observed [350]. 
 
11.2 Diesel modulates airway epithelial responses 
 
Airway epithelial cells have been identified as crucial regulators, as epithelial-derived cytokines 
and chemokines can recruit, activate and instruct both DCs and ILCs, promoting type 2 mediated 
immune responses [102]. In the first part of this dissertation, we investigated the role of the 
airway epithelium in the development of DEPs-induced inflammatory lung responses. More 
specifically, we were interested in the role of some epithelial-derived signaling pathways, i.e. 
chemerin and IL-33 signaling. As DCs have been recognized at the frontline of DEPs-induced 
immune responses [94], we investigated the role of the chemerin/ChemR23 signaling pathway, 
implicated in DC recruitment, during acute DEPs and combined DEPs+HDM exposure. Secondly, 
the role of the IL-33/ST2 signaling pathway, which contributes to the activation of both DCs and 
ILC2s, was investigated in DEPs-enhanced allergic airway inflammation. Our findings highlight a 
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complex regulation of the epithelial airway responses towards different inflammatory conditions 
or administration settings, i.e. prophylactic vs therapeutic.  
 
11.2.1 Chemerin/ChemR23 signaling 
 
First, we demonstrated that chemerin is increased in the lungs of mice that were exposed to acute 
DEPs and combined DEPs+HDM. This is in line with observations where increased chemerin was 
detected in the lungs of CS-exposed mice [120] and in serum of COPD patients compared to the 
control group [135]. Moreover, the cellular source of prochemerin was airway epithelial cells, 
confirming previous reports [120, 131]. 
Whereas the inflammatory lung responses were abrogated in ChemR23 KO mice upon acute DEPs 
exposure, ChemR23 KO mice that were exposed to combined DEPs+HDM had increased type 2 
mediated immune responses compared to WT controls. Our data therefore indicate that 
depending on the environmental stimuli, the chemerin/ChemR23 axis exerts different biological 
functions. Interestingly, this was also observed in other models wherein the ChemR23 axis had 
pro-inflammatory actions in response to CS [120], while anti-inflammatory properties were 
present during allergic airway responses [121].  
How exactly different environmental stimuli affect the chemerin/ChemR23 axis remains to be 
further investigated. In this context, it was demonstrated that chemerin variants with distinct 
pharmacological properties can be formed depending on which proteases are available in the 
environment. Serine proteases for instance can generate active chemerin fragments [129, 284], 
whereas mast cell chymase is associated with an anti-inflammatory chemerin fragment [285, 
286]. Since DEP inhalation induces massive neutrophil accumulation [94], one can hypothesize 
that upon acute DEPs exposure serine proteases will induce active chemerin, leading to cell 
chemotaxis into the airways. In contrast, one can speculate that during the DEPs-enhanced allergic 
airway inflammation, mast cells will induce the formation of chemerin-154, which exerts anti-
inflammatory actions [285], by for instance inhibiting macrophage activation [286]. To test this 
in our models of DEPs-induced inflammatory lung responses, additional experiments should be 
performed where either neutrophils or mast cells are depleted or protease inhibitors are 
administered. Moreover, discriminating the different chemerin variants that are formed during 
DEPs-induced airway inflammation will lead to additional insights into the complex biology of 
chemerin signaling.  
Secondly, one can wonder whether the effects of chemerin are indirectly mediated through the 
release of other (epithelial) mediators. Our group has previously shown that monocytes and 
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monocyte-derived DCs are recruited in a CCL2/CCR2, and to a lesser extent CCL20/CCR6 
dependent manner upon DEP inhalation [95]. As in DEPs-exposed ChemR23 KO mice lower CCL2 
and CCL20 levels were observed, this could imply that the reduced inflammatory lung responses 
upon DEP inhalation were an indirect consequence of chemerin on epithelial CCL2 and CCL20 
production. However, in DEPs+HDM-exposed ChemR23 mice, where an enhanced allergic airway 
inflammation was present, also impaired CCL2 levels were detected. The opposing role of 
chemerin can therefore not be solely held attributable to a feedback mechanism of chemerin on 
epithelial CCL2 or CCL20 production. Besides chemerin, resolvin E1 (RvE1) is identified as a 
second ligand of ChemR23 [134], that can exert anti-inflammatory properties, leading to the 
resolution of allergic airway inflammation  [294]. RvE1 is enzymatically derived from omega-3 
fatty acids. Interestingly, intake of these fatty acids have been associated with lower asthma 
prevalence [351]. However, since we demonstrated reduced RvE1 levels upon both acute DEPs 
and combined DEPs+HDM exposure, RvE1 cannot explain the opposing inflammatory responses 
that were observed in the ChemR23 KO mice in the two models. Of note, as the anti-inflammatory 
effects of chemerin were not restricted to ChemR23 expressing cells in the model of DEPs-
enhanced allergic airway inflammation, an indirect of chemerin was further suspected. This is in 
line with other models wherein it was demonstrated that chemerin can exert anti-inflammatory 
properties via an indirect effect on a non-leukocyte cell population (i.e. airway epithelium and 
endothelium) [121, 136]. Further studies should however be conducted to discover which 
mechanisms and mediators are influenced by chemerin. One could speculate that upon 
DEPs+HDM exposure, chemerin exerts anti-inflammatory effects by modulating leukocyte 
trafficking and/or multiple pro-inflammatory cytokines and chemokines. 
  
11.2.2 IL-33/ST2 signaling 
 
Expression analyses revealed that the mRNA levels of IL-33, present in structural cells, and ST2, 
located in hematopoietic cells, are significantly elevated in the lungs of DEPs+HDM-exposed mice. 
This was accompanied by increased full length and mature IL-33 protein levels in response to 
combined DEPs+HDM exposure. Accordingly, increased IL-33 expression was demonstrated in 
allergen or CS-exposed mice [159-161, 190] and asthmatic or COPD patients, which correlated 
with disease severity [125, 150, 187, 188]. Moreover, IL-33 production further increased in 
asthmatic bronchial epithelium that was exposed to PM [185].  
Administration of recombinant sST2 (r-sST2) to mice from the start of the exposure protocol, i.e. 
prophylactic setting, lowered the DEPs-enhanced allergic airway inflammation. When 
DEPs+HDM-exposed mice were treated with r-sST2, a decreased amount of BALF eosinophils, 
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total number and cytokine-expressing ILC2s and TH2 cells could be observed compared to PBS-
treated controls. These results indicate that IL-33/ST2 signaling has a prominent role during 
DEPs-enhanced allergic airway responses. Our observations were in line with other models where 
an attenuation of the HDM-induced inflammatory cell recruitment could be observed in ST2-, IL-
33 KO mice or upon r-sST2 administration [159-163]. However, the contribution of the IL-33/ST2 
axis in allergic airway inflammation has been a matter of debate since several years, as a 
contradiction between results was obtained with different exposure models and IL-33 disrupting 
agents [163, 352]. Indeed, the development of an allergic airway inflammation has also been 
shown to occur independently of the IL-33 axis. Using IL-33 KO mice for instance, absence of IL-
33 did not affect the HDM-driven airway inflammation, with the exception of cytokine-producing 
ILC2s [165]. Of note, also in our model r-sST2 lowered the total number and cytokine expressing 
ILC2s in sole HDM-exposed mice.   
In contrast to our BALF data however, prophylactic administration of r-sST2 had no significant 
effect on the inflammatory lung responses (i.e. lung eosinophilia and goblet cell metapalasia), type 
2 cytokine production in the MLN, HDM-specific IgG1 levels and AHR. Considering that we only 
observed a local response towards r-sST2, the half-life of r-sST2 or our intranasal application 
route could be questioned. It should however be noted that in a murine model of SpID-induced 
asthma, intratracheal administration of r-sST2 only modestly affected the inflammatory lung 
responses [301]. Moreover, also an intraperitoneal injection of r-sST2 at the time of HDM 
sensitization, showed no apparent differences in the type 2 immune responses in the lymph nodes 
and amount of goblet cells [161]. One can hypothesize that in our DEPs+HDM model the activity 
of r-sST2 is too limited to affect the inflammatory immune responses in the MLN and lung, and 
therefore additional experiments using ST2- or IL-33 KO mice could provide better insights. 
Interestingly, it was recently demonstrated that IL-33 blockade through r-sST2 prevented asthma 
in an age-dependent manner, wherein especially neonatal mice were susceptible for the treatment 
[161]. Maybe the r-sST2 treatment would also be more effective in DEPs+HDM-exposed neonatal 
mice. Moreover, considering that HDM-treated ST2 KO mice had a diminished goblet cell 
metaplasia and AHR in the peripheral lung, while no differences were observed in central airways 
[160], it would be worthwhile to investigate whether distinct effects of ST2 signaling in peripheral 
versus central airways can also be observed in our model of DEPs-enhanced allergic airway 
inflammation.  
As it was previously demonstrated that anti-IL-33 treatment could decrease a PM-induced asthma 
exacerbation [186], we were interested if r-sST2 could also be used as a therapeutic upon 
combined DEPs+HDM exposure. However, when r-sST2 was administrated only at the end of the 
exposure protocol, no differences in airway immune responses could be observed, indicative that 
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IL-33/ST2 signaling is more important during the onset of the DEPs-enhanced allergic airway 
inflammation. This was in line with de Kleer et al. where treatment with r-sST2 during the 
challenge phase had no effect on the HDM-induced allergic airway inflammation, in contrast to a 
decreased inflammatory cell recruitment when r-sST2 was administered during the sensitization 
phase [161]. For the moment, human studies with anti-IL-33 are ongoing [37, 168] and still have 
to prove their beneficial effect in asthmatic patients (please see 11.4).  
 
11.3 Innate lymphoid cells in pollutant-aggravated airway diseases 
 
ILCs are early regulators of tissue homeostasis immunity and inflammation. Although ILCs can 
exert important functions in pathogen control and tissue repair, dysregulation of ILC can lead to 
the development of inflammatory diseases, such as asthma and COPD [194]. In the second part of 
this dissertation, we investigated the contribution of ILCs in pollutant-aggravated airway diseases. 
First of all, considering that ILC2s have been implicated in the pathogenesis of allergic asthma, we 
investigated the contribution of ILC2s and their counterpart of the adaptive immune system, i.e. 
TH2 cells, during the aggravating effects of DEPs on allergic airway inflammation. Secondly, as 
human data concerning the different ILC subsets in the respiratory system were lacking, we 
characterized and quantified the different ILC subsets in ex vivo lung samples of control and COPD 
patients. Although we demonstrated that the relative abundance of ILCs can alter during 
pollutant-aggravated airway diseases, this does not by definition highlight a functional 
importance of the ILCs. 
 
11.3.1 Role of ILC2s in DEPs-enhanced allergic airway inflammation 
 
In our murine model, concomitant exposure to DEPs+HDM greatly enhances the allergic airway 
inflammation, characterized by excessive inflammatory cell recruitment, mucus metaplasia, type 
2 cytokine production, HDM-specific IgG1 and AHR. Interestingly, we observed that concomitant 
DEPs+HDM exposure increased the activity of both ILC2s and TH2 cells. As GATA-3 is an important 
transcription factor for the development and function of both cell types [315], the effects of GATA-
3 modulation were investigated. We demonstrated that a reduced GATA-3 expression led to a 
decreased activity of both ILC2s and TH2 cells in the BALF of DEPs+HDM-exposed mice, which was 
accompanied by decreased type 2 immune responses. These results indicate that enhancing 
effects of DEPs on allergic airway inflammation are dependent on an adequate GATA-3-mediated 
regulation of ILC2s and/or TH2. Moreover, the modest inflammation observed after sole HDM 
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exposure was also abrogated upon reduced GATA-3 expression, which was in line with earlier 
results where the allergic airway inflammation was inhibited in GATA-3 mutant mice [322]. Of 
note, as it was demonstrated that GATA-3 is required for the development of all non-cytotoxic ILC 
populations [353], one can wonder if also ILC1s or ILC3s are affected and contribute to the 
decreased inflammatory immune responses.   
Further, we observed that the aggravating effects of DEPs on allergic airway inflammation were 
completely abrogated in RAG KO mice, whereas the allergic airway responses only tended to 
decrease when ILC2s were absent. These data indicate a prominent role for the adaptive immune 
system during DEPs-enhanced allergic airway inflammation, whereas ILC2s only marginally 
contributed. Our results were however in contradiction with earlier reports where ILC2s were 
able to mediate an allergic airway inflammation even in the absence of an adaptive immune 
system [157, 158, 241, 354]. It should however be noted that in these studies recombinant IL-33, 
Alternaria extract or papain was used to induce specific allergic features. Moreover, by using ILC2 
deficient mice, it was proposed that ILC2s arise first and are required for mounting robust TH2 
cell responses [170, 245]. In accordance with our study, it was however recently demonstrated 
that exposure to HDM was also unable to promote an eosinophilic airway inflammation in RAG 
KO mice. Moreover, a specific contribution of T cells, but not B cells, was proposed for the 
induction of ILC2s, leading to a HDM-mediated airway inflammation [165]. In this regard, it would 
be interesting to investigate in our DEPs+HDM model the inflammatory responses in KO mice that 
specifically lack T or B cells. Furthermore, interaction between T cells and ILC2s which promote 
DEPs-enhanced allergic airway inflammation require further investigation. At least during a HDM-
mediated airway inflammation, it was proposed that both epithelium-derived signals, i.e. IL-33, as 
T cell-derived mediators such as IL-2 were needed to induce ILC2 activation [165]. Importantly, 
also mechanistic studies should be conducted to investigate how different environmental stimuli 
modulate the contribution of ILC2s. These insights would be helpful to predict which asthmatic 





Figure 20: Mechanisms involved in the aggravating effects of DEPs on allergic airway inflammation. Combined 
DEPs+HDM exposure increases the expression of epithelial-derived chemerin and IL-33. Whereas chemerin exerts anti-
inflammatory properties, IL-33 exerts a pro-inflammatory function, leading to the activation DCs and ILC2s. In contrast 
to the crucial role of TH2 cells, ILC2 were demonstrated to be dispensable during the aggravating effects of DEPs on 
allergic airway inflammation, despite their type 2 cytokine production.    
 
11.3.2 ILCs in human lung tissue 
 
In human lung tissue, we started by investigating whether all ILC subsets were present. To 
characterize the different ILCs, first specific surface markers were investigated. Non cytotoxic 
lung ILC1s were distinguished based on the lack of CD56 (exclude conventional NK cells) and 
expression of IL12Rb2, which was found to be upregulated in human ILC1s derived from tonsils 
[335]. To date, characterization of ILC1s remains however challenging as they are a highly 
heterogeneous population, wherein besides CD127+ ILC1s, also a second cytotoxic ILC1 
population was identified, characterized as CD127lowCD103+ ILC1s [326, 335, 355], and some 
ILC1s were found to lack the IL12Rb2 transcript [356]. In line with observations in human skin, 
intestines and nasal polyps [331, 357], lung ILC2s were defined by the expression of CRTH2. Lung 
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ILC3s were characterized as CD117 (c-kit) positive and a distinction was made based on the 
presence of the natural cytotoxicity receptor (NCR), i.e. NKp44, accordingly with studies in the gut 
and skin [337, 338]. Of note, NCR- ILC3s are a heterogeneous population, including both NCR- 
helper ILC3s as lymphoid tissue induces (LTi) cells [207]. For the future, it would therefore be 
interesting to expand our surface markers in order to distinguish between those two cell 
populations . Recently, neuropilin 1 (Nrp1) is suggested as an evolutionary conserved marker for 
human LTi cells [280].  
Secondly, we confirmed that our staining based on specific surface markers adequately 
discriminated between the different ILC subsets, as a clear expression of specific developmental 
transcription factors could be shown. Of note, we observed that T-bet expression was not limited 
to the ILC1 population but was also present in ILC3s. In intestinal tissue, it was already shown that 
in response to IL-12 ILC3s can upregulate T-bet expression [335]. Further studies should however 
be conducted to investigate whether the observed T-bet expression in ILC3s is due to ILC 
plasticity. 
Third, the expression of multiple cytokines, i.e. IFN-γ, IL-5, IL-17A, IL-22 and GM-CSF, was 
observed in the ILC population, indicative for the presence of all ILC subsets in human lung tissue.  
Especially the production of IFN- γ and GM-CSF seemed to be increased in human lung tissue. It 
would be interesting to explore these findings further as ILC3-driven GM-CSF production was 
indicated in intestinal homeostasis [220]. Moreover, it would be worthwhile to explore whether 
a shift would occur of one of these cytokine-expressing ILCs in a diseased state, such as COPD.  
We have demonstrated that under homeostatic conditions all three ILC populations are present 
in human lung with ILC3s, especially NCR- ILC3s, and ILC2s being the most prevalent. In line, 
predominantly ILC2s [358], that can be hold responsible for tissue homeostasis by expressing 
amphiregulin [357], were observed in normal skin tissue. Moreover, in the gut, IL-22-producing 
NCR+ ILC3s which are responsible for maintaining gut homeostasis, accounted for about 70% of 
the total ILC population [335]. One can wonder if the observed ILCs at steady state will also 
contribute to lung homeostasis by producing high amount of GM-CSF or amphiregulin.  
Interestingly, we demonstrated that in COPD GOLD I/II patients, the relative abundance of the ILC 
subsets tended to shift towards NCR- ILCs. In line, a marked enrichment of NCR- ILC3s was 
observed in lung tissue from patients with severe COPD (GOLD IV) compared to healthy controls 
and COPD GOLD I/II patients. Interestingly, recent advances detected ILC3s in inflammatory 
aggregates of COPD patients, indicative for a contribution of these ILCs in the formation of 
lymphoid aggregates and follicles [280]. In this context, functional studies to address the role of 
NCR- ILC3s in COPD, and more specifically in lymphoid follicle formation would be an added value. 
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In our study, we were unable to find an accumulation of ILC1s in COPD patients, which was in 
contrast with COPD GOLD IV patients [278]. A possible explanation could be that we have studied 
less severe COPD patients and used a different gating strategy to characterize ILC1s compared to 
the study performed by Bal and colleagues.  
 
11.3.3 Impact of glucocorticoids on ILCs 
 
Since the 1940s corticosteroids are widely used in the clinic for their proficient anti-inflammatory 
effects. To data, inhaled corticosteroids also remain the most common and effective treatment for 
asthma [3, 359, 360]. Their clinical success is largely attributed to their trans-repressive effects in 
which they negatively interfere with the activation of DNA-bound transcription factors, leading to 
a reduced expression of multiple pro-inflammatory genes [361, 362]. Besides the well-known 
interplay between the glucocorticoid receptor and the pro-inflammatory transcription factors NF-
κB and AP-1 [363], it was demonstrated that glucocorticoids also have potent inhibitory effects 
on T-bet and GATA-3 [364, 365], both involved in the development of T cells and ILCs [198].  
In the treatment of allergic asthma, an important effect of glucocorticoids is the suppression of 
TH2 cells and their typical type 2 cytokines, i.e. IL-4, IL-5 and IL-13 [359]. This suppressive effect 
of glucocorticoids can be mediated via the negative regulation of GATA-3, which is required for 
the transcription of TH2 cytokine genes [366, 367]. Since besides TH2 cells, also ILC2s depend on 
GATA-3, one can speculate that corticosteroids affect ILC2 function in the pathogenesis of allergic 
asthma. However, some in vitro studies indicated that ILC2s are more resistant to corticosteroids 
than TH2 cells [231, 368], suggesting that the inhibitory effects of corticosteroids are not likely 
mediated by the modulation of ILCs.  
Of note, in severe asthmatics, asthmatics who smoke or patients with COPD, decreased 
glucocorticoid responsiveness or even glucocorticoid-resistance is found [359, 360]. This 
reduction in corticoid responsiveness has often been ascribed to reduced expression of the 
glucocorticoid receptor or an altered affinity to its ligand/DNA-binding site [360]. Intriguingly, as 
the hypotheses was raised that especially ILCs would be of interest upon exposure to air 
pollutants [270], one could speculate that glucocorticoid insensitivity in these patients is 
mediated by the unresponsiveness of ILCs towards corticosteroids. In support of this, ILC2 
numbers were still increased in the airways of severe asthmatics, despite high doses of oral 
corticosteroids [230]. Nevertheless, further studies should be conducted to address the 
controversy regarding the responsiveness of ILCs towards corticosteroids. An interesting train of 
thoughts could be that glucocorticoids can modulate ILC activity or influence ILC plasticity, as each 
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ILC subset has the capacity to change its phenotype and function dependent on the nature of 
signals they encounter in the tissue. 
 
11.4 Potential implications to the patient  
 
Asthma is a complex and heterogeneous disease with different clinical presentations and 
underlying disease processes. As patients respond different to therapy, asthma phenotyping has 
become utterly crucial. Moreover, a thorough understanding of the different asthma phenotypes 
will further improve the responses to targeted therapies [6]. Intriguingly, also in this dissertation, 
the importance of asthma phenotyping came forward and could have important implications to 
the patient in terms of therapeutic strategies.  
First of all, targeting the chemerin/chemR23 axis could be of therapeutic interest for asthmatics 
considering its involvement in inflammatory cell recruitment. Given the anti-inflammatory 
actions of chemerin in the murine model of pollutant-aggravated allergic airway inflammation, 
chemerin agonists can be proposed as a novel therapeutic in the treatment of asthma. However, 
such chemerin agonists would be detrimental during a DEPs-induced lung inflammation in which 
chemerin exerts pro-inflammatory actions. Here, DEPs-induced inflammatory cell recruitment 
would rather be inhibited by blocking the chemerin/ChemR23 axis [369]. Based on these data, 
one can speculate that, in contrast to a non-allergic phenotype, allergic asthmatics could benefit 
from a chemerin agonist given their anti-inflammatory properties during allergen exposure. 
Nevertheless, before chemerin can even be considered as a new therapeutic, further research on 
the mechanisms underlying the opposing roles of chemerin should be conducted.  Furthermore, 
also during the developmental stage of a chemerin agonist, caution is advised as different 
chemerin variants can exert entire opposite functions.  
Secondly, both genetic and functional studies have identified IL-33 and its receptor as promising 
targets in the treatment of asthma [125, 153]. At the moment, IL-33 (AMG-282) and ST2 (CNTO-
7160) blocking antibodies are in early clinical development [370]. In our study, prophylactically 
inhibiting the IL-33 signaling pathway decreased the pollutant-aggravated allergic airway 
inflammation. However, when the allergic airway inflammation was already established, blocking 
IL-33 signaling had no longer a therapeutic effect. In contrast to most allergic studies, our study 
creates doubt concerning IL-33 as a potential therapeutic target. More specifically, our data 
indicate that pollutant exposure can influence the treatment response of allergic asthmatics 
towards IL-33. We therefore suggest that knowledge concerning pollutant exposure should be 
included when phenotyping the patient. Of note, as we cannot exclude that the used dose, 
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application route or half-life of r-sST2 could have underestimated the potential of IL-33 as a new 
therapeutic, further studies should be conducted.  At least recently, a press release stated that, in 
a phase 2 clinical trial, promising results were obtained with AMG-282 in atopic dermatitis 
patients [371].  
Thirdly, in the past several years, a lot of researchers focussed on ILCs as possible therapeutic 
targets in asthma. However, in our model of DEPs-enhanced allergic airway inflammation, we 
demonstrated a crucial role for the adaptive system, rather than ILC2s [300]. In line, the 
hypothesis was raised that ILC2s would be of more importance in non-allergic asthmatics that 
were exposed to pollutants, microbes or glycolipids [270]. In support of this, increased 
corticosteroid-resistant ILC2s have been identified in the airways of severe asthmatics [230]. It 
should however be mentioned that also in allergic asthmatics, increased ILC2s can be 
demonstrated [233]. Of note, one can hypothesize that the contribution of ILCs in allergic asthma 
can be related to the properties of the allergen, as in papain-induced airway inflammation a 
prominent role for ILC2s was established [170]. Based on these findings, phenotyping the patients 
and identifying the underlying atopic responses are crucial for personalized treatment.   
 
11.5 General Conclusion  
 
In this dissertation, we have applied a model of combined exposure to air pollutants and allergens 
to investigate the involvement of epithelial-derived mediators, ILC2s and TH2 cells during 
pollutant-enhanced allergic airway responses. We conclude that epithelial-derived chemerin and 
IL-33 are increased in response to combined DEPs+HDM. While neutralization of chemerin 
signaling aggravates the DEPs+HDM-induced airway inflammation, indicative for anti-
inflammatory properties, deficiency in IL-33 signaling decreased the enhanced effects of DEPs on 
allergic airway inflammation in a prophylactic setting. Despite the fact that both ILC2s and TH2 
were activated upon combined DEPs+HDM exposure, only TH2 cells appeared to be critical for the 
aggravating effects of DEPs on allergic airway inflammation, characterized by increased airway 
eosinophilia, mucus metaplasia, type 2 cytokine production, IgG1 production and AHR (Figure 
20).  
Furthermore, we demonstrated that all ILC subsets are present in human lung tissue and that their 
relative abundance can alter under pathological conditions, such as COPD. The observation of 
more NCR- ILC3s in COPD patients could highlight an important role of this ILC subset during the 





















Worldwide, millions of people suffer from chronic respiratory diseases leading to a high socio-
economic impact. The most common chronic airway diseases are asthma and chronic obstructive 
pulmonary disease (COPD) wherein both the airways and structural components of the lung are 
affected. Besides a genetic predisposition, several epidemiological and experimental studies have 
shown that exposure to air pollution can contribute to the induction and exacerbation of both 
asthma and COPD. Gaining insights into the molecular and cellular mechanisms underlying these 
pollutant-aggravated airway diseases is urgently needed for their prevention and treatment. 
The airway epithelium is an important line of defence against a wide variety of environmental 
factors. In response to such foreign particles, the airway epithelial cells can release pro-
inflammatory mediators that can attract and activate immune cells, such as dendritic cells (DCs) 
and innate lymphoid cells (ILCs), modulating inflammatory responses. In this dissertation, we 
used murine models to investigate how allergens (house dust mite, HDM) and air pollutants 
(diesel exhaust particles, DEPs) can modulate specific epithelial-derived mediators, leading to 
altered immune responses in the lung. Moreover, as a dysregulation of ILCs can be implicated in 
several inflammatory diseases, their contribution was investigated during the aggravating effects 
of DEPs on allergic airway inflammation and their abundance was investigated on ex vivo human 
lung samples.  
In chapter 7, we have studied the role of chemerin, an important chemoattractant of DCs in DEPs-
modulated immune responses. Preventing chemerin/ChemR23 signaling resulted in diminished 
inflammatory airway responses during acute DEPs exposure, whereas exaggerated allergic 
responses were demonstrated upon combined DEPs+HDM exposure. In chapter 8, the role of IL-
33, an important innate pro-type 2 cytokine, implicated in the activation of both DCs and ILC2s, 
was investigated. By administering a recombinant decoy receptor (r-sST2) that neutralizes IL-33 
activity, the involvement of the IL-33/ST2 signaling pathway in the onset of DEP-enhanced 
allergic airway inflammation was demonstrated. 
In chapter 9, the role of ILC2s in DEPs-enhanced allergic airway inflammation was investigated. 
Whereas both ILC2s as T helper 2 (TH2) cells can be implicated in the pathogenesis of asthma, 
little was known concerning their relative contribution during DEPs-enhanced allergic airway 
inflammation. First, we have demonstrated that both ILC2s and TH2 cells were increased upon 
combined DEPs+HDM exposure. Moreover, the DEP-enhanced allergic airway responses were 
dependent on a GATA-3-mediated regulation of ILC2s and TH2 cells. Finally, by using ILC2s or TH2-
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deficient mice, we demonstrated that predominantly TH2 cells were critical to orchestrate the 
enhanced effects of DEPs on allergic airway inflammation and hyperresponsiveness.  
Although research on ILCs has expanded rapidly the last decade, little was known concerning ILCs 
in the human respiratory system. In chapter 10, flow cytometric analyses on ex vivo human lung 
samples was performed to identify the different ILCs based on specific surface markers, 
transcription factors and cytokine production. We could demonstrate that all three ILC subsets 
are present in human lung tissue. Moreover, compared to control patients, we observed that the 
presence of the ILC subsets tended to change in patients with COPD, suggesting that they could be 







Wereldwijd lijden miljoenen mensen aan een chronische luchtwegaandoening wat een hoog 
sociaal economische impact met zich meebrengt. De meest voorkomende luchtwegaandoeningen 
zijn astma en chronisch obstructief longlijden (COPD) waarbij zowel de luchtwegen als structurele 
componenten van de long worden aangetast. Naast een genetische voorbeschiktheid, heeft 
epidemiologisch en experimenteel onderzoek reeds aangetoond dat voornamelijk blootstelling 
aan luchtverontreiniging bijdraagt aan de gestegen incidentie en ernst van zowel astma en COPD. 
Inzichten verwerven in de moleculaire en cellulaire mechanismen onderliggend aan de 
aggraverende werking van polluenten op luchtwegaandoeningen is dringend nodig voor een 
betere preventie en behandeling. 
Het luchtwegepitheel is een belangrijke barrière voor diverse omgevingsfactoren. Na blootstelling 
aan vreemde partikels kunnen epitheelcellen diverse mediatoren vrijlaten die bijdragen aan de 
rekrutering en activatie van immuuncellen, zoals dendritische cellen (DCs) en aangeboren 
lymphoïde cellen (ILCs), de welke een modulerende effect op het immuunsysteem kunnen 
uitoefenen. In deze thesis hebben we muismodellen ontwikkeld om te onderzoeken op welke 
wijze allergenen (huisstofmijt, HDM) en polluenten (diesel uitlaatpartikels, DEPs) epitheliale 
mediatoren beïnvloeden en de immuun responsen in de long wijzigen. Aangezien een ontregeling 
van ILCs reeds werd aangetoond in diverse inflammatoire aandoeningen, werd bovendien de 
bijdrage van ILCs bestudeerd tijdens de aggraverende werking van polluenten op allergische 
luchtweginflammatie en hun voorkomen bestudeerd in humane longstalen.  
In hoofdstuk 7, hebben we de rol van chemerine bestudeerd, een belangrijke chemoattractant van 
DCs in DEPs-geïnduceerde immuun responsen. Door de chemerine/ChemR23 signalering te 
verhinderen werd een daling van de inflammatoire luchtweg respons waargenomen na acute 
diesel blootstelling, in tegenstelling tot een gestegen allergische luchtweginflammatie na 
gecombineerd diesel en huisstofmijt blootstelling. In hoofdstuk 8, hebben we vervolgens de rol 
van IL-33 bestudeerd, een belangrijk cytokine betrokken bij de activatie van zowel DCs als ILC2s. 
Door toediening van een recombinante receptor die de IL-33 activiteit neutraliseert werd het 
belang van de IL-33/ST2 signalering aangetoond tijdens het aggraverend effect van DEPs op 
allergische luchtwegontsteking.  
In hoofdstuk 9 werd de rol van ILC2s tijdens de aggraverende werking van DEPs op allergische 
immuun responsen onderzocht. Terwijl een prominente rol voor zowel ILC2s als T helper 2 (TH2) 
cellen reeds werd aangetoond in de pathogenese van astma, was er weinig kennis voorhanden 
omtrent hun bijdrage tijdens het aggraverende effect van DEPs op allergische 
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luchtweginflammatie. Allereerst hebben we aangetoond dat zowel ILC2s als TH2 cellen gestegen 
zijn na een gecombineerde DEPs+HDM blootstelling. Bovendien zijn de DEPs-geïnduceerde 
allergische luchtweg responsen afhankelijk van een GATA-3-gemedieërde regulatie van ILC2s en 
TH2 cellen. Finaal, door gebruik te maken van proefdieren die deficiënt zijn in ILC2s of TH2 cellen, 
hebben we aangetoond dat voornamelijk TH2 cellen een cruciale rol vervullen tijdens de 
aggraverende werking van DEPs op allergische luchtwegontsteking en hyperresponsiviteit.  
Hoewel de laatste jaren enorm veel onderzoek werd uitgevoerd naar ILCs, was er weinig kennis 
omtrent ILCs in het respiratoir stelsel van de mens. In hoofdstuk 10, hebben we flow 
cytometrische analyse uitgevoerd op humane long stalen met als doel de verschillende ILC subsets 
te identificeren aan de hand van specifieke oppervlakte merkers, transcriptiefactoren en cytokine 
productie. We konden aantonen dat alle ILC subsets aanwezig zijn in humaan long weefsel. 
Bovendien, in vergelijking met controle patiënten, konden we een wijziging in de frequentie van 
ILC waarnemen bij patiënten met COPD, indicatief dat deze cellen betrokken kunnen zijn in de 

















































REVIEW: INSIGHTS IN PARTICULATE MATTER-
INDUCED ALLERGIC AIRWAY INFLAMMATION: FOCUS 
ON THE EPITHELIUM 
 
Exposure to air pollution is associated with many health problems, ranging from respiratory diseases 
to cardiovascular illness and all-cause mortality. In the lung, exposure to air pollution can lead to 
acute inflammation and modulate the onset and exacerbation of asthma. The mechanisms remain 
however largely unknown. We hypothesize that PM-induced cytokines are important mediators in 
the acute and aggravating effects of PM on airway inflammation. Targeting type-2 innate cytokines 
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Outdoor air pollution is a major environmental health problem throughout the world. In 
particular, exposure to particulate matter (PM) has been associated with the development and 
exacerbation of several respiratory diseases, including asthma. Although the adverse health 
effects of PM have been demonstrated for many years, the underlying mechanisms have not been 
fully identified. In this review, we focus on the role of the lung epithelium and specifically highlight 
multiple cytokines in PM-induced respiratory responses. We describe the available literature on 
the topic including in vitro studies, findings in humans (i.e. observations in human cohorts, human 
controlled exposure and ex vivo studies), and in vivo animal studies. In brief, it has been shown 
that exposure to PM modulates the airway epithelium and promotes the production of several 
cytokines, including IL-1, IL-6, IL-8, IL-25, IL-33, TNF-α, TSLP and GM-CSF. Further, we propose 
that PM-induced type-2 promoting cytokines are important mediators in the acute and 
aggravating effects of PM on airway inflammation. Targeting these cytokines could therefore be a 





Asthma is one of the most common chronic diseases worldwide, resulting in a serious global 
burden affecting as many as 334 million people [2, 4]. It is a chronic disease of the conducting 
airways characterized by a reversible airway obstruction, chronic airway inflammation, goblet 
cell metaplasia, airway hyperresponsiveness (AHR) and remodelling. Asthmatics suffer from 
symptomatic episodes of wheezing, coughing, breathlessness and chest tightness that vary over 
time and intensity [4].  
Asthma is a complex and heterogeneous disease with different underlying disease processes. 
Multiple phenotypes can be distinguished based on the patient’s clinical characteristics and 
inflammatory profile. The best characterized phenotype is (early-onset) allergic asthma, defined 
by the presence of allergen-specific immunoglobulin E (IgE) in serum and/or a positive skin prick 
test to common allergens, such as house dust mite (HDM), in association with type 2 mediated 
immune responses. Other phenotypes are i.e. late-onset eosinophilic asthma and smoking-
associated neutrophilic asthma [6, 7]. Despite the heterogeneous nature of asthma, an almost 
identical pathological phenotype can be observed, characterized by an impaired epithelial barrier 
with areas of epithelial damage, excessive mucus production and thickening of the airway smooth 
muscles. Moreover, an excessive airway inflammation can be observed, which is a multicellular 
process involving mainly dendritic cells (DC), eosinophils, neutrophils, CD4+ T lymphocytes and 
mast cells [5, 372]. 
There are several factors that can influence the development and phenotype of asthma (Figure 
1) [3]. Twin studies have shown that there is a considerable genetic component in asthma, 
indicating that individuals can be genetically predisposed to be protected or more susceptible 
from developing asthma [14]. Moreover, genome wide association studies (GWAS) have identified 
several genetic polymorphisms related with the pathogenesis of asthma, such as TSLP and IL-33, 
implicating an important role for airway epithelial damage in the induction of airway 
inflammation [16, 17]. Despite the power of GWAS to identify disease-associated loci, a significant 
proportion of asthmatics do not carry the known asthma gene polymorphisms [18]. Furthermore, 
over the last century there has been a strong increase in asthma which cannot be explained by 
genetics but rather by gene-by-environment interactions [2]. Epigenetic changes for instance, 
including DNA methylation, histone modifications and non-coding RNAs, are considered 
important additional mechanisms in the development of asthma and are highly influenced by 
environmental exposures [20, 373, 374]. Moreover, it has been clearly demonstrated that 
exposure to a wide variety of environmental factors, such as allergens, respiratory infections and 




Figure 1: Risk factors contributing to the hallmarks of asthma. The development of asthma is strongly regulated by 
heritable components (genetics and epigenetic mechanisms) and exposure to environmental factors. Asthma is a 
heterogeneous disease wherein multiple phenotypes can be distinguished based on clinical characteristics and the 
inflammatory profile. The disease is being characterized by a chronic airway inflammation, reversible airway 
obstruction and airway wall remodelling and hyperresponsiveness.  
 
AIR POLLUTION  
Exposure to outdoor ambient air pollution represents a high environmental risk to human health, 
leading to approximately 3 million deaths each year [55]. Several epidemiological studies have 
demonstrated a positive correlation between air pollution and adverse health effects, ranging 
from respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to 
cardiovascular illness and all-cause mortality, even at pollutant concentrations below the current 
national standards [60, 67-70]. This ambient pollution is a complex mixture of chemicals such as 
ozone, nitrogen dioxide (NO2), sulphur dioxide (SO2), biological substances and particulate matter 
(PM), derived from natural processes as well as from human activity, such as industry, cigarette 
smoke and traffic. Although all components of air pollution are harmful for human health, severe 
effects have been attributed to ambient PM since they can carry a broad range of toxic substances 
into the respiratory tract [56]. Ambient PM consists of solid and liquid particles that differ in their 
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chemical composition and are categorized based on their aerodynamic diameter (i.e. PM10, PM2.5 
and PM0.1). When inhaled, PM10 (particles smaller than 10µM) deposits mainly in the nose and 
large conducting airways, whereas the deposition of PM2.5 ( particles < 2.5µM) is located 
throughout the respiratory tract, particularly in the small airways and alveoli. The ultrafine PM 
(UFPM) fraction PM0.1 ( particles < 0.1µM) will further deposit in the pulmonary tissue and some 
will even translocate from the alveoli to the pulmonary circulation [60]. A major component of 
traffic-related ambient PM are diesel exhaust particles (DEPs). These particles consist of a carbon 
core which can adsorb several organic compounds, such as polycyclic aromatic hydrocarbons 
(PAHs) and quinones. Additional, traces of sulphates, nitrates and metals can be observed. The 
majority of DEPs belong to the highly respirable fine or ultrafine PM fraction [64, 65].  
Importantly, several key characteristics of ambient PM such as particle size, surface area and 
chemical composition will determine the specific mechanisms of PM-induced toxicological effects 
and their ability to induce lung injury and inflammation [57-59]. Emerging evidence has shown 
that, among different particles, especially UFPM has a great toxic potential due to the unique 
physical and chemical properties [59, 375, 376]. When the particle size decreases, the relative 
surface area increases, allowing a greater proportion of compounds to be displayed at the surface 
[57]. UFPM contains significantly more metals and a large number of organic carbon compounds 
compared to larger particles [63], which have been demonstrated to have pro-oxidant and pro-
inflammatory effects in the respiratory system [61-63]. In addition, the high potency of UFPM to 
induce airway injury and inflammation is also due to a higher number of particles per mass unit, 
higher deposition efficiency and long-term retention/delayed clearance in the pulmonary region 
[377, 378]. Furthermore, several studies support the concept that UFPM is less likely to be 
phagocytized by alveolar macrophages and reside only a short period on the luminal side of the 
airway epithelium, penetrating deep into the tissue and cellular targets, lodge into the 
mitochondria, where cell injury, reactive oxygen species (ROS) generation and cell death can 
occur [379, 380]. Finally, the small size of UFPM facilitates its translocation from the respiratory 
epithelium towards the systemic circulation, causing extra-pulmonary health effects [378].  
 
AIR POLLUTION AND THE AIRWAY EPITHELIUM 
The airways are continuously exposed to particulate matter from the environment. Different 
mechanical filters located in the nasopharyngeal (i.e. nose hairs and the turbulence in the nasal 
turbinates), tracheobronchial and alveolar region protect the airways against inhaled foreign 
particles. Especially the mucociliary escalator is identified as a crucial self-clearing process of the 
airways to remove inhaled pathogens and particulates. More specifically, a large proportion of 
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foreign particles are being trapped in the mucus layer on top of the airway epithelium and 
transported out of the airways by ciliary beating and coughing [381, 382]. Importantly, it was 
demonstrated that PM-exposed human bronchial epithelial cells (HBEC) progressively attenuate 
the ciliary beat frequency [105], suggestive for a delayed clearance of these particles out of the 
lung. The particles that escape those defence mechanisms will then enter the lower airways and 
alveolar region where they can be endocytosed and removed by alveolar macrophages [381, 382]. 
Upon ambient PM exposure, these macrophages are activated and secrete an array of pro-
inflammatory mediators, leading to apoptosis and induction of local and systemic inflammatory 
responses [383]. Interestingly, it was demonstrated that when exposed to ambient PM alveolar 
macrophages and airway epithelial cells can interact with each other to amplify the production of 
a variety of chemokines and cytokines, leading to inflammatory airway responses [384].  
Initially, the airway epithelium was considered as a passive barrier which can exclude harmful 
agents from the underlying tissue by a dense network of tight and adherens junctions. In response 
to ambient PM exposure, this epithelial integrity can however be affected, as demonstrated by a 
downregulation or disruption of the adhesion molecule E-cadherin or tight junction proteins, 
occludin and zonula occludens-1 [107-109]. Nowadays, it is widely accepted that the epithelial 
layer also has an active role in the respiratory defence mechanisms, regulating both innate and 
adaptive immune responses. First of all, several studies have shown that besides the specialized 
phagocytotic cells, such as the alveolar macrophages, ambient PM can also be endocytosed by 
airway epithelial cells [385-387]. Although limited data is available concerning the exact 
underlying pathways, it is presumed that different uptake mechanisms can occur depending on 
the particle’s characteristics [388, 389]. It was for instance demonstrated that the uptake of DEPs 
by lung epithelial cells was inhibited by cytochalasin D (CytoD), an inhibitor of actin-dependent 
uptake mechanisms, such as phagocytosis and micropinocytosis [390]. In contrast, uptake of 
UFPM was reported to be actin-independent [391]. Secondly, on the epithelial surface, different 
pattern recognition receptors (PRR) are expressed, which can be activated by pathogen-
associated molecular patterns (PAMPs) in combination with the release of damage-associated 
molecular patterns (DAMPs) [102, 117, 392] (Figure 2). Indeed, it was already demonstrated that 
ambient PM can trigger toll-like receptor (TLR)2 and TLR4. Both receptors signal through MyD88, 
which will lead to the translocation of NF-κB to the nucleus. Interestingly, depending on the 
particle’s composition, distinct TLR may be activated. Until now, it is however unclear which 
components are responsible for TLR activation [115, 116, 393, 394]. Moreover, in addition to a 
TLR ligand, ambient PM can also influence TLR expression and their ability to respond to other 
ligands, leading to altered inflammatory responses to subsequent stimuli [393]. Besides TLR, also 
cytosolic NOD-like receptors (NLR), i.e. NLRP3 (NOD-like receptor, pyrin domain containing 3), 
can be activated through environmental air pollutants and endogenous danger signals [393]. 
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However, there is still some controversy regarding the role of the NLPR3 inflammasome upon 
pollutant exposure [91, 395]. Alternatively, ambient PM can also enhance the expression and 
activation of different membrane-associated receptors, such as the epidermal growth factor 
receptor (EGFR) [396-401]. Dimerization of the EGFR will stimulate tyrosine kinase activity that 
can elicit PI3K/AKT signaling and mitogen-activated protein kinases (MAPK) (i.e. ERK, JNK and 
p38), both involved in the activation of the transcription factor NF-κB [61, 399, 402-405]. 
Importantly, after internalization or PRR activation, exposure to ambient PM/DEPs will activate 
oxidative stress responses in the airway epithelial cells. When lung epithelial cells are exposed to 
ambient PM/DEPs higher levels of intracellular ROS formation, activation of oxidative stress-
responsive genes, such as HMOX1, and oxidative damage have been demonstrated [406-410]. 
Ambient PM/DEPs exposure was further associated with the overexpression of several genes and 
increased phosphorylated proteins related to the MAPK or PI3K/AKT pathway [61, 402-404, 406, 
410-412]. Several studies also demonstrated that PM activates NF- κB signaling in airway 
epithelial cells to induce inflammation [410, 413-415].  
Figure 2: Mechanisms of PM-induced epithelial cytokine release. Exposure to PM induces production of ROS, 
epithelial disruption and activation of signalling pathways which are involved in the activation of NF-κB. Nuclear 
localization of NF-κB will then in turn lead to the transcription of NLRP3, involved in the NLPR3 inflammasome, and 
production of different cytokines. Both IL-33 and IL-1α are constitutively stored in the nucleus. Pro-IL-1β needs an 
additional cleavage to become functionally active. Conflicting results are obtained concerning the involvement of the 
NLPR3 inflammasome in the activation of pro-IL-1β. Symbols:                    activation;                       migration; 
transcription;                          secretion;   cleavage  
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AIR POLLUTION AND ASTHMA 
As stated above, DEPs can cause several adverse effects on their own, inducing acute inflammatory 
responses in the nose, throat and lungs [23]. Both human and animal studies have shown that 
ambient PM contributes to pulmonary inflammation through the induction of oxidative stress, 
influencing cell signaling pathways and production of inflammatory mediators, leading to 
inflammatory cell recruitment [90, 92, 94, 416]. Ambient PM inhalation also affects the autonomic 
nervous system (i.e. modulates heart rate variability [417]) and induces bronchoconstriction and 
cough by sensory nerve activation [418, 419]. In addition, ambient PM inhalation initiates airway 
inflammation by activation of irritant receptors and acid-sensitive pathways located on sensory C 
nerve fibers lining the nasal and pulmonary airways. This results in the release of neuropeptides, 
like substance P (SP), leading to the initiation and maintenance of PM-mediated airway 
inflammation [420]. In both human asthmatics and rodent models, it has been suggested that 
exposure to DEPs augments neuropeptide-release through sensory nerve activation, leading to 
increased adverse effects of ambient PM on respiratory diseases [421, 422].  
Various epidemiological studies provided evidence that exposure to traffic-related air pollution 
can cause as well as exacerbate both childhood and adult-onset asthma [60, 78-81]. Living near 
major roads was for instance associated with significantly more respiratory symptoms and 
adverse effects on lung function in children and adults [70, 82-85]. Moreover, when asthmatic 
individuals were exposed to high levels of particulate pollution, they were more likely to 
experience worsened symptoms and impaired lung function, leading to uncontrolled asthma and 
hospitalizations [79, 81, 87]. Controlled human exposure studies further confirmed that allergen-
specific responses, such as airway eosinophilia, type 2 cytokine expression and allergen-specific 
IgE, can be augmented when the individuals were exposed to DEPs and an (neo)-allergen [99-
101].  
Interestingly, the susceptibility towards the adverse effects of PM inhalation is dependent on 
genetic factors [423]. Polymorphisms in genes encoding for enzymes that regulate oxidative 
stress, GSTM1, GSTP1 and NQO1, are identified as risk factors for allergic diseases in response to 
DEPs [424]. High DEPs exposure during infancy for instance could be related to an increased risk 
of wheezing among carriers with GSTP1 polymorphism (GSTP1 Val105) [425]. Furthermore, the 
aggravating effect of DEPs on allergic airway inflammation, i.e. IgE and histamine production, was 
enhanced when individuals had single nucleotide polymorphisms (SNPs) in the GSTM1 and GSTP1 
gene [426]. Moreover, a GSTM1 variant status led to decreased FEV1 levels following DEPs and 
allergen co-exposure [427]. Finally, also genetic variants in the TLR2 and TLR4 genes influence 
the susceptibility to adverse effects of traffic-related ambient PM on childhood asthma [428].  
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By modulating various airway epithelial responses, i.e. endocytotic uptake, ROS generation and 
PRR activation, it is suggested that pollutants can initiate or contribute to the pathological features 
of asthma [23]. Below, we will elaborate on the modulating effects of ambient PM, and in more 
detail of DEPs, on cytokine expression. In a first part, we will summarize the influence of ambient 
PM/DEPs on multiple cytokines in human airway epithelial cells in vitro. Secondly, we will 
highlight some type 2 mediated cytokines that have been shown to be involved in allergic asthma, 
including also human  studies and in vivo animal studies. The strengths and limitations [23, 429, 
430] of the different research approaches are summarized in Table 1. PubMed and Web of Science 
were searched using “particulate matter” or “diesel exhaust particles” in combination with “IL-1 
OR IL-6 OR IL-8 OR IL-25 OR IL-33 OR GM-CSF OR TNF-α OR TSLP”. A filter for research in the 
lung was applied. Additional relevant references were obtained from the reference list of 
retrieved manuscripts. Publications in English were considered until the 18th of January 2018.  
 
Table 1: Advantages and limitations of basic and translational research to study the 
impact of PM on airway inflammation 




‘Real world’ exposure 
Mortality and morbidity 
endpoints 
Study acute and chronic effects 
Study susceptible populations 
Limited material  (mostly blood) 
Estimation PM exposure  
Confounding factors/exposures 
Difficult to demonstrate causality 
 
Controlled human 
exposure studies  
Well defined PM exposure  
Control confounding exposures 
Various endpoints possible 
Intervention studies 
Ethical issues 
Small subject numbers 
Exclusion of susceptible 
populations 
 
In vitro studies  Investigate specific cells of 
interest 
Possibility of mechanistic 
and/or intervention studies 
Different from the in vivo situation: 
artificial milieu with limited cell to 
cell interactions 
Difficult to mimic in vivo exposure 
Rodent in vivo 
studies  
Complete living organisms 





Possibility of mechanistic 
and/or intervention studies 
Fully sequenced and highly 
homologue genome with 
humans  
Relatively easily housed, bred 
and handled 
Differences in respiratory 
anatomy, physiology and immune 
system 
Difficult to mimic real life exposure  
 
 
PARTICULATE MATTER AND EPITHELIAL CYTOKINE EXPRESSION: HUMAN IN VITRO 
STUDIES (Supplemental Data – Table S1) 
To evaluate the pro-inflammatory responses induced by ambient PM and DEPs in vitro, the 
epithelial gene expression and protein release can be measured. When HBEC, derived from 
immortalized cell lines or normal donors, are exposed to ambient PM or DEPs, a strong 
upregulation of different epithelial cytokines  can be observed. The levels of IL-6 [406, 408, 410, 
411, 431-438], IL-8 [115, 385, 404, 407, 410-412, 414, 432, 434, 436-443] and TNF-α [432, 444] 
for instance were significantly increased in cells that were exposed to PM. Of note, also MIP-
3α/CCL20 [440, 445], an important chemokine involved in DC recruitment, was increased in HBEC 
upon ambient PM exposure. 
Over the years, a triad of epithelial-derived cytokines, i.e. interleukin (IL)-25, IL-33 and thymic 
stromal lymphopoietin (TSLP), have been identified as crucial regulators of various immune cells 
that contribute to the pathophysiology of asthma [306, 446, 447]. In support of this, genome wide 
association studies (GWAS) identified that polymorphisms in genes encoding for TSLP, IL-33 and 
its receptor IL1RL1 are associated with asthma risk [16, 17]. Several studies demonstrated 
increased TSLP and IL-33 expression in the airways of asthmatics, which positively correlated 
with disease severity [124-126]. Moreover, in a subset of asthmatics, an increased epithelial 
expression of IL-25, which correlated with IL-25 plasma levels, could be demonstrated. 
Interestingly, no increase of IL-33 or TSLP was found in these patients [223], indicating the 
heterogeneity and complexity of the disease.  In addition, IL-1 and granulocyte colony stimulating 
factor (GM-CSF) have also been identified as important type-2 promoting cytokines [117] and 
were both increased in the bronchial epithelium of asthmatics [448, 449]. Interestingly, these 
typical type 2 promoting cytokines, including, IL-1α [411, 440], IL-1β [395, 404, 410, 432, 434, 
435, 437, 440, 450], IL-33 [123], TSLP [122] and GM-CSF [385, 403, 432, 439, 440, 451, 452], were 
also increased in PM-exposed normal HBEC. In contrast, IL-25 levels were undetectable [452] or 
decreased [185]. Importantly, the number of studies regarding the modulating effects of PM on 
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asthmatic HBEC are limited and further research is needed. Considering that asthmatic epithelium 
is more susceptible towards oxidants that can affect apoptosis and epithelial damage, compared 
to normal airway epithelium [104, 453], epithelial cells from asthmatics could be more sensitive 
towards the oxidative effects of PM. For the moment, this hypothesis is supported by the fact that 
elevated IL-33 production could be observed in PM-exposed asthmatic-derived epithelial cells 
whereas this was not the case for normal HBEC that were exposed to PM [185]. Of note, as the IL-
33 function can be modified by oxidation [148], it could be that PM-generated ROS and oxidative 
stress could have important implications on IL-33 oxidation and subsequently its function. 
Furthermore, in asthmatic epithelium pro-inflammatory cytokines are constitutively more 
present and further increase upon low PM concentrations whereas in normal HBEC only the 
higher PM levels increased the release of IL-8 and GM-CSF [454]. Asthmatic ALI epithelial cell 
cultures also enhanced inflammatory responses towards PM, including increased IL-6, IL-8 and 
GM-CSF release, compared to non-asthmatic ALI cultures that were exposed to PM [455].  Further 
research where HBEC are exposed to PM in combination with allergens could be an interesting 
tool to investigate the aggravating effects of pollutants on allergen-induced epithelial responses. 
Although it is clear that DEPs and PM can upregulate the expression of numerous pro-
inflammatory epithelial cytokines, not all studies reported an altered cytokine expression [406, 
408, 411, 452]. Differences in epithelial responses can be explained by variations in chemical 
composition, more specifically by the amount of adsorbed organic compounds, metals and 
presence of endotoxins on the particle’s surface. By extracting ambient PM or DEPs for instance, 
it was demonstrated that especially the organic compounds were the main contributors to 
epithelial cytokines release, i.e. IL-1β, IL-6, IL-8 and GM-CSF [61, 402, 434, 456, 457]. Moreover, 
employment of metal chelators led to a significant decrease in IL-1α, IL-8 and GM-CSF expression, 
indicative for the contribution of metals in cytokine production [407, 440]. Removal of surface-
bound endotoxins led to decreased cytokine responses, i.e. IL-1α and GM-CSF [440, 458], 
implicating endotoxins in the PM-induced epithelial cytokine release. In line, epithelial responses  
differed when sample collection was performed over different time periods or locations [403, 450, 
459, 460]. Furthermore, epithelial cytokine expression can be influenced by the particle’s size 
[115, 403, 441, 458, 461], as well as the experimental set-up, the selected PM dose and epithelial 
cell culture [433, 441, 461-463].  
 
HOW DOES PARTICULATE MATTER INFLUENCE EPITHELIAL CYTOKINE EXPRESSION?  
Mechanistic studies have already provided some insights on how pollutants modulate epithelial 
cytokine expression (Figure 2). Endocytotic uptake mechanisms or activation of PPR for instance 
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are required for the induction of airway epithelial cytokine release upon PM exposure. Addition 
of CytoD, an inhibitor of actin-dependent uptake mechanisms, resulted in a significant reduction 
of PM-induced IL-8 and GM-CSF levels [402, 407], whereas a blocking antibody to TLR2 inhibited 
the PM-induced IL-8 expression [115]. Moreover, DEPs-induced IL-8 and GM-CSF release was 
blocked by neutralizing antibodies towards EGFR or autocrine ligands of the EGFR, indicating that 
activation of the EGFR is an important pathways in DEPs-induced cytokine release [396, 412, 464]. 
A crucial role for ROS formation during epithelial cytokine production was also identified, as 
different PM-induced cytokines, i.e. IL-1α, IL-1β, IL-6, IL-8 and GM-CSF, were significantly 
decreased after treatment with radical scavengers/antioxidants [61, 399, 402, 407, 410, 433, 
440].   
Exposure to pollutants can lead to the activation of several signaling pathways which will 
modulate cytokine gene expression. Upon DEPs exposure, the upregulation of epithelial cytokines 
could be attributed to de novo protein and mRNA synthesis [402, 439]. Moreover, signal 
transduction via the MAPK or PI3K pathway was found to be crucial for cytokine production, as 
treatment with specific tyrosine kinases, MAPK or PI3K  inhibitors led to a diminished release of 
IL-1β, IL-6, IL-8 and GM-CSF in DEPs-exposed HBEC [61, 399, 402-404, 410]. Furthermore, by 
using specific NF-κB inhibitors or luciferase reporter gene assays, it was demonstrated that PM-
induced NF-κB activation controls IL-1β, IL-6 and IL-8 production [410, 414, 433]. Importantly, 
the production of ROS has been associated with the redox-sensitive transcription factor NF-κB 
and the upstream signaling pathways. Pretreatment with antioxidants significantly inhibited DEP-
induced ERK/AKT phosphorylation, NF-κB activation, and subsequent cytokine production, i.e. IL-
1β, IL-6, IL-8 and GM-CSF [61, 404, 410, 414, 433]. Overall, one can state that the PM-induced 
inflammatory responses, such as cytokine production, are predominantly mediated by the NF-κB 
pathway which is activated by ROS and MAPK. Of note, dependent on the amount of organic 
compounds that are present on DEPs, a differential transcriptional regulation of IL-8 expression 
was proposed. Whereas exposure to DEPs with a lower organic content involved the NF-κB 
pathways to induce IL-8 promotor activity, high organic DEPs were associated with an AP-1-
dependent mechanism [465].  
However, identifying additional upstream signaling pathways that regulate cytokine production 
in response to pollutants is of great interest for new intervention strategies. Recently, a novel 
mechanism was proposed whereby the expression of TSLP was regulated by miRNA-375 via the 
aryl hydrocarbon receptor (AhR). More specifically, it was suggested that the suppressive effects 
of Ahr on NF-κB’s transcriptional activity are downregulated by miRNA-375, leading to increased 
TSLP expression [466]. Moreover, increased IL-6 and IL-8 production upon PM exposure was 
suggested to depend on a sustained activation of NF-κB, which was regulated by a ROS/PI3K/AKT-
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dependent downregulation of miRNA-331 expression in airway epithelial cells [415]. Notably, 
mechanistic insights concerning the altered expression of typical type-2 promoting cytokines, i.e. 
IL-25, IL-33 and TSLP, towards PM exposure are highly lacking.   
 
PARTICULATE MATTER AND TYPE-2 PROMOTING CYTOKINES: EXPRESSION AND 
MECHANISMS IN HUMANS AND MURINE IN VIVO MODELS (Supplemental Data - Table S2 and 
S3) 
Considering that in the pathogenesis of allergic asthma, typical type-2 promoting cytokines, i.e. IL-
1, IL-25, IL-33, GM-CSF and TSLP, have been implicated, we will now further elucidate on their 
role using human studies and in vivo animal studies.  
By collecting data from PM measuring stations, estimating the proximity to major roads or 
performing controlled human exposure and ex vivo studies, associations between pollution 
exposure and inflammatory markers are being explored in humans. When IL-1β or GM-CSF was 
measured locally, in exhaled breath, lavage fluid or bronchial tissue, no associations with PM could 
be observed [467-469].The effect of PM on local cytokine release is however an underexplored 
research field, with a limited number of studies available. In contrast, most human studies 
investigate the effect of air pollution using blood, in which the identified cytokines can have either 
an epithelial or hematopoietic origin. Notably, exposure to PM has generally been related to an 
increased expression of IL-1β in the blood of adults, children and during prenatal life [470-477]. 
One study also observed a correlation between a joint increase in TSLP+IL-33 cord blood levels 
and heavy street traffic during pregnancy [478] (see table S2 for a detailed overview).  
In vivo research in mice, i.e. using specific knockout strains and monoclonal antibodies, can 
provide additional insights into potential mechanisms how air pollution can modulate (allergic) 
airway inflammation and offer the opportunity to validate hypotheses that have been generated 
by human studies. First, during acute DEPs-induced inflammatory lung responses, an increased 
expression of IL-1β [91, 395, 400, 479-487] and GM-CSF [89, 452] in BALF and lung tissue were 
observed, whereas 1 study reported IL-25, IL-33 and TSLP as undetectable [452]. Moreover, the 
increased IL-1β and GM-CSF levels could be linked to PM or DEPs-induced inflammation and AHR 
[89, 91, 485]. Interestingly, using a mouse model of acute DEP-induced lung inflammation, IL-
1β/IL-1RI signaling was identified as a critical regulatory pathway of the inflammatory responses 
towards DEPs [91]. Some murine in vivo studies however did not demonstrate an upregulation of 
IL-1β [483, 488]  or GM-CSF [479, 489] after acute PM or DEPs exposure, possibly due to different 
exposure protocols, time of sampling, murine strains and pollutant composition. Secondly, in 
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murine models of DEPs-enhanced allergic airway inflammation, increased pulmonary levels of IL-
1α [490] and GM-CSF [490, 491] in OVA models and higher IL-25 [300], IL-33 [300] and GM-CSF 
[492] levels in the HDM models were observed. In other studies however, similar or decreased 
GM-CSF levels were found in DEPs+OVA-exposed mice compared to sole OVA exposure [186, 493-
497] or were undetectable during DEPs+HDM administration [498] (see table S3 for a detailed 
overview). Notably, in these studies the exact cellular origin of these cytokines was however not 
determined. Moreover, to date, most studies only focused on cytokine expression, whereas 
mechanistic studies to unravel the contribution of these type-2 promoting cytokines in DEPs-
induced development and aggravation of allergic asthma are scarce. 
Besides the release of typical type-2 promoting cytokines, also chemokines, like CCL2/MCP-1, 
CCL20/MIP-3α and chemerin, are released upon DEPs exposure, contributing to recruitment of 
DC towards the pulmonary tissue [94, 95, 369]. DEPs are internalized by DC, that in response to 
the type-2 promoting cytokines will mature and migrate towards the MLN [94, 122, 123, 451], 
which was found to occur in a CCR7-dependent manner [94]. DEPs can thereby bind allergens 
onto their surface, acting as carriers to increase allergen deposition. Moreover, co-administration 
of allergens and pollutants can facilitate the penetration of allergens into the airway mucosa, 
resulting in a higher recruitment, uptake, maturation and migration of these DC [23, 499]. In the 
mediastinal lymph nodes, DEPs can affect the responses towards allergens by enhancing TH2 cell 
polarization [94, 122, 123, 451]. In this manner, DEPs can increase the allergic responses, 
characterized by increased inflammatory cell influx, type 2 cytokine production, immunoglobulin 
production, mucus metaplasia and AHR [23, 300, 369, 500] (Figure 3). In addition to the 
modulating effects of DEPs on the DC-TH2 pathway, also innate lymphoid cells type 2 (ILC2) can 
become activated by the secretion of some specific type-2 promoting cytokines [198, 199]. 
Recently, it was however demonstrated that the aggravating effect of DEPs on allergic airway 
inflammation was predominantly dependent on the adaptive immune system, rather than ILC2 
[300]. In addition to the effects of pollutants on asthma development, murine exacerbations 
models can be used to evaluate the aggravating effects of PM or DEPs on allergen-induced airway 
inflammation [23]. Interference with anti-IL-33 for instance suggested a role for IL-33 during an 
acute PM-induced exacerbation in a model of established chronic allergic asthma [186].  
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Figure 3: Diesel exhaust particles affect epithelial cytokines in the pathogenesis of allergic airway 
inflammation. Exposure to DEPs will activate the airway epithelium to secrete specific chemokines, leading to an 
increased recruitment of monocyte-derived DC to the pulmonary tissue. Specific epithelial-derived cytokines in 
combination with allergen and pollutant uptake will result in increased DC maturation, migration towards the MLN and 
induction of Th2 responses. The same epithelial-derived cytokines will also activate ILC2. These Th2 cells and ILC2 will 
then in turn secrete specific type 2 cytokines inducing airway eosinophilia, mucus metaplasia, airway wall remodelling 
and airway hyperresponsiveness. Cells and mediators that increase upon combined allergen and pollutant exposure are 
indicated with a black arrow   .     = pollutants,    = allergen, CCL = C-C motive chemokine ligand, DC = dendritic cell, IgE 
= Immunoglobulin E, IL = interleukin, ILC2 = innate lymphoid cell type 2, Th = T helper. Therapeutic targets are indicated 
in a red box.  
 
Despite many asthmatic features, i.e. pulmonary inflammation, remodelling and AHR, that can be 
replicated in murine models, also important interspecies differences in immunology, respiratory 
physiology and anatomy should be taken into account [23, 501]. The expression of human IL-33 
for instance is mainly localized in bronchial epithelial cells whereas in the mouse IL-33 is 
predominantly expressed by alveolar type II pneumocytes [139], which may be important when 
investigating the effects of air pollution in in vivo models. Moreover, differences in particle 
distribution due to a distinct pulmonary lobulation, bronchial branching and altered clearance 
and filtering processes can affect the pulmonary responses towards PM exposure [23]. Caution is 
therefore advised when extrapolating results obtained from murine models to the human 
188 
 
situation. Furthermore, some general differences between human and murine studies have been 
summarized in table 1. 
 
POTENTIAL THERAPEUTIC TARGETS IN THE TREATMENT OF POLLUTANT-INDUCED 
AIRWAY INFLAMMATION 
In addition to standard therapy, poor-controlled, severe asthmatics with a specific asthmatic 
phenotype are treated with a few approved biologics, i.e. anti-IgE (omalizumab) or anti-IL-5 
(mepolizumab or reslizumab)) [502]. Moreover, also several biologics that target the type-2 
promoting cytokines, i.e. anti-TSLP (Tezepelumab) [50], anti-GM-CSF [503] and anti-IL-33 [169], 
have entered (pre)clinical trials to evaluate their efficacy as add-on therapy in asthmatics. 
Intriguingly, as severe asthmatic phenotypes are associated with exposure to air pollutants, 
microbes and glycolipids [270], this raises the hypothesis that these biologicals would also be 
beneficial within the context of PM exposure. Furthermore, considering that exposure to air 
pollution can lead to the development of neutrophilic asthma [6] and reducing IL-1β levels 
diminished airway neutrophilia, targeting IL-1 signalling  pathways could also be beneficial [504].  
Besides modifying the expression of type-2 promoting cytokines, implications of PM on allergic 
inflammation and asthma exacerbations are for a significant part due to the production of ROS 
[505]. As pretreatment with antioxidants can affect intracellular signaling pathways and decrease 
cytokine production [61, 404, 410, 414, 433], enhancing the levels of the antioxidant superoxide 
dismutase (SOD) or influencing the glutathione (GSH) system for instance could be a another 
approach to lower oxidative stress and airway inflammation [506-509]. Especially since both 
asthma and  PM exposure have already been associated with a significant reduction in SOD or 
polymorphisms in genes implicated in the GSH system [424, 426, 510-512]. Moreover, also dietary 
antioxidants [508, 513], such as selenium, were already associated with reduced oxidative stress 
and lung inflammation in a model of PM-induced lung injury [487]. Furthermore, selenium 





CONCLUSIONS AND FUTURE PERSPECTIVES 
Although PM is without a doubt associated with an increased risk of asthma development and 
exacerbations, specific mechanisms are incompletely known. Epidemiological studies, as well as 
the use of both in vitro and in vivo models, have revealed a central role for the airway epithelium 
and type-2 promoting cytokines during pollutant exposure. The modulating effects of particulate 
matter on multiple cytokines can therefore be proposed as an important driver of allergen-
induced airway responses. It is however crucial that the interaction of multiple environmental 
factors and the mechanisms involved are further elucidated. Additional research on the role of 
type-2 promoting cytokines during pollutant-enhanced airway inflammation may lead to the 
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TABLE S1: PARTICULATE MATTER AND EPITHELIAL CYTOKINE EXPRESSION: HUMAN IN VITRO STUDIES 




16HBE14o- cells DEPs (SRM 1650) and 
CB (carbon black) at 10 
µg/cm2 for 6- 48h 
Time-dependent DEPs-induced ↑ IL-8 and GM-CSF secretion.  
CB ineffective. 
 




0.1-100 µg/mL DEPs 
for 24h 
Time and dose dependent ↑ IL-8 mRNA expression upon DEPs 
exposure 
 
Involvement ROS and NF-κB  
Takizawa et 
al., 1999 
16HBE14o- cells 2.5-20 µg/cm2 DEPs 
(SRM 1650) for 6-48h 
Time and dose dependent ↑ GM-CSF release in the presence of DEPs 
 
Importance organic compounds (lower effect of extracted DEPs and 
CB ineffective), ROS, tyrosine kinases and de novo protein synthesis 
Boland et al., 
2000  
16HBE14o- cells 10 µg/cm2 DEPs, 
organic extracts of 
DEPs, stripped DEPs 
(SRM 1650) or carbon 
black for 24h 
↑ GM-CSF secretion by DEPs and organic extracts of DEPs.  
 
Importance organic compounds (lower effect of stripped DEP and 
no effect of CB), involvement of ROS and MAPK pathways 
Bonvallot et 
al., 2001  
BEAS-2B cell 
line 
100 µg/mL PM at 
different locations for 
4-16h 
↑ IL-6 release by all PM samples Veronesi et 
al., 2002 
16HBE14o- cells DEPs (SRM 1650), RPM 
(SRM 1648), 
atmospheric PM2.5 and 
CB at 10-30 µg/cm2 for 
24h   
Dose dependent ↑ GM-CSF release after DEP/PM exposure. DEPs 
had a higher effect compared to PM.  
CB are ineffective. 
Baulig et al., 
2003  
16HBE14o- cells 10 µg/cm² multiple 
PM2.5 samples/DEPs for 
24h 




16HBE14o- cells PM2.5  and DEPs 
(SRM1650) at 10 
µg/cm2 for 24h  
Causal relationship between amphiregulin and GM-CSF production 
in response to DEPs and PM 
Blanchet et 
al., 2004  
L132 cell line PM2.5 at 18-75 µg/mL 
for 24- 72h 
Time and dose dependent PM2.5-induced ↑ IL-1β, IL-6, IL-8, TNF-α 
release and IL-1β, IL-6, IL-8, TNF-α and GM-CSF mRNA expression 
Dagher et al., 
2005  
16HBE14o- cells PM2.5 at 10 µg/cm2 for 
24h 
↑ GM-CSF protein levels after PM exposure 
 
EGFR ligands involved in GM-CSF release 
Rumelhard 
et al., 2007  
16HBE14o- cells Coarse, intermediate, 
fine and ultrafine PM 
for 24h at 1 or 10 
µg/cm2 
Dose dependent ↑ GM-CSF release following PM exposure. GM-CSF 
levels decreased with increasing aerosol size 
 
Role for endotoxins 
Ramgolam 
et al., 2009  
16HBE14o- cells DEPs (SRM1650), CB or 
PM2.5 samples  at 10 
µg/cm2  for 24h 
↑ GM-CSF protein after treatment with DEPs and PM2.5 from all sites. 
CB are ineffective 
 
ROS induction, EGFR and MAP kinases signalling pathways involved 
in the GM-CSF release.  




1.25-20 µg/cm² coarse 
and fine PM or 5-80 
µg/cm² SRM1648 for 
24h 
Dose-dependent ↑ IL-8 release following coarse PM and SRM1648. 





Organic PM2.5 at 1-100 
µg/mL for 24h  
Polar organic extracts induce dose-dependent ↑ IL-1β secretion Fuentes-




10 µg/cm² DEPs with 
varying organic content 
for 4h 
↑ IL-8 mRNA expression with DEPs exposure to low and high 
organic content 




Different PM samples at 
3-12 µg/cm² for 24-72h 
Dose-dependent ↑ IL-1β, IL-6 and IL-8 mRNA levels for all different 
PM samples. No differences in TNF-α mRNA  
↑ IL-6, IL-8 and TNF-α protein levels in the three PM samples. No 
difference in IL-1β protein levels 





 16HBE14o- cells PM2.5 at 0.1-10 µg/cm2 




Time-dependent PM2.5-induced GM-CSF ↑ at both mRNA and protein 
level 
 
GM-CSF release dependent on autocrine effect of EGFR ligands 
Ramgolam 
et al., 2012  
BEAS-2B cell 
line 
12.5 or 25 µg/mL PM2.5 
or PM10 6-24h  
PM2.5 -induced ↑ IL-1α and IL-6 release, ↑IL-8 only after 24h 
IL-1β was undetectable 
Watterson 
et al., 2012 
BEAS-2B cell 
line 
100 µg/mL DEPs for 4h ↑ IL-1β, IL-6 and IL-8 mRNA and protein levels when exposed to 
DEPs 
Totlandsdal 
et al., 2012 
BEAS-2B cell 
line 
100 µg/mL DEP for 2,4 
or 6h 




500 µg/mL PM10 (EHC-
93)  for 24h 
PM10-induced↑ IL-1β and GM-CSF production. IL-1β release 
proceeds GM-CSF production.  
No detection of TSLP, IL-25 and IL-33 
 
NLRP3 inflammasome-dependent  
Hirota et al., 
2015  
16HBE cells PM2.5 at 25-150 µg/mL 
for 5 and 24h 
Dose and time-dependent ↑ IL-6 production  
Decrease in IL-8 and TNF-α 
 




100 µg/mL PM2.5 from 
six cities of China for 
24h 
↑ IL-1β mRNA levels by all PM2.5 samples 
 
Association with concentration of metals (Ni) on PM 




2.5-10 µg/cm² PM2.5 
and 10 µg/cm² DEPs for 
24h 
 
Dose dependent ↑ IL-8 release after PM/DEPs exposure 
 
Involvement ROS and endocytosis 
Importance metals 




100 µg/mL PM10  from 
three different 
locations 
↑ IL-8 release by all PM samples Van Den 









 BEAS-2B cell 
line 
5µg/cm² diesel UFP for 
20h 
↑ IL-6 release after DEP 
No difference in IL-8 and TNF-α 
 













10-100 µg/mL DEPs or 
2.5-2500 µg/mL 
suspended PM for 2-
48h 
Dose dependent ↑ IL-8 and GM-CSF  release by DEPs exposure 
 
De novo protein synthesis  
Ohtoshi et 







coarse PM at 25-100 
µg/mL for 18h 
Dose dependent ↑ GM-CSF release to ultrafine/fine PM. No dose-
response was detected for the larger PM fractions or carbon 
particles of the fine sizes. 
 
Involvement of MAPK-signaling cascade  
Reibman et 
al., 2002  
HBEC from 
airway biopsy  
50-250 µg/mL coarse, 
fine and ultrafine PM 
for 24h 
PM-induced ↑ IL-8 release 
 
Involvement of TLR2  
Becker et al., 
2005 




µg/mL PM for 1-24h 
Dose and time-dependent ↑ IL-6 release to PM 
 
Involvement of ROS and NF-κB pathway 
Zhao et al., 
2008 
HBEC (Lonza) 10 µg/mL PM for 3h PM-treated HBEC ↑ IL-1α, IL-1β, IL-8 and GM-CSF mRNA levels 
 
Role for endotoxin on the particles and ROS production 
Wong et al., 
2011 
HBEC from 
brush biopsy  
20-80 µg/cm² PM10 and 
PM2.5 for 4h 
Dose-dependent ↑ IL-8 mRNA levels to each particle type   
 
Similar responses in BEAS-2B cell line 
Silbajoris et 
al., 2011 
HBEC by brush 
biopsy  
25-100 µg/ mL DEPs 
for 24h  
Dose-dependent ↑ IL-1β and IL-8 protein expression by DEPs 
exposure 
Involvement glutathione S-transferases (GSTs) through ROS-
associated ERK and Akt activation. 
Wu et al., 
2012  
HBEC from 5 
healthy subjects 
500 µg/mL PM10 (EHC-
93)  for 24h 
↑ IL-1β production by PM10 exposure 
 
Involvement NLRP3 inflammasome 





 HBEC ( Lonza)  3  µg/cm2 DEPs and fine 
PM for 6, 18h 
Dose dependent DEPs-induced ↑ TSLP mRNA 
 
miRNA-375 involved in the TSLP regulation 






4 treatments of 4h 
(spaced 48h) with DEPs 
(SRM1650; 2, 5 and 10 
µg/cm2) or coarse / fine 
/ ultrafine PM (1, 5 and 
10 µg/cm2) 
 ↑ GM-CSF release after each DEPs/PM treatment that could be 
maintained up to 5 weeks post exposure. PM had a lower effect than 
DEPs 
↑ IL-6 release after DEPs/PM treatment that could be maintained up 
to 5 weeks post exposure 
↑ IL-1β release at the beginning of the PM treatment 







Coarse, fine and 
ultrafine PM at 50-250 
µg for 4h 
↑ IL-6 and IL-8 in submerged PM-exposed HBEC 
No response in ALI cultures 





10-200 µg/mL DEPs for 
18-24h 
DEPs-induced dose-dependent ↑ IL-8 mRNA and protein level 
 
Involvement of EGFR/autocrine ligands and MAPK pathway 




1.1 – 11.1 µg/cm² 
coarse, fine and 
ultrafine PM for 24h 
Dose-dependent PM-induced ↑IL-8 release 
 






50 µg/mL PM10 or CB 
for 24h 
PM10 stimulated ↑ IL-1β, IL-6 and IL-8 mRNA expression. CB is 
ineffective. 
Kumar et al., 
2015  
HBEC 100-500 µg/cm³ Urban 
PM 1649b (NIST) for 
24h 
Dose-dependent ↑ IL-1β, IL-6 and IL-8 at both mRNA and protein 
level after PM exposure 
 
Involvement of ROS, MAPK pathway and NF-κB  








0-100 µg/mL DEPs for 
24h 
HBEC of asthmatics constitutively ↑ GM-CSF secretion compared to 
non-asthmatics 






100 µg/mL PM (EHC-
93) for 24-96h 
PM-exposed HBEC from asthmatics have an enhanced ↑ IL-6, IL-8 





CO-CULTURE mDC from blood 





10µg/mL DEPs for 48h ↑ GM-CSF release in the presence of DEP-treated HBEC 
 
GM-CSF-induced DC maturation  
Bleck et al., 
2006 
mDC from blood 






3 µg/cm2 DEPs for 4- 
18h 
↑ TSLP  mRNA and protein expression in DEPs-exposed HBEC 
 
TSLP induced maturation and T cell proliferation of DC 
Bleck et al., 
2008  
HBEC 
mDC from blood 
3 µg/cm2 DEPs for 6- 
48h 
DEP-treated HBEC ↑ IL-33 transcription and protein levels 
 
IL-33 induced functional mDC maturation 











PM for 24h  Monoculture HBEC + PM exposure: 
↑ IL-33 production in HBEC from severe asthmatics  
PM-induced ↓ IL-25 mRNA in control subjects 
No effect on TSLP 
 
Co-culture HBEC + moDC + PM 
No effect on TSLP, IL-33 or IL-25 
(PM impaired TSLP and IL-33 levels that was increased in co-culture 
of severe asthmatic HBEC) 
Gras et al., 
2017  





TABLE S2:  PARTICULATE MATTER AND TYPE-2 PROMOTING CYTOKINES: FINDINGS IN HUMANS  
Study population Material Observations epithelial cytokines Reference 
ADULT 15 healthy volunteers 
exposed to diluted DE and 
air for 1h 
Bronchial tissue  
Bronchial wash 
cells 
≈ IL-1β and GM-CSF gene transcript levels after DE exposure 
compared with air  
Salvi et al., 2000  
Intranasal instillation 
300µg NIST 1650 DEP 
both asthmatic and non- 
asthmatic subjects 
Nasal lavage ≈ GM-CSF protein levels post DEP exposure Kongerud et al., 2006  
 






Nasal lavage fluid 
(NLF) 
≈ IL-1β protein levels in both NLF and EBC between traffic-
controllers and office workers 
Lima et al., 2013  
Colaus study 
Monitoring PM10 on the 
day of visit 
Blood  Positive association 
↑ IL-1β protein levels for every 10µg/m3 elevation in PM10  
Tsai et al., 2012  
40 subjects (20 near 
highway and 20 urban 
residents) 
Blood Positive association 
↑ IL-1 protein levels with proximity to highways or heavy traffic 
Brugge et al., 2013 
[471][471][472][473] 
15 healthy subjects 
exposed to DE and filtered 
air for 2h 
Blood ↑ IL-1β protein levels post DE exposure  Krishnan et al., 2013  
23 healthy adults walking 
2 hours along three 
diverse roadways 
Mobile PM sampling 
Blood  Positive association 
↑ IL-1β protein levels with increasing concentrations PM2.5 


















↑: cytokine increases in response to DEPs/PM, ↓: cytokine decreases in response to DEPs/PM, ≈: equal cytokine levels  
  
 72 healthy subjects 
Monitoring PM2.5  
Blood Positive association 
↑ IL-1β  protein levels with a 10µg/m3 increase in PM2.5  
Pope et al., 2016  
85 male subjects (45 taxi 
drivers vs. 40 office 
workers) 
Blood  ↑ IL-1β protein levels in taxi drivers compared to the control 
group 




Birth cohort  
Monitoring maternal 
exposure to PM10 in the 
third trimester 
Proxy traffic-related air 
pollution (distance to 
major roads) 
Cord blood  Positive association 
↑ IL-1β protein levels with PM10  
GM-CSF expressed only in 2% of samples 
 
No strong associations between major road distance and cytokine 
concentrations 
Latzin et al., 
2011  
MIREC study  
Self-reported exposure to 
street traffic 
Cord blood Positive association 
Jointly ↑ TSLP and IL-33 protein levels with heavy street traffic 
Ashley-Martin 
et al., 2015  
MIREC study  
Monitoring Maternal 
exposure to PM2.5  
Cord blood No association of TSLP and IL-33 protein levels with PM2.5 Ashley-Martin 
et al., 2016  
CHILDREN Residential distance to a 
major road of 577 control 
and asthmatic children 
Blood ↑ IL-1β or IL-33 protein levels in children with asthma compared 
to controls.  
No associations of IL-1β or IL-33 protein levels with residential 
distance to a major road 
Rosser et al., 
2016  
 27 children with asthma 
and 12 controls (without 
asthma) 
Blood ↑ IL-1β release after ex-vivo stimulation with traffic-related 
particulate matter for 24h 





TABLE S3: PARTICULATE MATTER AND TYPE-2 PROMOTING CYTOKINES: IN VIVO ANIMAL MODELS  
Animal Exposure protocol Observations epithelial cytokines Reference 
Acute effects 
of DEPs/PM 




0.25mg/mL DEP in 40µL every 
other day for 2 weeks 
DEP-stimulated ↑ GM-CSF mRNA total lung tissue 
 
Role for GM-CSF in AHR, BALF cell recruitment and mucus 
metaplasia 




5-50 mg DEPS (NIST) 
↑ IL-1β mRNA in BALF cells day 1 and 30 post exposure with 
high DEPs levels 
≈ GM-CSF mRNA lung tissue 
Rao et al., 2005 
[479][479][480][481] 
Male ICR mice (6 
weeks) 
Intratracheal administration 
500µg DEPs  
DEP-induced ↑ IL-1β protein levels in lung tissue supernatants 
compared to vechicle 






≈ BALF IL-1β levels  in DEPs and control-exposed groups Stoeger et al., 2006  
rats Intratracheal administration 
1-5 mg DEPs on day 1 





100µg DEPs on day 1, 4 and 7 
↑ BALF IL-1β upon DEPs compared to saline 
 
Role of IL-1 signalling in DEP-induced inflammation 
Independent of NLRP3 inflammasome and caspase-1 
Provoost et al., 2011 
IRC mice (6 
weeks) 
Intratracheal administration 
2.5-10 mg/kg PM2.5 at day 0  
 
Dose-dependent ↑ BALF IL-1β after PM instillation 
 





200 µg PM10 on day 0 
PM-induced ↑ BALF IL-1β 
 
Role for NLRP3 inflammasome 
Hirota et al., 2012 
Male wister rats 
(8 weeks) 
Intratracheal administration 
7.5 mg/kg body weight PM10 or 
PM2.5 for 14 days  
↑ lung IL-1β in the PM groups compared to the controls 
 





100µg PM10 on day 0, 3 and 6 
↑ IL-1β in the BALF of PM10-treated mice compared to sham 
≈ IL-1β mRNA lung and blood 







200 µg PM10 on day 0 
PM-induced ↑ IL-1β and GM-CSF in BALF 
No detection of IL-25, IL-33 and TSLP 
 
Role for NLRP3 inflammasome 
Hirota et al., 2015 
Male Wistar rats Intratracheal administration 
0.375-24 mg/kg body weight 
PM2.5 on day 1, 3, 5, 7 and 9 
PM-induced ↑ IL-1β mRNA and protein level compared to 
saline exposure 
Li et al., 2015 
Male BALB/c 
mice (8 weeks) 
Intratracheal administration 
5.5 – 100µg PM2.5 
↑ IL-1β expression after PM exposure 
 
Positive correlation with tissue inflammation and BALF 
neutrophils 







4 mg/kg PM2.5 for 5 
consecutive days 
↑ IL-1β mRNA after PM exposure, not on protein level 
 
↑ EGF-EGFR-Akt-NFkB signalling 
 




0.5 mg PM2.5 at day 0 and 2 
PM-induced ↑ IL-1β expression at day 7 and release in the 
BALF at day 3  




40mg/kg PM2.5 every other day 
for 3 tiimes 








Male ICR mice 
(6-7 weeks) 
Intratracheal administration 
100µg DEP every week for 6 
weeks - 1µg OVA every 3 weeks 
for 6 weeks 
OVA + DEPs : ↑ GM-CSF protein levels lung compared to 
vehicle; ≈ GM-CSF levels compared to OVA 
Takano et al., 
1997  
Male ICR mice (6 
weeks) 
12h/day, 7 days/week 0.3-3 
mg soot/m3 DE for 40 weeks 
10µg OVA IP at week 16 
1% OVA aerosol at a 3 week 
intervals during last 24 weeks 
OVA + DE: dose-dependent ↑ GM-CSF protein levels lung 
compared to vehicle and OVA group 
Takano et al., 
1998  





mice (6 weeks) 
1 mg OVA IP at day 7 
12 hours/day 2.2 m3 DE 
inhalation for 5 weeks + 1% 
OVA aerosol at week 5 
OVA + DE: ↑ GM-CSF protein levels lung compared to DE-saline 
group; ≈ GM-CSF levels compared to OVA 
 
 
OVA + DE: ↓ GM-CSF secretion in lung supernatants compared 
to air – OVA 
Miyabara et 




al., 1998 03 
Male C3H/He 
and BALB/c mice 
(8-10 weeks) 
Intratracheal administration 
1mg OVA IP at day 7 
1x/week DEPs for 5 weeks + 1% 
OVA aerosol at week 5  
OVA + DEPs : ↑ GM-CSF protein levels lung compared to 
vehicle-saline; ≈ GM-CSF levels compared to OVA 
Miyabara et 
al., 1998 104 
Male BALB/c 
mice (7 weeks) 
Intraperitoneal injection 
10 µg OVA + 2mg DEPs on day 
0.  
OVA + DEPs: ↑ GM-CSF and IL-1α in the peritoneal exudate 
fluid compared to OVA 
 
Role for CD8+  T cells in GM-CSF production 
Fujimaki et al., 
2001  
C57BL/6N and 
CBA/JN mice ( 6 
weeks) 
Intratracheal administration 
0-50µg DEPs + 1µg HDM (Derf) 
four times at 2 week interval 
HDM + DEPs: ↑ GM-CSF in lung homogenate compared to 
HDM  
Not detected in CBA/JN mice 
Sadakane et 




 Female BALB/c 
mice (6-8 
weeks) 
200-2000 µg/m3 DEPs + 1% 
OVA aerosol for 10 days 
≈ GM-CSF BALF levels compared to OVA and saline Whitekus et 




20µg OVA IP on day 1 
2 mg/m3 DEPs + 1% OVA 
inhalation on day 14-17 
≈ GM-CSF BALF levels compared to OVA Hao et al., 
2003 
BALB/c, ICR and 
C3H/He mice (6 
weeks) 
Intratracheal administration 
0-50µg DEPs + 1µg HDM (Derf) 
four times at 2 week interval 





IP 50 µg OVA on day 0 and 14 
3 mg/m3 OVA aerosol for 
30min/day, 3 days/week for 4 
weeks 
50µg PM10 or 30 mg/m3 OVA 
aerosol on day 49 
OVA + DEPs: ↑ IL-33 mRNA and protein BALF levels compared 
to carbon black; ≈ GM-CSF levels compared to chronic OVA 
exposure 
 
Role for IL-33 in inflammatory cell recruitment 






25µg DEPs and 1 µg HDM on 
day 1, 8 and 15 
DEPs + HDM: ↑ IL-25 and IL-33 protein lung levels compared to 
saline, sole DEP or HDM 
De Grove et 
al., 2017  
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drinken/eten, spelletjesavond,… zorgde telkens voor de nodige hilariteit en ontspanning. Ook 
onze ‘playdates’ met de kinderen staan hoog aangeschreven. Mijn (schoon)broers, 
(schoon)zussen, neefjes en nichtjes – Steven, Greet, Jinte, Brent, Kris, Mieke, Lore, Lander, mijn 
metekindje Lise, Kristien en Bert – elke samenkomst is een groot feest! Jullie staan telkens paraat 
om te helpen en hebben ook volop meegeleefd met dit doctoraat. Ik wil jullie dan ook bedanken 
voor jullie interesse, de fijne tijd die we altijd samen hebben en onvoorwaardelijke steun! Ook 
mijn grootouders verdienen hier een bijzonder plaatsje en grote dankjewel! “Ik heb toch veel aan 
u gedacht”, is een zin die ik meermaals van hen mocht horen! Mijn schoonouders, Luc & Carine, 
hartelijk dank voor jullie interesse in mijn werk.  
 
Mama en papa, mijn grootste supporters, ik ben jullie ontzettend dankbaar voor alles! Dankjewel 
voor het warme nest waarin we mogen opgroeien hebben! Dankjewel voor het vertrouwen en de 
vele kansen die jullie mij gegeven hebben! Geen vraag is ooit teveel… Jullie toewijding voor ons en 
de vele kleinkinderen is ongelooflijk! Ik zie jullie graag!  
 
Tot slot, mijn gezin, Dieter, Jorben & Nolan. Dieter, je ondersteuning tijdens dit doctoraat was 
opnieuw onwaarschijnlijk! Werken in het weekend of tot in de vroege/late uurtjes, lunch brengen, 
tussendoor even snel passeren, een weekje afwezigheid,… Niets was teveel en ondertussen hield 
jij ons gezinnetje recht! Bedankt voor je onvoorwaardelijke liefde en steun! Jorben & Nolan, mijn 
mannetjes, jullie betekenen alles voor mij! Jullie laten mij relativeren en brengen mij elke dag 
opnieuw zoveel vreugde! Dieter, Jorben & Nolan, jullie zijn mijn grote liefde! 
 
Katrien 
